<SEC-DOCUMENT>0000912061-17-000022.txt : 20170802
<SEC-HEADER>0000912061-17-000022.hdr.sgml : 20170802
<ACCEPTANCE-DATETIME>20170802091304
ACCESSION NUMBER:		0000912061-17-000022
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20170630
FILED AS OF DATE:		20170802
DATE AS OF CHANGE:		20170802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NATURAL HEALTH TRENDS CORP
		CENTRAL INDEX KEY:			0000912061
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-MISCELLANEOUS NONDURABLE GOODS [5190]
		IRS NUMBER:				592705336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36849
		FILM NUMBER:		17998551

	BUSINESS ADDRESS:	
		STREET 1:		609 DEEP VALLEY DRIVE
		STREET 2:		SUITE 395 (EAST BUILDING)
		CITY:			ROLLING HILLS ESTATES
		STATE:			CA
		ZIP:			90274
		BUSINESS PHONE:		310-541-0888

	MAIL ADDRESS:	
		STREET 1:		609 DEEP VALLEY DRIVE
		STREET 2:		SUITE 395 (EAST BUILDING)
		CITY:			ROLLING HILLS ESTATES
		STATE:			CA
		ZIP:			90274
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>nhtc20170802_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:86089a4b8b3949149ae3448dc352ec91,x:0ad4bb0341af4fcc867b437691d5d7ac-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2017 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nhtc="http://www.naturalhealthtrendscorp.com/20170630" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2016-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2017Q2YTD" name="dei:AmendmentFlag" id="Fact-C699FAD9E9C753A6AD131EA191678B22-wk-Fact-C699FAD9E9C753A6AD131EA191678B22" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q2YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-6B8C77B1AE2E53F2989C0F4036FC1F08-wk-Fact-6B8C77B1AE2E53F2989C0F4036FC1F08">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q2YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-C62A7C9619D05BBFADF7504F79B94C58-wk-Fact-C62A7C9619D05BBFADF7504F79B94C58">Q2</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q2YTD" name="dei:DocumentFiscalYearFocus" id="Fact-763FDFA098E55234A07EA913A5654B58-wk-Fact-763FDFA098E55234A07EA913A5654B58">2017</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q2YTD" name="dei:EntityCentralIndexKey" id="Fact-7138BBCD6AE35CA09E4385B565A7CB8E-wk-Fact-7138BBCD6AE35CA09E4385B565A7CB8E">0000912061</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q2YTD" name="dei:EntityCurrentReportingStatus" id="Fact-6453A0EDC18F5D7280F62870F7A7348E-wk-Fact-6453A0EDC18F5D7280F62870F7A7348E">Yes</ix:nonNumeric><ix:nonNumeric contextRef="FD2017Q2YTD" name="dei:EntityFilerCategory" id="Fact-DA59C20086A657D6B78924C8AE909A68-wk-Fact-DA59C20086A657D6B78924C8AE909A68">Accelerated Filer</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2016Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-C6B348288D7453FFAD01757FE2FEB5FA-wk-Fact-C6B348288D7453FFAD01757FE2FEB5FA">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2017Q2" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-5C628AADC2EC591AB1B647DFCFCCECFC-wk-Fact-5C628AADC2EC591AB1B647DFCFCCECFC">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2016Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-DDCC2E5DAD2853C6A38668D3B7B49766-wk-Fact-DDCC2E5DAD2853C6A38668D3B7B49766">50000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q2" name="us-gaap:CommonStockSharesAuthorized" id="Fact-652A6975F7CD5EC3891D8BDADB634755-wk-Fact-652A6975F7CD5EC3891D8BDADB634755">50000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2016Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-2723FD60FEF25491B7840621001DD570-wk-Fact-2723FD60FEF25491B7840621001DD570">12979414</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q2" name="us-gaap:CommonStockSharesIssued" id="Fact-2F05C60051DC56678DCD5D7602BEC761-wk-Fact-2F05C60051DC56678DCD5D7602BEC761">12979414</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2016Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-29DFE6C8D6015A049C61FE7FBF29E902-wk-Fact-29DFE6C8D6015A049C61FE7FBF29E902">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2017Q2" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-5372D56CFF4752869E4B19D5A4F58D59-wk-Fact-5372D56CFF4752869E4B19D5A4F58D59">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2016Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-9F3BECED263E569B89C87060F95A5AAD-wk-Fact-9F3BECED263E569B89C87060F95A5AAD">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q2" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-8E28A08DFB95526DBEE8EFE82A6D9237-wk-Fact-8E28A08DFB95526DBEE8EFE82A6D9237">5000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2016Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-11CB6C4AA1F45EB984064FACA08BEACA-wk-Fact-11CB6C4AA1F45EB984064FACA08BEACA">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q2" name="us-gaap:PreferredStockSharesIssued" id="Fact-49A839F4F1265C7C98CF72620B409640-wk-Fact-49A839F4F1265C7C98CF72620B409640">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2016Q4" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-764D0CEE7B085412B27E2AC5B72156E5-wk-Fact-764D0CEE7B085412B27E2AC5B72156E5">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q2" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-835E0D5FD9445209BF14DF67B4237412-wk-Fact-835E0D5FD9445209BF14DF67B4237412">0</ix:nonFraction><ix:nonNumeric contextRef="D2016Q2Apr08-Apr08_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-7FDAA9058813378A24658B0B22CE1D7C-wk-Fact-7FDAA9058813378A24658B0B22CE1D7C">P3Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2016Q4" name="us-gaap:TreasuryStockShares" id="Fact-D46EC1FFD59F593FAC078ADAE260AB76-wk-Fact-D46EC1FFD59F593FAC078ADAE260AB76">1692218</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2017Q2" name="us-gaap:TreasuryStockShares" id="Fact-B13112F0353E52AB832B9353CDD981FC-wk-Fact-B13112F0353E52AB832B9353CDD981FC">1637524</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="nhtc-20170630.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="FD2017Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3jul28-jul28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:MunicipalBondsAndNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:MunicipalBondsAndNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:FinancialInstitutionInstrumentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:FinancialInstitutionInstrumentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q2Apr07_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-04-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2Apr08-Apr08_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-08</xbrli:startDate>
			<xbrli:endDate>2016-04-08</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2015Q3Jul28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1jan24-jan24">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-24</xbrli:startDate>
			<xbrli:endDate>2017-01-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q1Jan12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-01-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Apr24-Apr24">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-24</xbrli:startDate>
			<xbrli:endDate>2017-04-24</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">nhtc:SecuritiesClassActionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-02-01</xbrli:startDate>
			<xbrli:endDate>2013-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-29</xbrli:startDate>
			<xbrli:endDate>2015-04-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000912061</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-31</xbrli:startDate>
			<xbrli:endDate>2017-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="complaint">
		<xbrli:measure>nhtc:complaint</xbrli:measure>
	</xbrli:unit></ix:resources></ix:header></div><div><a id="s72D1CD55C9AB54B9B4039CBA6AFF4513"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM </span><span><ix:nonNumeric id="d140105964e333-wk-Fact-CC935D88AB7C5EAAB87E4B17208D2DFF" name="dei:DocumentType" contextRef="FD2017Q2YTD"><span style="font-size:12pt;font-weight:bold;">10-Q</span><span style="font-size:12pt;">&#160;</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:12pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Mark One)</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">&#254;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the quarterly period ended </span><span style="font-family:inherit;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d140105964e369-wk-Fact-7F008383D95E577AB90E6473978DD8AB" name="dei:DocumentPeriodEndDate" contextRef="FD2017Q2YTD" format="ixt:datemonthdayyearen">June 30, 2017</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">OR</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the transition period from ______ to _______</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commission File Number: 001-36849</span></div><div style="line-height:120%;padding-top:13px;text-align:center;font-size:18pt;"><span><ix:nonNumeric id="d140105964e410-wk-Fact-5898EDAC997057C5A024EB1AF5B90E66" name="dei:EntityRegistrantName" contextRef="FD2017Q2YTD"><span style="font-size:18pt;font-weight:bold;">NATURAL HEALTH TRENDS CORP.</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:18pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Delaware</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59-2705336</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(State or other jurisdiction of</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(I.R.S.&#160;Employer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">incorporation or organization)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">609 Deep Valley Drive</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Suite 395</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rolling Hills Estates, California  90274</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Address of principal executive offices, including zip code)</span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Registrant&#8217;s telephone number, including area code:  (310) 541-0888</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </span><span style="font-family:Wingdings;font-size:10pt;">&#254;</span><span style="font-family:inherit;font-size:10pt;"> No </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for shorter period that the registrant was required to submit and post such files).&#160;Yes </span><span style="font-family:Wingdings;font-size:10pt;">&#254;</span><span style="font-family:inherit;font-size:10pt;"> No </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):&#160;</span></div><div style="line-height:120%;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Large accelerated filer </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accelerated filer </span><span style="font-family:Wingdings;font-size:10pt;">&#254;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-accelerated filer&#160;&#160; </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Smaller&#160;reporting company </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging growth company </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:10pt;">o</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="font-family:Wingdings;font-size:10pt;">o</span><span style="font-family:inherit;font-size:10pt;"> No </span><span style="font-family:Wingdings;font-size:10pt;">&#254;</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At July 28, 2017, the number of shares outstanding of the registrant&#8217;s common stock was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140105964e584-wk-Fact-47742066D4C05B6E9346B5A19EE38B24" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2017Q3jul28-jul28" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,341,890</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sA33D714679745778BCDA8BA9DCAADF23"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURAL HEALTH TRENDS CORP.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Report on Form 10-Q</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">June&#160;30, 2017</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX&#160;</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:86%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Page</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB7D81079DC905B41A7E3FCCB61F8D32C"><span style="font-family:inherit;font-size:10pt;">PART I - FINANCIAL INFORMATION</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E449C16C62C5E59BB1D373BF675400D"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E449C16C62C5E59BB1D373BF675400D"><span style="font-family:inherit;font-size:10pt;">Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3E449C16C62C5E59BB1D373BF675400D">1</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s85F837BC586B5C94B939AAAC528E04C0"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s85F837BC586B5C94B939AAAC528E04C0"><span style="font-family:inherit;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s85F837BC586B5C94B939AAAC528E04C0">12</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38ABB05876A05EDEBC3825FB27CEAFDC"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38ABB05876A05EDEBC3825FB27CEAFDC"><span style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s38ABB05876A05EDEBC3825FB27CEAFDC">18</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C69928E3CCD58E6A6FD4FB6E754B796"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C69928E3CCD58E6A6FD4FB6E754B796"><span style="font-family:inherit;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5C69928E3CCD58E6A6FD4FB6E754B796">19</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB386BDC638A850858002BFB7DEEA4091"><span style="font-family:inherit;font-size:10pt;">PART II - OTHER INFORMATION</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC632A3E02B3B5BD8B65086AEE2D95CA6"><span style="font-family:inherit;font-size:10pt;">Item 1.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC632A3E02B3B5BD8B65086AEE2D95CA6"><span style="font-family:inherit;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC632A3E02B3B5BD8B65086AEE2D95CA6">20</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s69571EBE31A156348F6CB86F3EB715C8"><span style="font-family:inherit;font-size:10pt;">Item 1A.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s69571EBE31A156348F6CB86F3EB715C8"><span style="font-family:inherit;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s69571EBE31A156348F6CB86F3EB715C8">20</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s049D147CFF2E584E992D9EDF4EEDA282"><span style="font-family:inherit;font-size:10pt;">Item 2.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s049D147CFF2E584E992D9EDF4EEDA282"><span style="font-family:inherit;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4FC4B5BD240551269A50732B281DD54E">20</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4B60F855CF6052FB8AFB8F3E7CF6A597"><span style="font-family:inherit;font-size:10pt;">Item 3.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4B60F855CF6052FB8AFB8F3E7CF6A597"><span style="font-family:inherit;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4B60F855CF6052FB8AFB8F3E7CF6A597">21</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s316AB8A1A50151199159D38A03C415F9"><span style="font-family:inherit;font-size:10pt;">Item 4.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s316AB8A1A50151199159D38A03C415F9"><span style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s316AB8A1A50151199159D38A03C415F9">21</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA6E767A16B3E5E4F9C0B6EBB843650C5"><span style="font-family:inherit;font-size:10pt;">Item 5.</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA6E767A16B3E5E4F9C0B6EBB843650C5"><span style="font-family:inherit;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA6E767A16B3E5E4F9C0B6EBB843650C5">21</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4A5EC12823975A2DBD04A12538155A46"><span style="font-family:inherit;font-size:10pt;">Item 6.</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4A5EC12823975A2DBD04A12538155A46"><span style="font-family:inherit;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s4A5EC12823975A2DBD04A12538155A46">21</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAD535F987ECE546CA30D6280844C6094"><span style="font-family:inherit;font-size:10pt;">Signatures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAD535F987ECE546CA30D6280844C6094">22</a></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s0A2081CE77765D72955B66835D3A0AE6"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This Quarterly Report on Form 10-Q, in particular &#8220;Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; includes &#8220;forward-looking statements&#8221; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). When used in this report, the words or phrases &#8220;will likely result,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;will continue,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;believe&#8221; and similar expressions are intended to identify &#8220;forward-looking statements&#8221; within the meaning of the Exchange Act. These statements represent our expectations or beliefs concerning, among other things, future revenue, earnings, growth strategies, new products and initiatives, future operations and operating results, and future business and market opportunities.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward-looking statements in this report speak only as of the date hereof, and forward-looking statements in documents incorporated by reference speak only as of the date of those documents. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. We caution and advise readers that these statements are based on certain assumptions that may not be realized and involve risks and uncertainties that could cause actual results to differ materially from the expectations and beliefs contained herein.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For a summary of certain risks related to our business, see &#8220;Item 1A. Risk Factors&#8221; in our most recent Annual Report on Form 10-K, which includes the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We could be adversely affected by management changes or an inability to attract and retain key management, directors and consultants;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Because our Hong Kong operations account for a substantial portion of our overall business, and substantially all of our Hong Kong business is derived from the sale of products to members in China, any material adverse change in our business relating to either Hong Kong or China would likely have a material adverse impact on our overall business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Our operations in China are subject to compliance with a myriad of applicable laws and regulations, and any actual or alleged violations of those laws or government actions otherwise directed at us could have a material adverse impact on our business and the value of our company;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Our failure to maintain and expand our member relationships could adversely affect our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We are currently being sued in three lawsuits alleging, among other things, that we made materially false and misleading statements regarding the legality of our business operations in China;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We are currently involved in, and may in the future face, litigation claims and governmental proceedings and inquiries that could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Although our members are independent contractors, improper member actions that violate laws or regulations could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Direct-selling laws and regulations may prohibit or severely restrict our direct sales efforts and cause our revenue and profitability to decline, and regulators could adopt new regulations that harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">The high level of competition in our industry could adversely affect our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Challenges by third parties to the legality of our business operations could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">An increase in the amount of compensation paid to members would reduce profitability;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Currency exchange rate fluctuations could lower our revenue and net income;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Changes in tax or duty laws, and unanticipated tax or duty liabilities, could adversely affect our net income;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Transfer pricing regulations affect our business and results of operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Our products and related activities are subject to extensive government regulation, which could delay, limit or prevent the sale of some of our products in some markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Failure of new products to gain member and market acceptance could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">New regulations governing the marketing and sale of nutritional supplements could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Regulations governing the production and marketing of our personal care products could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">If we are found not to be in compliance with good manufacturing practices our operations could be harmed;</span></div></td></tr></table><div><br/></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Failure to comply with domestic and foreign laws and regulations governing product claims and advertising could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Adverse publicity associated with our products, ingredients or network marketing program, or those of similar companies, could harm our financial condition and operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to risks relating to product concentration and lack of revenue diversification;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We rely on a limited number of independent third parties to manufacture and supply our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Growth may be impeded by the political and economic risks of entering and operating foreign markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We may be held responsible for certain taxes or assessments relating to the activities of our members, which could harm our financial condition and operating results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We may be unable to protect or use our intellectual property rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We do not have a comprehensive product liability insurance program and product liability claims could hurt our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Our internal controls and accounting methods may require modification;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">If we fail to achieve and maintain an effective system of internal controls in the future, we may not be able to accurately report our financial results or prevent fraud.&#160;As a result, investors may lose confidence in our financial reporting;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We rely on and are subject to risks associated with our reliance upon information technology systems;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">System failures and attacks could harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Terrorist attacks, cyber-attacks, acts of war, epidemics or other communicable diseases or any other natural disasters may seriously harm our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Because our systems, software and data reside on third-party servers, our access could be temporarily or permanently interrupted;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">We may experience substantial negative cash flows, which may have a significant adverse effect on our business and could threaten our solvency;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">If we experience negative cash flows, we may need to seek additional debt or equity financing, which may not be available on acceptable terms or at all.&#160;If available, it could have a highly dilutive effect on the holdings of existing stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Disappointing quarterly revenue or operating results could cause the price of our common stock to fall;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock is particularly subject to volatility because of the industry in which we operate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock continues to experience wide fluctuations in trading volumes and prices. This may make it more difficult for holders of our common stock to sell shares when they want and at prices they find attractive; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">Future sales by us or our existing stockholders could depress the market price of our common stock.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional factors that could cause actual results to differ materially from our forward-looking statements are set forth in this report, including under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and in our financial statements and the related notes.</span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sB7D81079DC905B41A7E3FCCB61F8D32C"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s3E449C16C62C5E59BB1D373BF675400D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;&#160;</span></div><div><a id="s9B69757750A55DEBAE582ACB3520AE44"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURAL HEALTH TRENDS CORP.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share data)</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Unaudited)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ASSETS</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e523-wk-Fact-3AA82854F4645D1AB8EF2F2C66F367FA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e542-wk-Fact-A2AA8FBEA98E5148B2B2DF86BC44772E" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e557-wk-Fact-C3892C3D315C53C6B25F942DE2609AED" name="us-gaap:InventoryNet" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e576-wk-Fact-CA40D84676FE51C69BEF362012C658B4" name="us-gaap:InventoryNet" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e596-wk-Fact-1AF2A66C40DD53968850E52A749E9E7E" name="us-gaap:OtherAssetsCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e615-wk-Fact-E9F8DD8F7D9757A8B232DD4FA64E5062" name="us-gaap:OtherAssetsCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e635-wk-Fact-A11727D52D005F0EA2256E34BFD26876" name="us-gaap:AssetsCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">149,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e654-wk-Fact-1992C72F5A96537AA85B2B606760B9E1" name="us-gaap:AssetsCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e674-wk-Fact-8833098BC9D4566AADBAA98CD898225D" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e693-wk-Fact-3E0D4410D6A3573AB73FADD5487DE8FC" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e713-wk-Fact-1FBD9C55DAED56359FC74F25A0D735F2" name="us-gaap:Goodwill" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e732-wk-Fact-293E31DB5FD250CD855D78EBA2264D53" name="us-gaap:Goodwill" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e752-wk-Fact-2380E4EE1D47588C8F8CDAB7A188B700" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e771-wk-Fact-CEBD8310F93B521FBAD3C2D46179B4BE" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,963</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e792-wk-Fact-C1DDE47B74975713BE0A5C63480AA60D" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e811-wk-Fact-2CF98BCCEAF75E8386826D9F88AD1D16" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">692</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e836-wk-Fact-8513E9E21B745A1FB997624E2EF10F66" name="us-gaap:Assets" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e855-wk-Fact-7EB1190A4B635A1A85F18337885A834C" name="us-gaap:Assets" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">148,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e957-wk-Fact-1C9365259CC859659838F14C0D408B4C" name="us-gaap:AccountsPayableCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e976-wk-Fact-A4F687A68956522894DB87C2ECB4A426" name="us-gaap:AccountsPayableCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e991-wk-Fact-910DC38D62CA5AF4862F98088CF510EC" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1010-wk-Fact-01BD7D4DF303542190CFC58185DA6A0B" name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">663</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued commissions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1030-wk-Fact-27463135780C5AB095B3C44C998B5370" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1049-wk-Fact-2FF0793CA2A75B7A978C31604D0EC9FA" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1069-wk-Fact-359548B1D77C57B684BDEA3F8F35201F" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1088-wk-Fact-8C9710A778E9599096A351B362BA4521" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1108-wk-Fact-9D3CAF31D16A588DA7F9C3244ABDBF2B" name="us-gaap:DeferredRevenueCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1127-wk-Fact-AD2E7EA24D6B541E8BED8AA07A7F5C98" name="us-gaap:DeferredRevenueCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,948</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts held in eWallets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1147-wk-Fact-E18824088544586B858EA6B0088E03A3" name="us-gaap:OtherDeferredCreditsCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1166-wk-Fact-788AA76BE68A57509100D6352810F0DB" name="us-gaap:OtherDeferredCreditsCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1186-wk-Fact-96C2F0CD2DA7579C8771A832B058DBDD" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1205-wk-Fact-B5F8DC4ECF9358B98F2F733C7599A61E" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,633</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1226-wk-Fact-9B92F8B30E2A537DA9CD736BCC157131" name="us-gaap:LiabilitiesCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">54,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1245-wk-Fact-2A5BEBF47A545C35A27CDEA2FB634FA7" name="us-gaap:LiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1265-wk-Fact-93C34655C1CA5982955975E545E73B07" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1284-wk-Fact-5EBCE7D251265DDA9C08DF60F553F9EE" name="us-gaap:DeferredTaxLiabilitiesNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term incentive</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1304-wk-Fact-EAAF18B446C0578BB4CB70E36667D353" name="us-gaap:DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1323-wk-Fact-5409876514B55214AFD303879D5AD5D3" name="us-gaap:DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1343-wk-Fact-9CE69A9F8BE95B8792A8674ADAF54918" name="us-gaap:Liabilities" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1362-wk-Fact-11150E6FF15559F19AB72F8F5C620007" name="us-gaap:Liabilities" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commitments and contingencies (Note 8)</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1382-wk-Fact-A4159D55600159A2B5F07DA371703F6C" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2017Q2" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1401-wk-Fact-C42933BABE8C53DCA84F486D1AB65BB6" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2016Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1462-wk-Fact-7C2CEFD47A705A74AC812689C1D51ECE" name="us-gaap:PreferredStockValue" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1481-wk-Fact-F3B0BB396A4C5022A0A186D5BE127855" name="us-gaap:PreferredStockValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1501-wk-Fact-9BCEA8069B3550CCB11FE6F256AC7E48" name="us-gaap:CommonStockValue" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1520-wk-Fact-4ECECC92B2CA546597F0990DD76F4FD8" name="us-gaap:CommonStockValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1540-wk-Fact-F2FF25620A2B5CDBBDAB799B9724275E" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1559-wk-Fact-622ECBFCDDE65C9C89AFCA24BAB4F4A1" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">86,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Retained earnings</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1579-wk-Fact-11598074D26C5835BAB6C0D2CB1F7405" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1598-wk-Fact-D75755ED70BA55FE882785BB151726A8" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">38,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108584e1618-wk-Fact-30B39A386426516DB0029ACA843E2490" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108584e1638-wk-Fact-94ADD82D1FF754DC991BE04AB2AF63A8" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108584e1660-wk-Fact-395E2A4DB30C588DB36098BA5203F1DF" name="us-gaap:TreasuryStockValue" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108584e1680-wk-Fact-90E3E830EF0F592B83745CFC011F5C94" name="us-gaap:TreasuryStockValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,889</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1701-wk-Fact-D09DE923BA2758AFA3BCEB4BBDC1C702" name="us-gaap:StockholdersEquity" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94,399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1720-wk-Fact-05A423782CD25002B98C997AB4803800" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1745-wk-Fact-34C94BCF069B5AB5B0713CFF2FDD1667" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108584e1764-wk-Fact-3FDB436DB9CE58C18CE48E1955E10167" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">148,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5FA91464CC1D594087001E3A0D8DA881"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURAL HEALTH TRENDS CORP.&#160;</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except per share data)</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e530-wk-Fact-19EDD3862600543FAA77FE93F6DE68F8" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e549-wk-Fact-118DB6B34C9D580B877EF776E4066E90" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80,391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e568-wk-Fact-10703331B9675673A80158339141914E" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">111,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e588-wk-Fact-AC707A81DB3E58A8A0E3CA19E072D3D4" name="us-gaap:SalesRevenueGoodsNet" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e603-wk-Fact-E1FBFDD077915042BB3F994736D63341" name="us-gaap:CostOfGoodsSold" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,793</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e622-wk-Fact-6BEAAD2188445DD68F8670A0BDE5B977" name="us-gaap:CostOfGoodsSold" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e641-wk-Fact-9625AC4DB0B5582B82DF4CB2C2639F8C" name="us-gaap:CostOfGoodsSold" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e661-wk-Fact-88EF8E76940153B38CA4712BB088D742" name="us-gaap:CostOfGoodsSold" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e681-wk-Fact-18F52E88BF63541C95E521118495BDA2" name="us-gaap:GrossProfit" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">41,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e700-wk-Fact-52F0CE528A035024AF67A9413ED2713D" name="us-gaap:GrossProfit" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e719-wk-Fact-7436575141CC50EE85B1339013A72172" name="us-gaap:GrossProfit" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e739-wk-Fact-FD34310F69D750D39AE42602530ABD68" name="us-gaap:GrossProfit" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commissions expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e841-wk-Fact-2126BD95B22E522598652CF2D2B10F46" name="us-gaap:SalesCommissionsAndFees" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e860-wk-Fact-CEE2B304A0B15A11A84A33F19309D1E6" name="us-gaap:SalesCommissionsAndFees" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e879-wk-Fact-CFA7559DEB095EE68F507BBC9CFDFEBF" name="us-gaap:SalesCommissionsAndFees" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e899-wk-Fact-64F1FB144EA85820B4D8D062ACE1C5BA" name="us-gaap:SalesCommissionsAndFees" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e919-wk-Fact-B8480EEB3EC85D189D9172077E33958B" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,590</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e938-wk-Fact-EE91CB9297E25C279B2381BF288CF876" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e957-wk-Fact-09BBDF58479F59EC84495EAABC5F260A" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e977-wk-Fact-7ED76C85FEAC5BCEB59D8F3DFBB1BB44" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e997-wk-Fact-7E70A531D35A5E58A2B942B2132A172E" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1016-wk-Fact-C93ED2AEC9475C3B93AF402B6089E934" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1035-wk-Fact-67EB13EF9DA659DF95DD03879711A654" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1055-wk-Fact-56E27883658B5E1F898F4EE0BBF3FBA4" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1075-wk-Fact-18E8D481BD815D41A45D5DC94DA7CD8E" name="us-gaap:OperatingExpenses" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1094-wk-Fact-078B151574A4508296DAC94FC8294F7D" name="us-gaap:OperatingExpenses" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,405</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1113-wk-Fact-DCF123B4894152BA9D108B22E1D5798F" name="us-gaap:OperatingExpenses" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">64,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1133-wk-Fact-4E7BB785C18653BCA053ACA154C55E9B" name="us-gaap:OperatingExpenses" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">96,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1153-wk-Fact-3A195B7F7B705C2BB7895F4B2BDDE2B5" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1172-wk-Fact-7E915E69CFCB561381959593BBCBB024" name="us-gaap:OperatingIncomeLoss" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1191-wk-Fact-3881E0529B4654419030175D014B2853" name="us-gaap:OperatingIncomeLoss" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,859</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1211-wk-Fact-6AB128F1DCC35C15A3D57D90EF21E64F" name="us-gaap:OperatingIncomeLoss" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1232-wk-Fact-434FE4CAFB1A55E290DBFF644851F2CF" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1251-wk-Fact-FC4F361559C755B5B466E30C78235DDF" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1270-wk-Fact-BC5C58595419554BB014B8247D720764" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140110624e1290-wk-Fact-D70B273BA14E594090337860B52BC45F" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1311-wk-Fact-B1CE882C14F552F783B81577281E564A" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1330-wk-Fact-4F9BC74FD8065CD8A602ACA28839C438" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,943</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1349-wk-Fact-B0886BC91812547AA43B90AB2C888261" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1369-wk-Fact-6248EE52061853FD9441BEBC2D57D061" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1389-wk-Fact-DD9A1FF729135378B790097B57C86BAA" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1408-wk-Fact-2452C9E617655DF996BACC121FC8E5B2" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1427-wk-Fact-4EFFE706DCDB5C14BF042C7587221669" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1447-wk-Fact-6E50736E919850FD9D380DD0B1213BCC" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1472-wk-Fact-D61402E6386B5C61B3849B9F0DCF9F22" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1491-wk-Fact-DF72591BFB29537FBDB5F63B4DBCACB5" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1510-wk-Fact-FDB9EDA593AA50B180B5D35A4B8A57FF" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1530-wk-Fact-6F6E769DCE635A8CABA8AA041D956C79" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income per common share:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1632-wk-Fact-FBACBE76C19E51CC99DB4928E995AF32" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1651-wk-Fact-AAD38C082ED154B7B796EF0670C263F2" name="us-gaap:EarningsPerShareBasic" contextRef="FD2016Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1670-wk-Fact-38443D75E9DD543F99E829329809E8F9" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1690-wk-Fact-7C6568F703C05D17AF158FD73D17F193" name="us-gaap:EarningsPerShareBasic" contextRef="FD2016Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1710-wk-Fact-8668D6CDF5025FE3BA7A8F58844DA616" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1729-wk-Fact-C2A89157206D5BE09D1792A84B8FF350" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2016Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1748-wk-Fact-4AEEBC57085E50509438D69D785C316E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1768-wk-Fact-1F89FCF28B465D52937865903C7BDE05" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2016Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average number of common shares outstanding:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1865-wk-Fact-F27EE613B03C529FAA1DA48DDEF41D21" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1884-wk-Fact-9D22B566BD3259B6B981DB468373FAE5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1903-wk-Fact-319773D3A7055A938DC73A32DEA77711" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1923-wk-Fact-08CEF2868AB95027B651C8C44CF023A1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1943-wk-Fact-B47A8C791E6D53959FE8EA71B94B688D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1962-wk-Fact-6D49C0B279A75205BFE9396C6E3F858C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,359</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e1981-wk-Fact-710C76C6816A567E9C9D7E636DA87F20" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e2001-wk-Fact-3729BD5585A35D6E93600443EC04AA33" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash dividends declared per common share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e2026-wk-Fact-67B0D700CD8658428C195857773236B5" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="FD2017Q2QTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e2045-wk-Fact-C513F47104A353FA904F998ABE9042B2" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="FD2016Q2QTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e2064-wk-Fact-CFA2588D329857EFA585E012C0FB94AC" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="FD2017Q2YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140110624e2084-wk-Fact-98AFEC15B83E5F2FA8548FC6AC5C2849" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="FD2016Q2YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s557F53F20CEB53E9838E001680A16994"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURAL HEALTH TRENDS CORP.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e531-wk-Fact-D61402E6386B5C61B3849B9F0DCF9F22" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e550-wk-Fact-DF72591BFB29537FBDB5F63B4DBCACB5" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e569-wk-Fact-FDB9EDA593AA50B180B5D35A4B8A57FF" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e589-wk-Fact-6F6E769DCE635A8CABA8AA041D956C79" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss), net of tax:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e686-wk-Fact-5AAED4E89C9955548441660101032048" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e705-wk-Fact-E9CD31AF417B5EC08DC63FD505AF90EA" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e725-wk-Fact-C380429C12C551CDADB0C6A5E68B1D1F" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e745-wk-Fact-F12C496D555F524FA738A86F3C84D07E" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Release of cumulative translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e766-wk-Fact-FF1C6573449A52A2B7876263BB3F01C6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e785-wk-Fact-03325943F3D95B42BFC2F1D337EC76A0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e804-wk-Fact-ED56B829A9D35F7886D2C9002FE046FF" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e825-wk-Fact-DB0876E2F40859B6B7E94D2C683DB55D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net change in foreign currency translation adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e845-wk-Fact-55D14D5384525744B349B6193EC6D1A8" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e864-wk-Fact-4CBB89A5539C564AA5AF3819B210493F" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e884-wk-Fact-209134B29D2C513891537F098AF98088" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e905-wk-Fact-A6E2A9CE019F5B42885D332B8DEF104B" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized gains (losses) on available-for-sale securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e926-wk-Fact-99EF4E60B0A45C4FB960914662E3D925" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e945-wk-Fact-61A24CED9D0E547D81D05EB12DA76E96" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140108581e965-wk-Fact-BC76D84C67E154E6B4EB0000DCE0C785" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e986-wk-Fact-04105E7E589F594C8D40471C3710DD4E" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e1011-wk-Fact-184AC27D51995C8CA70B9C0465F6BE8B" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e1030-wk-Fact-BAE98B2FCCD05DBC85C369645C34B9C2" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e1049-wk-Fact-617095AFD85155128F3F81E467564CF3" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140108581e1069-wk-Fact-4D92E2A167275EB3A5922F3F6090AD6E" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s606E6B631CDB5A2488C4CB8CDB0182BF"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURAL HEALTH TRENDS CORP.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e481-wk-Fact-FDB9EDA593AA50B180B5D35A4B8A57FF" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e500-wk-Fact-6F6E769DCE635A8CABA8AA041D956C79" name="us-gaap:NetIncomeLoss" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e556-wk-Fact-C3CB49480FE151DC97AC4DFBFD783BB7" name="us-gaap:Depreciation" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e575-wk-Fact-C17A1553321B58C79B2BA2BF3CF91B88" name="us-gaap:Depreciation" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e595-wk-Fact-AAA7961F57765A88B04EFF2CEBA840E6" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e614-wk-Fact-C7DFCDD33A645CD3824820C753A4CF83" name="us-gaap:ShareBasedCompensation" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cumulative translation adjustment realized in net income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e634-wk-Fact-F945138E37575EEDAD1CA72DA410796F" name="nhtc:CumulativeTranslationAdjustmentRealizedInNetIncome" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e654-wk-Fact-2E5D94AD790352318D518A538E87F598" name="nhtc:CumulativeTranslationAdjustmentRealizedInNetIncome" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e715-wk-Fact-72F923B26BE9501C87CE352A642C96BC" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e734-wk-Fact-D5A31F3103FA522FA0E5F7D09A55A490" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e755-wk-Fact-CDFC399539A853B5A362CBEC51516CB7" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e774-wk-Fact-929C61A92C475D9DA3D1C9E5C26941A1" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e796-wk-Fact-1E1D68D2BCF254AB973B284711948415" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e816-wk-Fact-8C0F9FBAFDA152E0AB09172E7B6487FD" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e836-wk-Fact-F285910711FB579A957F7E6536FBF3B9" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e855-wk-Fact-1C9C4875BD9858E2B2F8991DA1EB795B" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">665</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes payable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e875-wk-Fact-F3BE8BEADB085710884D61CE1FC3838B" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e894-wk-Fact-91AF54D9286952C9BD6C760B35E6757A" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">487</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued commissions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e914-wk-Fact-86CC265A893550C9818D8B4AFAFB7340" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e934-wk-Fact-9AF36A05478D5487A8867D5E9A8E9D32" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e955-wk-Fact-5FEDBA088C3D53F78D2AD850E47F726A" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e975-wk-Fact-2A20AA77717E5E2094EE5EE062F5CC00" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e995-wk-Fact-1D08560749DC5675B96017C7E214BDDB" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">939</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1015-wk-Fact-D1F2E0EB290C5121B8587D9CCD17031A" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,816</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts held in eWallets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1035-wk-Fact-C34EB581A27458BF9C33AAC6E47CCDCC" name="us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">327</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1055-wk-Fact-A8435CDC47BD53E9B278F436896E775E" name="us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1075-wk-Fact-5FB7D006114B58D9A7812549CF934F6E" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1095-wk-Fact-33089CDC7DDD5E65B5E325EA516792F8" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term incentive</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1115-wk-Fact-5CDD1F30565252EC8672206F2DB14A94" name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1135-wk-Fact-E137E5BD41595B8C841A534433FF2FD8" name="us-gaap:IncreaseDecreaseInDeferredCompensation" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">506</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1156-wk-Fact-F2F7F3EE976D56BCB6948530AD2E3701" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,629</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1175-wk-Fact-C4ECC46C7F1F5284886183304ADAAF01" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1237-wk-Fact-72876B38D29358E5ABEC2A52CD579EC6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1257-wk-Fact-BAAC0AA05D275110B9595E79C7356BCB" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1278-wk-Fact-D134BF3E0BFA518F88969A63928990D1" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1298-wk-Fact-AD38695C86BA5394A7F1677F04BFCC34" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Repurchase of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1360-wk-Fact-1ACB4BCD50F7542EBDAAD42383BECD69" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1379-wk-Fact-6B5C0D1193295197A18A777B1A06F932" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividends paid</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1400-wk-Fact-45938F983B8D51FE919F635605AE926B" name="us-gaap:PaymentsOfDividends" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1420-wk-Fact-C8390782BC735C8BA5ABED202F93B35E" name="us-gaap:PaymentsOfDividends" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1441-wk-Fact-7A9BEB25595857B68B2B65071C3CC84E" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1461-wk-Fact-EF8559A2C9C55B94BBFD38A4006AF330" name="us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">24,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of exchange rates on cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1482-wk-Fact-C43A56C3A05D528EB3E2F20203D7F1CF" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140112316e1502-wk-Fact-109F3D16D34D509C899D2F2CCAF1A741" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1523-wk-Fact-9F87D6EFA2CF56F5918CACC311FB5012" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1542-wk-Fact-84AB090FF3D75EF9824209052D7EB57D" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,735</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CASH AND CASH EQUIVALENTS, beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1562-wk-Fact-A2AA8FBEA98E5148B2B2DF86BC44772E" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1581-wk-Fact-F7C88DE6505C5CFEA429FF8C91B8F8C2" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2015Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">104,914</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CASH AND CASH EQUIVALENTS, end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1606-wk-Fact-3AA82854F4645D1AB8EF2F2C66F367FA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1625-wk-Fact-DA660D4D08295F82824AF5E6E84A52C7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">109,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Issuance of treasury stock for employee awards, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1687-wk-Fact-521233C58CC5551BABBB52031E6A7B2F" name="us-gaap:StockIssued1" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140112316e1706-wk-Fact-042E2971234050B7A9FB5E55D3B179E0" name="us-gaap:StockIssued1" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6F354A4B11BD565B962495D3E42A0BFF"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NATURAL HEALTH TRENDS CORP.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sBB9DBB2793C25E6B99867B79B94DBF45"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1.&#160;<ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="TextSelection-AA3CD9FEA0BC5C9188030139D4819B2F-0-wk-Fact-1CBC66B36C075730AED2041C52CA6F3F" continuedAt="TextSelection-AA3CD9FEA0BC5C9188030139D4819B2F-1" escape="true">NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION</ix:nonNumeric></span></div><ix:continuation id="TextSelection-AA3CD9FEA0BC5C9188030139D4819B2F-1" continuedAt="TextSelection-AA3CD9FEA0BC5C9188030139D4819B2F-2"><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Operations</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural Health Trends Corp. (the &#8220;Company&#8221;), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and &#8220;quality of life&#8221; products under the &#8220;NHT Global&#8221; brand.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company&#8217;s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company&#8217;s 2016 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-4F7FC6D8F39F56DDA1313E30E71232EA-0-wk-Fact-149BA93DD0FE55FA824FDA7F97856BD0" continuedAt="TextSelection-4F7FC6D8F39F56DDA1313E30E71232EA-1" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4F7FC6D8F39F56DDA1313E30E71232EA-1" continuedAt="TextSelection-4F7FC6D8F39F56DDA1313E30E71232EA-2"><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-AA3CD9FEA0BC5C9188030139D4819B2F-2"><ix:continuation id="TextSelection-4F7FC6D8F39F56DDA1313E30E71232EA-2">The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</ix:continuation></ix:continuation></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sB1C1B5DE71A75667BD378F666093C7CB"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2. <ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-970EBE6DE1925947925A0ADE4C66387A-0-wk-Fact-85B499B7BBB95CDC945976F2687EF554" continuedAt="TextSelection-970EBE6DE1925947925A0ADE4C66387A-1" escape="true">ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-970EBE6DE1925947925A0ADE4C66387A-1" continuedAt="TextSelection-970EBE6DE1925947925A0ADE4C66387A-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company&#8217;s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as &#8220;lessees&#8221;, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-970EBE6DE1925947925A0ADE4C66387A-2" continuedAt="TextSelection-970EBE6DE1925947925A0ADE4C66387A-3"><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</span><span style="font-family:inherit;font-size:10pt;">. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.  </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Inventory: Simplifying the Measurement of Inventory.</span><span style="font-family:inherit;font-size:10pt;"> Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.&#160; Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.&#160; The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company&#8217;s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#160; It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.&#160; Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.&#160; In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-970EBE6DE1925947925A0ADE4C66387A-3">Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company&#8217;s present or future financial statements.</ix:continuation></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s7BE91ADD17515BAC8D0F1D9E99037762"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3. <ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-0-wk-Fact-F955B6DF3DC15ED7B52B388394A6AB7F" continuedAt="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-1" escape="true">NET INCOME PER COMMON SHARE</ix:nonNumeric></span></div><ix:continuation id="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-1" continuedAt="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-D89389B3408B58DAA596932B18659D05-0-wk-Fact-B2CF69829DC8539A98401959A29089AF" escape="true">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.</ix:nonNumeric></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e836-wk-Fact-D594914EC3AD52EB9E1CCD751FA111DA" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e850-wk-Fact-F27EE613B03C529FAA1DA48DDEF41D21" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e869-wk-Fact-FBACBE76C19E51CC99DB4928E995AF32" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e889-wk-Fact-4C15CCC8774259D38447FADF5992DE99" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e903-wk-Fact-9D22B566BD3259B6B981DB468373FAE5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e922-wk-Fact-AAD38C082ED154B7B796EF0670C263F2" name="us-gaap:EarningsPerShareBasic" contextRef="FD2016Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.08</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1068-wk-Fact-BEAFAB226B1F52BE89D96EA917AC0E29" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1121-wk-Fact-5DC1361012865C95901EAD58101EF9E5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2016Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1272-wk-Fact-6147BD709F6B536BB694AA7AC9205471" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1286-wk-Fact-B47A8C791E6D53959FE8EA71B94B688D" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1305-wk-Fact-8668D6CDF5025FE3BA7A8F58844DA616" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1325-wk-Fact-6130B523B9685517868A341CA020B320" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1339-wk-Fact-6D49C0B279A75205BFE9396C6E3F858C" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,359</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1358-wk-Fact-C2A89157206D5BE09D1792A84B8FF350" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2016Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.07</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-2" continuedAt="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-3"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-3"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1867-wk-Fact-1EA18075EDA0BEF30917F8DB94A49F51" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1881-wk-Fact-319773D3A7055A938DC73A32DEA77711" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1900-wk-Fact-38443D75E9DD543F99E829329809E8F9" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1920-wk-Fact-A5296EE4D907E0526C09F8DB945C5A1F" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1934-wk-Fact-08CEF2868AB95027B651C8C44CF023A1" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2016Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e1953-wk-Fact-7C6568F703C05D17AF158FD73D17F193" name="us-gaap:EarningsPerShareBasic" contextRef="FD2016Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2099-wk-Fact-6B38254AB7F761EB4C0AF8DB94CC1A6A" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2017Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2152-wk-Fact-FA6F882A485954C1155EF8DB95AEDC9B" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="FD2016Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2303-wk-Fact-B8FA38C05D3EA9E87D63F8DB9503B62A" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2317-wk-Fact-710C76C6816A567E9C9D7E636DA87F20" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2336-wk-Fact-4AEEBC57085E50509438D69D785C316E" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2356-wk-Fact-AC85A2865F77E1DBCBF9F8DB93FB4A7E" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2370-wk-Fact-3729BD5585A35D6E93600443EC04AA33" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2016Q2YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">11,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140114937e2389-wk-Fact-1F89FCF28B465D52937865903C7BDE05" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2016Q2YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s66DA0491F65F5ECC9C80B4389A10091A"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4. BALANCE SHEET COMPONENTS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock" id="TextSelection-49A4B293BADB5342948C20A6F2D13A65-0-wk-Fact-8EFB8A135F975C7D9CC69DA444076FB8" continuedAt="TextSelection-49A4B293BADB5342948C20A6F2D13A65-1" escape="true">The components of certain balance sheet amounts are as follows (in thousands):</ix:nonNumeric></span></div><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-49A4B293BADB5342948C20A6F2D13A65-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e438-wk-Fact-ADD66E252E2459018E069B9B5258314B" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e457-wk-Fact-4161C8E13F295A6CACA27C42E3D7D5C4" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">52,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e472-wk-Fact-5F79524428015B8BBB1C8E7B27534CF3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e491-wk-Fact-48778628390A52078FCA35C1D622DB7F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e516-wk-Fact-3AA82854F4645D1AB8EF2F2C66F367FA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e535-wk-Fact-A2AA8FBEA98E5148B2B2DF86BC44772E" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e596-wk-Fact-6E47884F95675448A6D92250AB43E1A4" name="nhtc:AccruedSalesReturns" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e615-wk-Fact-648A7E0F00A75F19880606B484BBD548" name="nhtc:AccruedSalesReturns" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e630-wk-Fact-41F252402B2451F2ABD76FDE9933FBD1" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e649-wk-Fact-567EB8E2324C5654A9FDC02EF5911901" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e669-wk-Fact-C9A5272CEBD055FBB338407ED8CC44F3" name="nhtc:AccruedWarehousingAndInventoryRelatedExpense" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e688-wk-Fact-BF76E790B02A565F91C5D76A1D73D7E8" name="nhtc:AccruedWarehousingAndInventoryRelatedExpense" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,816</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e713-wk-Fact-359548B1D77C57B684BDEA3F8F35201F" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140115433e732-wk-Fact-8C9710A778E9599096A351B362BA4521" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sE963FF018251535BA384F6DDF8E071EA"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5. <ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-CA8897956A1F5194ABF47EB547698EC0-0-wk-Fact-ABF49CB6010F51F8BDEB6692B8039CA4" continuedAt="TextSelection-CA8897956A1F5194ABF47EB547698EC0-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-CA8897956A1F5194ABF47EB547698EC0-1" continuedAt="TextSelection-CA8897956A1F5194ABF47EB547698EC0-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="TextSelection-10C62694C78D525091877436ACA4F7C2-0-wk-Fact-96DE4352E52E5B91A87A74B25B7639E8" continuedAt="TextSelection-10C62694C78D525091877436ACA4F7C2-1" escape="true">As of </ix:nonNumeric></span><ix:continuation id="TextSelection-10C62694C78D525091877436ACA4F7C2-1" continuedAt="TextSelection-10C62694C78D525091877436ACA4F7C2-2"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company&#8217;s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.&#160; Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-10C62694C78D525091877436ACA4F7C2-2"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders&#8217; equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.</ix:continuation></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-15A75ED0FE515E38A2FFAA72085FCB64-0-wk-Fact-8BAC3353B04458ADAC226DDE88EC6252" escape="true">The carrying amounts of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</ix:nonNumeric></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.&#160; The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-CA8897956A1F5194ABF47EB547698EC0-2" continuedAt="TextSelection-CA8897956A1F5194ABF47EB547698EC0-3"><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="TextSelection-3997CC6C5EE75EDE9F5FBEEFD08BFBB5-0-wk-Fact-506B1EDF693F5668B7B4C062C3DD9E15" continuedAt="TextSelection-3997CC6C5EE75EDE9F5FBEEFD08BFBB5-1" escape="true">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):</ix:nonNumeric></span></div><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-3997CC6C5EE75EDE9F5FBEEFD08BFBB5-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e655-wk-Fact-995E53AC9C905B54B54CD0D641033F0C" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e674-wk-Fact-0E1D1C5BD82E51F2858351A60B4309EC" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e693-wk-Fact-80361866D9BE5E2599E0698F00752E19" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e713-wk-Fact-E9DF4E8C0B8F5377A874E4942F34337B" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e732-wk-Fact-4C4CAEF1D8B055BEA851119F95DF912B" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e752-wk-Fact-95F5D842644B52C69AA4C98398F7650C" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e767-wk-Fact-B73F3666CE465087ACA63BAA01A36117" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,312</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140116371e786-wk-Fact-EF3F21B501B550EEAE8E461B03A02FED" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e806-wk-Fact-9A27E0C2A701570D8746169948E6AAC0" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e826-wk-Fact-5AE684A50E5D53B4BA77FB28828A69B2" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140116371e845-wk-Fact-2F92F22DA426568B803081F264380A73" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e865-wk-Fact-3A1A797C3AC357EC945D2260927C8153" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e886-wk-Fact-C9C8EF44DD4D5574A759D853938F9385" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e905-wk-Fact-C19E61808A3C5C64BC6245EE800334D9" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e924-wk-Fact-704BE284139A50B08F9CC7F19B7EB981" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e944-wk-Fact-69DF516653D15EC3A0D913B7DF0E69CF" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e963-wk-Fact-13EBD4A2F32355A1B30D82C9577DFA62" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e982-wk-Fact-5466F584218A57C48DED3960F1A5A1CC" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e1008-wk-Fact-0F613783AC655526992F914358E837B0" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140116371e1027-wk-Fact-94425517E9E35CC483D273269D150C33" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e1047-wk-Fact-AFC110069CDF5045A324B16BAE218D2A" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e1067-wk-Fact-23B2839937EA5FC79EA611EB8CCDDA34" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,470</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140116371e1086-wk-Fact-AE9171DEB4EB57909FC2E685B2387038" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140116371e1107-wk-Fact-A140FB09A5A259FCB6E8F93BF4BDA6AB" name="us-gaap:AvailableForSaleSecurities" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-CA8897956A1F5194ABF47EB547698EC0-3">Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.</ix:continuation></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1432BF9BE03E581FB5FBC612405876B1"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6<ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-0-wk-Fact-BA57C4FAD99B51FDA37420A5F54275E7" continuedAt="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-1" escape="true">. STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-1" continuedAt="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-2"><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:DividendsDeclaredTableTextBlock" id="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-0-wk-Fact-E94DB659DF27ED42403BF476DB9CAB6E" continuedAt="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-1" escape="true">The following table summarizes the Company&#8217;s cash dividend activity for the </ix:nonNumeric></span><ix:continuation id="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-1" continuedAt="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-2"><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></ix:continuation></div><ix:continuation id="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-2" continuedAt="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-3"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:19%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e453-wk-Fact-7B27CEF701E829ED2BD7F47B37795F82" name="nhtc:CommonStockSpecialDividendsPerShareDeclared" contextRef="D2017Q2Apr24-Apr24" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e472-wk-Fact-DEBF135DE69A86771020F47D0BD1139D" name="us-gaap:DividendsCommonStockCash" contextRef="D2017Q2Apr24-Apr24" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e513-wk-Fact-0117148D3D719A6BE967F47AB148E76E" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2017Q2Apr24-Apr24" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e532-wk-Fact-67385CD98D4F992BDAE4F47D0D5C90F4" name="us-gaap:DividendsCash" contextRef="D2017Q2Apr24-Apr24" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e578-wk-Fact-E51DFB4631FF0995C1B0F47A556330D6" name="nhtc:CommonStockSpecialDividendsPerShareDeclared" contextRef="D2017Q1jan24-jan24" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e597-wk-Fact-B2F394276D2F8C9B159EF47D0F73680E" name="us-gaap:DividendsCommonStockCash" contextRef="D2017Q1jan24-jan24" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,962</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e643-wk-Fact-DFF3F9A2B90D7D5A3637F47A28F36A4F" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2017Q1jan24-jan24" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e662-wk-Fact-491D3E207D1606453247F47D11443891" name="us-gaap:DividendsCash" contextRef="D2017Q1jan24-jan24" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,019</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e713-wk-Fact-7E011E9B459E01788D02F47CA66B0637" name="us-gaap:CommonStockDividendsPerShareCashPaid" contextRef="FD2017Q2YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e732-wk-Fact-B78FDDCC25FAF53B215DF47D3E935553" name="us-gaap:DividendsCash" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-3">Payment of any future dividends on shares of common stock will be at the discretion of the Company&#8217;s Board of Directors.</ix:continuation></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company&#8217;s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e776-wk-Fact-D3C00224E15C58E5BDABAE675A02E18D" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2015Q3Jul28" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e780-wk-Fact-1D5EFD2B18F15EB89FF05BCFF862D5D9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2016Q1Jan12" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company&#8217;s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e788-wk-Fact-34ACB83307545729BAE2776BB96A19CA" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="FI2017Q1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e792-wk-Fact-1D5EFD2B18F15EB89FF05BCFF862D5D9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2016Q1Jan12" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">70.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e806-wk-Fact-ACEB555003CD5BA299BFB01A84232C98" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q2QTD" unitRef="usd" decimals="-2" scale="0" format="ixt:numdotdecimal">8,600</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e810-wk-Fact-01FDC42BA45959FDAFDB4BA7BAA3ED91" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q2QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e822-wk-Fact-D59F6E2181323C57370EEECBB260A40A" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q2YTD" unitRef="usd" decimals="-2" scale="0" format="ixt:numdotdecimal">17,300</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e827-wk-Fact-1DABF51730BBB16C7A31EECC2C3BCDA1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2016Q2YTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">84,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the six months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company&#8217;s 2016 annual meeting of stockholders. The modification of the award resulted in an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e839-wk-Fact-FF5926FAADDF558FB33731E92E93BEB1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" contextRef="FD2017Q1QTD" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">64,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> in stock-based compensation expense for the three months ended March 31, 2016.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-2" continuedAt="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-3"><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company&#8217;s annual meeting of stockholders held on April 7, 2016, the Company&#8217;s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company&#8217;s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e848-wk-Fact-437C62F4CC9F5AB9A291F1B5D9C0D601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="I2016Q2Apr07_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e856-wk-Fact-38158A305A615CEFAD9B270256B8CA36" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2017Q2" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">2,393,873</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2016 Plan. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 24, 2017, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e865-wk-Fact-BA9DD32F196B5B7FAE0205737A962C2F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D2016Q2Apr08-Apr08_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">56,260</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e869-wk-Fact-ED27019DCA7354C3852E456E562AD498" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="D2017Q1jan24-jan24" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and are subject to forfeiture in the event of the employee&#8217;s termination of service to the Company under specified circumstances.  </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-8DBBA6AD563852E695F197EA41A92E27-0" continuedAt="TextSelection-8DBBA6AD563852E695F197EA41A92E27-1">The following table summarizes the Company&#8217;s restricted stock activity under the 2016 Plan:</ix:continuation></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><ix:continuation id="TextSelection-8DBBA6AD563852E695F197EA41A92E27-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:65%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e943-wk-Fact-56EB344B39F6545499999B9D617EC6C0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">38,256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e962-wk-Fact-F24DC685DE1C5BEC86F5E80AE9A490C8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">34.13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e977-wk-Fact-C483CECEA26D5F3290BCF4DD3F8E3767" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">56,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e991-wk-Fact-B348A5C91A8C553EABE7D814F4A89726" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">25.44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1011-wk-Fact-ADEF727F14E75C8BAC91F2DA43427602" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">17,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1026-wk-Fact-A8221C602D545AB8AFCDEC58C8399E95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">29.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1046-wk-Fact-35BE3DB744105DDD9F67CC6741C5199B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1061-wk-Fact-88AFC1319CD354CC92E47DD129CC8451" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1081-wk-Fact-14BABB04612252D3BC3FEA3F9DAD9969" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">75,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1095-wk-Fact-86EF8357F14F5B4DB5C4502C8A64B458" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="TextSelection-9980EA910A8D51E2BAC2F8316249E498-0-wk-Fact-09A739915ECF55CFA03081AC4F678059" continuedAt="TextSelection-9980EA910A8D51E2BAC2F8316249E498-1" escape="true">The following table summarizes the Company&#8217;s other restricted stock activity:</ix:nonNumeric></span></div><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-9980EA910A8D51E2BAC2F8316249E498-1" continuedAt="TextSelection-8DBBA6AD563852E695F197EA41A92E27-0"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:65%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1174-wk-Fact-AF48513F717B5419ACC8B09C29F3B1F3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">22,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1193-wk-Fact-64CEA29FCD9C50C2B3365F441E2DF962" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1208-wk-Fact-A24922CE68CC5586A8B66321788414DC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1222-wk-Fact-73934EA40DB75559A3772448CB3C9124" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1242-wk-Fact-0EA770EEBD375BD18D8E1E083DBACADD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1257-wk-Fact-BC4B55CECCA15178A1A87F0B9898EC41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1277-wk-Fact-2194322C18A851F58F0625CBC7B444A9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1292-wk-Fact-88102746948E570F9C2A9799D5E4A2E3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1312-wk-Fact-406316C7399C5306B9DC1409EFC0AE13" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1326-wk-Fact-3C632D7676C25720A5BC76C724C3B3A9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, total unrecognized stock-based compensation expense related to non-vested restricted stock was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117901e1350-wk-Fact-78130CCAC3085C23B3E78F332BB7AD5B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" unitRef="usd" decimals="INF" scale="0" format="ixt:numdotdecimal">18,500</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d140117901e1354-wk-Fact-EB2FB6F0DDCB520A9776A2FB7C0B1299" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember" format="ixt-sec:duryear">0.5</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-C2C23202DC395509B42D3711EE0EA731-0-wk-Fact-397FC8AD8AFE5DAFAB54898D3AE3689C" continuedAt="TextSelection-C2C23202DC395509B42D3711EE0EA731-1" escape="true">The changes in accumulated other comprehensive loss by component for the first </ix:nonNumeric></span><ix:continuation id="TextSelection-C2C23202DC395509B42D3711EE0EA731-1" continuedAt="TextSelection-C2C23202DC395509B42D3711EE0EA731-2"><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of 2017 were as follows (in thousands):</span></ix:continuation></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><ix:continuation id="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-3"><ix:continuation id="TextSelection-C2C23202DC395509B42D3711EE0EA731-2"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1473-wk-Fact-29546F7F32AE55D593C77D2FD3E24BD5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1493-wk-Fact-EF1E2F7A117253A39082F7F054626D6E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1513-wk-Fact-4D5477BA04A657CEBEAB12FBFB5A9ABC" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1530-wk-Fact-0A5A61BF66E052ADB13F4A4F600CE3CD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1549-wk-Fact-F6F245C7DF475D98B2036784C5B76A88" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1569-wk-Fact-D6DDF706380D5A7DAF8AB792EEC839E9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1590-wk-Fact-BC3C37FAA79A5446AE9F7205AADF9722" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140117901e1610-wk-Fact-D813FB1249F95F829653203067B344FE" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1629-wk-Fact-78DE1BC2837154A2A860BEC6AEF05957" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1656-wk-Fact-06FD9962244E564B98AB2312E8F67DEE" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1676-wk-Fact-38041457CF5E549E88974A76310AA3C0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(<ix:nonFraction id="d140117901e1696-wk-Fact-3341CE0E42FC5E9BA941BF6690F2CF9A" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">907</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></ix:continuation></ix:continuation><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6F769E571C1A5C149626382E73FC9DFE"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7. <ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-18D663A331DA504EACEF78127BC74993-0-wk-Fact-F2391EE38DE458328D32743D4C6B46EB" continuedAt="TextSelection-18D663A331DA504EACEF78127BC74993-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-18D663A331DA504EACEF78127BC74993-1" continuedAt="TextSelection-18D663A331DA504EACEF78127BC74993-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries.  The Company repatriated </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140117982e328-wk-Fact-EEB747A7041742C2F65E8B1FC8588408" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextRef="FD2016Q1QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses.  Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced.  The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings.  The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has accrued tax liabilities for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-18D663A331DA504EACEF78127BC74993-2">The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.</ix:continuation></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1A3C0979DDA45C928EA9282686BC1472"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8. <ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-0-wk-Fact-B733E047AAE9500CB6CBABDBD19F6F51" continuedAt="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-1" continuedAt="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-2"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140118085e334-wk-Fact-3E01F93EA344532A8E843F872D7B658F" name="us-gaap:LossContingencyNewClaimsFiledNumber" contextRef="D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember" unitRef="complaint" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;">, Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the &#8220;Individual Defendants&#8221;), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants&#8217; motion to dismiss on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.&#160; If approved, the proposed settlement will be fully funded by the Company&#8217;s insurers.&#160; Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-2" continuedAt="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-3"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the &#8220;Derivative Complaints&#8221;). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company&#8217;s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> action pending conclusion of the related federal class action in the United States District Court for the Central District of California:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Li v. Natural Health Trends Corp</span><span style="font-family:inherit;font-size:10pt;">. A nearly identical stipulated stay was entered in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> case on February 8, 2017.  The Company believes that these claims are without merit and intends to vigorously defend against them.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-3">The consolidated class action, if a settlement is not finalized and approved by the Court, and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company&#8217;s operating results and financial condition.</ix:continuation> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s8767AC7EA128597C82540254DCD69423"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9. <ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-0-wk-Fact-987DE0B8801357D98B4C7E206817109D" continuedAt="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-1" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-1" continuedAt="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (&#8220;BHS&#8221;) regarding the manufacture and sale of a product called&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Soothe</span><span style="font-family:inherit;font-size:10pt;">&#8482;.  George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS.  Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140118134e333-wk-Fact-9C24EF50BF74531FB880205A4C940A71" name="nhtc:RoyaltyRate" contextRef="D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide.  Royalties recognized for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e345-wk-Fact-0F0EBCBED1B25E3CA9F8C1846F439837" name="us-gaap:RoyaltyExpense" contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="-2" scale="0" format="ixt:numdotdecimal">500</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e350-wk-Fact-E1208BA95B785C6EBBBD5D9329430B46" name="us-gaap:RoyaltyExpense" contextRef="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="-2" scale="0" format="ixt:numdotdecimal">800</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e354-wk-Fact-6B2937D627305401B3F1303EEE923725" name="us-gaap:RoyaltyExpense" contextRef="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">1,200</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e358-wk-Fact-96FCB73716D252819CC04DB32402ED1D" name="us-gaap:RoyaltyExpense" contextRef="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="-2" scale="0" format="ixt:numdotdecimal">2,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d140118134e375-wk-Fact-16F2E4AD11075BF78088A7DC92A22508" name="nhtc:NumberOfDaysTerminationNotice" contextRef="D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" format="ixt-sec:durday">120</ix:nonNumeric> days</span></span><span style="font-family:inherit;font-size:10pt;">&#8217; notice.  Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><ix:continuation id="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-2" continuedAt="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-3"><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor&#8482;.</span><span style="font-family:inherit;font-size:10pt;">&#160; Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d140118134e388-wk-Fact-801EA8A210B253B08B604D7DAAB2587D" name="nhtc:RoyaltyRate" contextRef="D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue.  Such provision was effective retroactively to January 1, 2015.  Such royalties were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e392-wk-Fact-8E26C7887D0951E493E48AD8BA88FA21" name="us-gaap:RoyaltyExpense" contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">86,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e396-wk-Fact-C7D5DB04D12351C090EAC23358F84094" name="us-gaap:RoyaltyExpense" contextRef="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">141,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e409-wk-Fact-07B77D1C7F9EE9DED00DEEE9D2D3D2A9" name="us-gaap:RoyaltyExpense" contextRef="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">177,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118134e413-wk-Fact-A196ECCDECF732C7408BEEEA4A66BE6C" name="us-gaap:RoyaltyExpense" contextRef="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">280,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d140118134e430-wk-Fact-7B7D16FCAEA3502FBEC92804F4D88900" name="nhtc:NumberOfDaysTerminationNotice" contextRef="D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember" format="ixt-sec:durday">120</ix:nonNumeric> days</span></span><span style="font-family:inherit;font-size:10pt;">&#8217; notice or, under certain circumstances, with </span><span style="font-family:inherit;font-size:10pt;">no</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-3"> notice.  Otherwise, the agreement terminates March 31, 2020.</ix:continuation></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s7B34DC1AD3B15B55A91EE6201298B38C"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10. <ix:nonNumeric contextRef="FD2017Q2YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-0-wk-Fact-EB0C454083A35577B0BD1E8BA7AA8660" continuedAt="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-1" escape="true">SUBSEQUENT EVENT</ix:nonNumeric></span></div><ix:continuation id="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-1" continuedAt="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-2"><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></ix:continuation><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><ix:continuation id="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-2" continuedAt="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-3"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118184e334-wk-Fact-1B6D4C0AB17D57EAA8160601D97FDFED" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.11</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d140118184e338-wk-Fact-844756D400EF581CB65659A18D740C7F" name="nhtc:CommonStockSpecialDividendsPerShareDeclared" contextRef="D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.25</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends are payable on </span><span style="font-family:inherit;font-size:10pt;">August&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-3">. Payment of any future dividends on shares of common stock will be at the discretion of the Company&#8217;s Board of Directors.</ix:continuation></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><a id="s85F837BC586B5C94B939AAAC528E04C0"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-left:42px;text-indent:-42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Business Overview</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are an international direct-selling and e-commerce company. Subsidiaries controlled by us sell personal care, wellness, and &#8220;quality of life&#8221; products under the &#8220;NHT Global&#8221; brand. Our wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. We also operate through an engagement of a third-party service provider in Russia and Kazakhstan.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our member network operates in a seamless manner from market to market, except for our China market where we sell to consumers through an e-commerce platform, and our Russia and Kazakhstan market where our engagement of a third-party service provider results in a different economic structure than in our other markets. Otherwise, we believe that all of our other operating segments are similar in the nature of the products sold, the product acquisition process, the types of customers products are sold to, the methods used to distribute the products, and the nature of the regulatory environment. There is no separate segment manager who is held accountable by our chief operating decision-makers, or anyone else, for operations, operating results and planning for neither the China market nor the Russia and Kazakhstan market on a stand-alone basis, and neither market is material for the periods presented. As such, we consider ourselves to be in a single reporting segment and operating unit structure.&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, we were conducting business through </span><span style="font-family:inherit;font-size:10pt;">107,290</span><span style="font-family:inherit;font-size:10pt;"> active members, compared to </span><span style="font-family:inherit;font-size:10pt;">113,710</span><span style="font-family:inherit;font-size:10pt;"> three months ago and </span><span style="font-family:inherit;font-size:10pt;">126,440</span><span style="font-family:inherit;font-size:10pt;"> a year ago. We consider a member &#8220;active&#8221; if they have placed at least one product order with us during the preceding year. Our priority is to focus our resources in our most promising markets, which we consider to be Greater China and countries where our existing members have the connections to recruit prospects and sell our products, such as Southeast Asia. We have also begun to invest some resources in Mexico and Peru. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate approximately </span><span style="font-family:inherit;font-size:10pt;">97%</span><span style="font-family:inherit;font-size:10pt;"> of our net sales from subsidiaries located outside the Americas, with sales of our Hong Kong subsidiary representing </span><span style="font-family:inherit;font-size:10pt;">89%</span><span style="font-family:inherit;font-size:10pt;"> of net sales in the latest fiscal quarter. Because of the size of our foreign operations, operating results can be impacted negatively or positively by factors such as foreign currency fluctuations, and economic, political and business conditions around the world. In addition, our business is subject to various laws and regulations, in particular regulations related to direct selling activities that create uncertain risks for our business, including improper claims or activities by our members and potential inability to obtain necessary product registrations. For further information regarding some of the risks associated with the conduct of our business in China, see generally in &#8220;Part I, Item 1A, Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2016, and more specifically under the captions &#8220;Risk Factors - Because our Hong Kong operations account for a substantial portion of our overall business...&#8221; and &#8220;Risk Factors - Our operations in China are subject to compliance with a myriad of applicable laws and regulations...&#8221;. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China has been and continues to be our most important business development project.  We operate an e-commerce direct selling model in Hong Kong that generates revenue derived from the sale of products to members in Hong Kong and elsewhere, including China. Substantially all of our Hong Kong revenues are derived from the sale of products that are delivered to members in China. Through a separate Chinese entity, we operate an e-commerce retail platform in China.  We believe that neither of these activities requires a direct selling license in China, which we do not currently hold.  We have previously sought to obtain a direct selling license, and in August 2015 initiated the process for submitting a new preliminary application for a direct selling license in China.  If we are able to obtain a direct selling license in China, we believe that the incentives inherent in the direct selling model in China would incrementally benefit our existing business.  We do not expect that any increased sales in China derived from obtaining a direct selling license would initially be material and, in any event may be partially offset by the higher fixed costs associated with the establishment and maintenance of required service centers, branch offices, manufacturing facilities, certification programs and other legal requirements.  We are unable to predict whether and when we will be successful in obtaining a direct selling license to operate in China, and if we are successful, when we will be permitted to conduct direct selling operations and whether such operations would be profitable.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><a id="sD54C4F5F241651C3A04DEC43116CA2A1"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Statement Presentation</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We mainly derive revenue from sales of products. Substantially all of our product sales are to independent members at published wholesale prices. Product sales are recorded when the products are shipped and title passes to independent members, which generally is upon our delivery to the carrier that completes delivery to the members. We estimate and accrue a reserve for product returns based on our return policies and historical experience. Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. We bill members for shipping charges and recognize the freight revenue in net sales. Event and training revenue is deferred and recognized as the event or training occurs. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales consists primarily of products purchased from third-party manufacturers, freight cost for transporting products to our foreign subsidiaries and shipping products to members, import duties, packing materials, product royalties, costs of promotional materials sold to our members at or near cost, and provisions for slow moving or obsolete inventories. Cost of sales also includes purchasing costs, receiving costs, inspection costs and warehousing costs.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Member commissions</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</span><span style="font-family:inherit;font-size:10pt;">are our most significant expense and are classified as an operating expense. Under our compensation plan, members are paid weekly commissions by our subsidiary in which they are enrolled, generally in their home country currency, for product purchases by their down-line member network across all geographic markets. Our China subsidiary maintains an e-commerce retail platform and does not pay any commissions. This &#8220;seamless&#8221; compensation plan enables a member located in one country to enroll other members located in other countries where we are authorized to conduct our business. Currently, there are basically two ways in which our members can earn income:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">through commissions paid on product purchases made by their down-line members; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:14pt;padding-left:36px;"><span style="font-family:inherit;font-size:14pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:14pt;"><span style="font-family:inherit;font-size:10pt;">through retail markups on sales of products purchased by members at wholesale prices (in the majority of our markets, sales are for personal consumption only and income may not be earned through retail mark-ups on sales in that market).</span></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:58px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each of our products is designated a specified number of bonus volume points. Commissions are based on total personal and group bonus volume points per weekly sales period. Bonus volume points are essentially a percentage of a product&#8217;s wholesale price. As the member&#8217;s business expands from successfully enrolling other members who in turn expand their own businesses by selling product to other members, the member receives higher commissions from purchases made by an expanding down-line network. In some of our markets, to be eligible to receive commissions, a member may be required to make nominal monthly or other periodic purchases of our products. Certain of our subsidiaries do not require these nominal purchases for a member to be eligible to receive commissions. In determining commissions, the number of levels of down-line members included within the member&#8217;s commissionable group increases as the number of memberships directly below the member increases.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under our current compensation plan, certain of our commission payouts may be limited to a hard cap dollar amount per week or a specific percentage of total product sales. In some markets, commissions may be further limited. In some markets, we also pay certain bonuses on purchases by up to three generations of personally enrolled members, as well as bonuses on commissions earned by up to three generations of personally enrolled members. Members can also earn income, trips and other prizes in specific time-limited promotions and contests we hold from time to time. Member commissions are dependent on the sales mix and, for the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, represented </span><span style="font-family:inherit;font-size:10pt;">43%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">47%</span><span style="font-family:inherit;font-size:10pt;">, respectively, of net sales. Occasionally, we make modifications and enhancements to our compensation plan to help motivate members, which can have an impact on member commissions.We may also enter into agreements for business or market development, which could result in additional compensation to specific members.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses consist of administrative compensation and benefits (including stock-based compensation), travel, credit card fees and assessments, professional fees, certain occupancy costs, and other corporate administrative expenses. In addition, this category includes selling, marketing, and promotion expenses (including the costs of member training events and conventions). Because our various member conventions are not always held at the same time each year, interim period comparisons will be impacted accordingly.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The functional currency of our international subsidiaries is generally their local currency. Local currency assets and liabilities are translated at the rates of exchange on the balance sheet date, and local currency revenues and expenses are translated at average rates of exchange during the period. Equity accounts are translated at historical rates.&#160; The resulting translation adjustments are recorded directly into accumulated other comprehensive income.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales by our foreign subsidiaries are generally transacted in the respective local currencies and are translated into U.S. dollars using average rates of exchange for each monthly accounting period to which they relate.&#160; Most of our product purchases from third-party manufacturers are transacted in U.S. dollars.&#160; Consequently, our sales and net earnings are affected by changes in currency exchange rates, with sales and earnings generally increasing with a weakening U.S. dollar and decreasing with a strengthening U.S. dollar, see &#8220;Item 3. Quantitative and Qualitative Disclosures About Market Risk&#8221; and more specifically under the caption &#8220;Foreign Currency Exchange Risk&#8221; for further information.&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s15C4D197B2E352D3894F3E3E05E40905"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth our operating results as a percentage of net sales for the periods indicated.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating expenses:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commissions expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42.9</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14.5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total operating expenses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62.7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income from operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income before income taxes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.6</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23.4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax provision</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Sales</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth revenue by market for the periods indicated (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Americas</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,641</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,995</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,101</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,058</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.0</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Hong Kong</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45,688</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73,347</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100,255</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">141,506</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">China</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,247</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.4</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,500</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,001</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5,815</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Taiwan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,729</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,899</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2,887</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,124</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2.0</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">South Korea</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">129</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">191</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">251</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">392</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Singapore</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Russia and Kazakhstan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">229</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">222</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">446</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">427</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">730</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">205</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,254</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1.1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">337</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51,465</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80,391</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">111,339</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">154,737</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales were </span><span style="font-family:inherit;font-size:10pt;">$51.5 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$80.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the comparable period a year ago, a decrease of </span><span style="font-family:inherit;font-size:10pt;">$28.9 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">36%</span><span style="font-family:inherit;font-size:10pt;">.&#160; Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased </span><span style="font-family:inherit;font-size:10pt;">$27.7 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">38%</span><span style="font-family:inherit;font-size:10pt;">, over the comparable period a year ago. The sales decrease was primarily attributable to the slowdown we have been experiencing in our Asian markets since the third quarter of 2016. In addition, Hong Kong experienced a decrease of </span><span style="font-family:inherit;font-size:10pt;">21,800</span><span style="font-family:inherit;font-size:10pt;"> active members, or </span><span style="font-family:inherit;font-size:10pt;">19%</span><span style="font-family:inherit;font-size:10pt;">, from June&#160;30, 2016 to June&#160;30, 2017, which contributed to the decrease in product sales volume.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside of our Hong Kong business, net sales decreased </span><span style="font-family:inherit;font-size:10pt;">$1.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;">, over the comparable three month period a year ago, driven by a </span><span style="font-family:inherit;font-size:10pt;">50%</span><span style="font-family:inherit;font-size:10pt;"> decrease in our China e-commerce business and a </span><span style="font-family:inherit;font-size:10pt;">18%</span><span style="font-family:inherit;font-size:10pt;"> decrease in the Americas, offset by a </span><span style="font-family:inherit;font-size:10pt;">256%</span><span style="font-family:inherit;font-size:10pt;"> increase in Europe. The </span><span style="font-family:inherit;font-size:10pt;">$1.3 million</span><span style="font-family:inherit;font-size:10pt;"> net sales decrease in our China e-commerce business was primarily the result of decreased sales of our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Home </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Wellness</span><span style="font-family:inherit;font-size:10pt;"> product lines. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales were </span><span style="font-family:inherit;font-size:10pt;">$111.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$154.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the comparable period a year ago, a decrease of </span><span style="font-family:inherit;font-size:10pt;">$43.4 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">28%</span><span style="font-family:inherit;font-size:10pt;">.&#160; Hong Kong net sales, substantially all of which were shipped to members residing in China, decreased </span><span style="font-family:inherit;font-size:10pt;">$41.3 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">29%</span><span style="font-family:inherit;font-size:10pt;">, over the comparable period a year ago. Hong Kong experienced a decrease of </span><span style="font-family:inherit;font-size:10pt;">21,800</span><span style="font-family:inherit;font-size:10pt;"> active members, or </span><span style="font-family:inherit;font-size:10pt;">19%</span><span style="font-family:inherit;font-size:10pt;">, from June&#160;30, 2016 to June&#160;30, 2017, which contributed to the decrease in product sales volume.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outside of our Hong Kong business, net sales for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> decreased </span><span style="font-family:inherit;font-size:10pt;">$2.1 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">16%</span><span style="font-family:inherit;font-size:10pt;">, over the comparable </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month period a year ago, driven by a </span><span style="font-family:inherit;font-size:10pt;">48%</span><span style="font-family:inherit;font-size:10pt;"> decrease in our China e-commerce business, offset by a </span><span style="font-family:inherit;font-size:10pt;">272%</span><span style="font-family:inherit;font-size:10pt;"> increase in net sales in Europe. The </span><span style="font-family:inherit;font-size:10pt;">$2.8 million</span><span style="font-family:inherit;font-size:10pt;"> net sales decrease in our China e-commerce business was primarily the result of decreased sales of our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Home</span><span style="font-family:inherit;font-size:10pt;"> product line.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, deferred revenue was </span><span style="font-family:inherit;font-size:10pt;">$4.0 million</span><span style="font-family:inherit;font-size:10pt;">, which primarily consisted of </span><span style="font-family:inherit;font-size:10pt;">$1.7 million</span><span style="font-family:inherit;font-size:10pt;"> pertaining to unshipped product orders, </span><span style="font-family:inherit;font-size:10pt;">$1.9 million</span><span style="font-family:inherit;font-size:10pt;"> pertaining to auto ship advances and </span><span style="font-family:inherit;font-size:10pt;">$440,000</span><span style="font-family:inherit;font-size:10pt;"> pertaining to unamortized enrollment package revenue.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Gross Profit</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit was </span><span style="font-family:inherit;font-size:10pt;">81.0%</span><span style="font-family:inherit;font-size:10pt;"> of net sales for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">81.3%</span><span style="font-family:inherit;font-size:10pt;"> of net sales for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</span><span style="font-family:inherit;font-size:10pt;">. The gross profit margin percentage decrease was primarily due to lower event revenue, offset by lower logistics costs.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross profit was </span><span style="font-family:inherit;font-size:10pt;">81.1%</span><span style="font-family:inherit;font-size:10pt;"> of net sales for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">81.0%</span><span style="font-family:inherit;font-size:10pt;"> of net sales for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</span><span style="font-family:inherit;font-size:10pt;">. The gross profit margin percentage increase was primarily due to lower logistics costs, offset by lower event revenue.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commissions</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commissions were </span><span style="font-family:inherit;font-size:10pt;">42.9%</span><span style="font-family:inherit;font-size:10pt;"> of net sales for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, compared with </span><span style="font-family:inherit;font-size:10pt;">47.1%</span><span style="font-family:inherit;font-size:10pt;"> of net sales for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">43.2%</span><span style="font-family:inherit;font-size:10pt;"> of net sales for the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, compared with </span><span style="font-family:inherit;font-size:10pt;">47.1%</span><span style="font-family:inherit;font-size:10pt;"> for the comparable period a year ago. The decrease as a percentage of net sales for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> primarily resulted from lower estimated costs for on-going cash and other incentive programs.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling, general and administrative expenses were </span><span style="font-family:inherit;font-size:10pt;">$6.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">three months ended June 30, 2017</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$12.4 million</span><span style="font-family:inherit;font-size:10pt;"> in the same period a year ago. For the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">, selling, general and administrative expenses were </span><span style="font-family:inherit;font-size:10pt;">$16.1 million</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$23.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the comparable period a year ago. Selling, general and administrative expenses decreased by </span><span style="font-family:inherit;font-size:10pt;">47%</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">31%</span><span style="font-family:inherit;font-size:10pt;">, respectively, during the three and six month periods mainly due to decreases in employee-related costs and event costs, as well as a decrease in credit card fees and assessments due to lower net sales, offset by an increase in professional fees as compared to the same period in the prior year.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">An income tax provision of </span><span style="font-family:inherit;font-size:10pt;">$2.6 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$2.7 million</span><span style="font-family:inherit;font-size:10pt;"> was recognized during the three month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and 2016, respectively, and </span><span style="font-family:inherit;font-size:10pt;">$5.4 million</span><span style="font-family:inherit;font-size:10pt;"> was recognized during each of the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and 2016. As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, we determined that a portion of our undistributed foreign earnings were no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We repatriated $19.8 million to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses.  Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to existing U.S. net operating losses was reduced.  We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA84872B7BF34572EB0F9AFE970031E65"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, our cash and cash equivalents totaled </span><span style="font-family:inherit;font-size:10pt;">$136.3 million</span><span style="font-family:inherit;font-size:10pt;">. Total cash and cash equivalents increased by </span><span style="font-family:inherit;font-size:10pt;">$10.3 million</span><span style="font-family:inherit;font-size:10pt;"> from </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">. We consider all highly liquid investments with original maturities of three months or less, when purchased, to be cash equivalents. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;">$73.2 million</span><span style="font-family:inherit;font-size:10pt;"> in available-for-sale investments classified as cash equivalents. In addition, cash and cash equivalents included </span><span style="font-family:inherit;font-size:10pt;">$130.4 million</span><span style="font-family:inherit;font-size:10pt;"> held in bank accounts overseas, which included </span><span style="font-family:inherit;font-size:10pt;">$6.1 million</span><span style="font-family:inherit;font-size:10pt;"> held in banks located within China subject to foreign currency controls.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, the ratio of current assets to current liabilities was </span><span style="font-family:inherit;font-size:10pt;">2.74</span><span style="font-family:inherit;font-size:10pt;"> to 1.00 and we had </span><span style="font-family:inherit;font-size:10pt;">$95.0 million</span><span style="font-family:inherit;font-size:10pt;"> of working capital. Working capital as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> increased </span><span style="font-family:inherit;font-size:10pt;">$10.9 million</span><span style="font-family:inherit;font-size:10pt;"> compared to our working capital as of </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, due primarily to an increase in cash from operations during the </span><span style="font-family:inherit;font-size:10pt;">six months ended June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash provided by operations was </span><span style="font-family:inherit;font-size:10pt;">$20.6 million</span><span style="font-family:inherit;font-size:10pt;"> for the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> compared with </span><span style="font-family:inherit;font-size:10pt;">$30.4 million</span><span style="font-family:inherit;font-size:10pt;"> in the comparable period of </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">. The decrease in operating cash flows resulted primarily from the decrease in product orders, offset by a reduction in inventories and inventory-related deposits.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flows used in investing activities totaled </span><span style="font-family:inherit;font-size:10pt;">$170,000</span><span style="font-family:inherit;font-size:10pt;"> during the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> and consisted primarily of software development costs and buildout costs for our expansion into Peru and Vietnam. Cash flows used in investing activities totaled </span><span style="font-family:inherit;font-size:10pt;">$524,000</span><span style="font-family:inherit;font-size:10pt;"> during the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of 2016 and consisted primarily of software development costs of&#160;$426,000&#160;for our Oracle ERP upgrade and enhancement of our back office software platform.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flows used in financing activities during the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> consisted solely of the following dividend payments (in thousands, except per share amounts):  </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.35</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,964</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,133</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.35</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3,962</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.09</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1,019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">0.89</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10,078</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 31, 2017, the Board of Directors declared a quarterly cash dividend of $0.11 and a special cash dividend of $0.25 on each share of common stock outstanding. Such dividends are payable on August 31, 2017 to stockholders of record on August 21, 2017.  Payment of any future dividends on shares of common stock will be at the discretion of our Board of Directors.</span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flows used in financing activities during the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of 2016 totaled </span><span style="font-family:inherit;font-size:10pt;">$25.0 million</span><span style="font-family:inherit;font-size:10pt;">, and consisted primarily of </span><span style="font-family:inherit;font-size:10pt;">$23.7 million</span><span style="font-family:inherit;font-size:10pt;"> in stock repurchases. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our existing internal liquidity, supported by cash on hand and cash flows from operations should be adequate to fund normal business operations and address our financial commitments for the foreseeable future.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not have any significant unused sources of liquid assets. If necessary, we may attempt to generate more funding from the capital markets, but currently we do not believe that will be necessary.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our priority is to focus our resources on investing in our most important markets, which we consider to be Greater China and countries where our existing members may have the connections to recruit prospects and sell our products, such as Southeast Asia. We will continue to invest in our Mainland China entity for such purposes as establishing China-based manufacturing capabilities, increasing public awareness of our brand and our products, sourcing more Chinese-made products, building a chain of service stations, opening additional Healthy Lifestyle Centers or branch offices, adding local staffing and other requirements for a China direct selling license application. We also have invested some resources in Mexico and Peru. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><a id="s688A49B986E052AEA1722AD46C3F6180"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A summary of our significant accounting policies is provided in Note&#160;1 of the Notes to Consolidated Financial Statements in &#8220;Item 8. Financial Statements and Supplementary Data&#8221; of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017. The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. The process of determining significant estimates is fact specific and takes into account historical experience and current and expected economic conditions. To the extent that there are material differences between the estimates and actual results, future results of operations will be affected.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Critical accounting policies and estimates are defined as both those that are material to the portrayal of our financial condition and results of operations and as those that require management&#8217;s most subjective judgments.&#160; Management believes our critical accounting policies and estimates are those related to revenue recognition, as well as those used in the determination of liabilities related to sales returns, member commissions and income taxes.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition.&#160;&#160;</span><span style="font-family:inherit;font-size:10pt;">Product sales are recorded when the products are shipped and title passes to independent members. Product sales to members are made pursuant to a member agreement that provides for transfer of both title and risk of loss upon our delivery to the carrier that completes delivery to the members, which is commonly referred to as &#8220;F.O.B. Shipping Point.&#8221; We primarily receive payment by credit card at the time members place orders. Our sales arrangements do not contain right of inspection or customer acceptance provisions other than general rights of return. Amounts received for unshipped product are recorded as deferred revenue.  Such amounts totaled </span><span style="font-family:inherit;font-size:10pt;">$1.7 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$2.2 million</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. Shipping charges billed to members are included in net sales. Costs associated with shipments are included in cost of sales. Event and training revenue is deferred and recognized as the event or training occurs.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Enrollment package revenue, including any nonrefundable set-up fees, is deferred and recognized over the term of the arrangement, generally twelve months. Enrollment packages provide members access to both a personalized marketing website and a business management system. No upfront costs are deferred as the amount is nominal. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, enrollment package revenue totaling </span><span style="font-family:inherit;font-size:10pt;">$440,000</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$430,000</span><span style="font-family:inherit;font-size:10pt;"> was deferred, respectively. Although we have no immediate plans to significantly change the terms or conditions of enrollment packages, any changes in the future could result in additional revenue deferrals or could cause us to recognize the deferred revenue over a longer period of time. Additionally, deferred revenue includes advances for auto ship orders. In certain markets, when a member&#8217;s cumulative commission income reaches a certain threshold, a percentage of the member&#8217;s weekly commission is held back as an advance and applied to an auto ship order once the accumulated amount of the advances is sufficient to pay for the pre-selected auto ship package of the member.&#160; Such advances were </span><span style="font-family:inherit;font-size:10pt;">$1.9 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$2.3 million</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Allowance for Sales Returns. </span><span style="font-family:inherit;font-size:10pt;">An allowance for sales returns is provided during the period the product is shipped.&#160; The allowance is based upon the return policy of each country, which varies from 14 days to one year, and their historical return rates, which range from 1% to 7% of sales.&#160; Sales returns were 1% of sales for the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">.&#160; The allowance for sales returns was </span><span style="font-family:inherit;font-size:10pt;">$2.3 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$1.6 million</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.&#160; No material changes in estimates have been recognized during the periods presented.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commissions.</span><span style="font-family:inherit;font-size:10pt;"> Independent members earn commissions based on total personal and group bonus volume points per weekly sales period.&#160; Each of our products are designated a specified number of bonus volume points, which is essentially a percentage of the product&#8217;s wholesale price.&#160; We accrue commissions when earned and as the related revenue is recognized and pay commissions on product sales generally two weeks following the end of the weekly sales period.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Independent members may also earn incentives based on meeting certain qualifications during a designated incentive period, which may range from several weeks to up to a year.&#160; These incentives may be both monetary and non-monetary in nature.&#160; For each individual incentive, we estimate the total number of qualifiers as well as the expected per qualifier cost and accrue all costs associated with incentives throughout the qualification period.  We regularly review and update, if necessary, the estimates of both qualifiers and cost as more information is obtained during the qualification period.  Any resulting change in total cost is recognized over the remaining qualification period. Accrued commissions, including the estimated cost of our international recognition incentive program and other supplemental programs, totaled </span><span style="font-family:inherit;font-size:10pt;">$12.7 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$13.6 million</span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes.&#160;</span><span style="font-family:inherit;font-size:10pt;"> Deferred income taxes are recognized for differences between the financial reporting and tax bases of assets and liabilities at enacted statutory rates for the years in which the temporary differences are expected to be recovered or settled. We evaluate the probability of realizing the future benefits of any of our deferred tax assets and record a valuation allowance when we believe a portion or all of our deferred tax assets may not be realized. Deferred tax expense or benefit is a result of changes in deferred tax assets and liabilities. Based on the technical merits of our tax position, tax benefits may be recognized if we determine it is more likely than not that our position will be sustained on examination by tax authorities. The complex nature of these estimates requires us to anticipate the likely application of tax law and make judgments on the largest benefit that has a greater than fifty percent likelihood of being realized prior to the completion and filing of tax returns for such periods.  As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, we no longer have a valuation allowance against our U.S. deferred tax assets. We maintain a valuation allowance in certain foreign jurisdictions with an overall tax loss. The valuation allowance will be reduced at such time as management believes it is more likely than not that the deferred tax assets will be realized. Any reductions in the valuation allowance will reduce future income tax provision.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Provision for income taxes depends on the statutory tax rates in each of the jurisdictions in which we operate. An income tax provision of </span><span style="font-family:inherit;font-size:10pt;">$2.6 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$2.7 million</span><span style="font-family:inherit;font-size:10pt;"> was recognized during the three month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and 2016, respectively, and </span><span style="font-family:inherit;font-size:10pt;">$5.4 million</span><span style="font-family:inherit;font-size:10pt;"> was recognized during each of the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> month periods ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and 2016. As a result of capital return activities, we determined that a portion of our current undistributed foreign earnings are no longer deemed reinvested indefinitely by our non-U.S. subsidiaries. We will continue to periodically reassess the needs of our foreign subsidiaries and update our indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, we expect to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, we have accrued tax liabilities for earnings that we plan to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimate what our effective tax rate will be for the full fiscal year at each interim reporting period and record a quarterly tax provision based on that estimated effective tax rate. Throughout the year that estimated rate may change based on variations in our business, changes in our corporate structure, changes in the geographic mix and amount of income, applicable tax laws and regulations, communications with tax authorities, as well as our estimated and actual level of annual pre-tax income. We adjust our income tax provision in the reporting period in which the change in our estimated rate occurs so that the year-to-date provision is consistent with the anticipated annual tax rate.&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s38ABB05876A05EDEBC3825FB27CEAFDC"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We have operations both internationally and within the United States, and we are exposed to market risks in the ordinary course of our business. These risks include primarily interest rate, foreign exchange and inflation risks.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Interest Rate Fluctuation Risk</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our cash and cash equivalents consist of cash, available-for-sale securities, comprising municipal notes, bonds and corporate debt, money market funds and time deposits. The primary objective of our investment in available-for-sale securities is to preserve principal while maximizing income without significantly increasing risk. Because our cash and cash equivalents have a relatively short maturity, our portfolio's fair value is relatively insensitive to interest rate changes. In future periods, we will continue to evaluate our investment policy relative to our overall objectives.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Foreign Currency Exchange Risk </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We have foreign currency risks related to our revenue and expenses denominated in currencies other than the U.S. dollar.  Our most significant foreign exchange exposure, the Hong Kong dollar, is for now pegged to the U.S. dollar. Our foreign currency exchange rate exposure to South Korean won, Taiwan dollar, Japanese yen, Chinese yuan, Russian ruble, Kazakhstani tenge, Singaporean dollar, Malaysian ringgit, Canadian dollar, and European euro represented approximatel</span><span style="font-family:inherit;font-size:10pt;">y 8% and 7%  </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">of our revenue during each of the</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">month periods ended</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">and</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">2016</span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, respectively. We have experienced and will continue to experience fluctuations in our net income as a result of transaction gains and losses related to translating certain balances denominated in currencies other than the U.S. dollar.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our foreign currency exchange rate exposure may increase in the near future as we develop opportunities in Southeast Asia, Canada, Central America, South America and Europe. Additionally, our</span><span style="font-family:inherit;font-size:10pt;"> foreign currency exchange rate exposure would significantly increase if the Hong Kong dollar were no longer pegged to the U.S. dollar. We also experience indirect exchange rate exposure to the Chinese yuan, which affects our Chinese members&#8217; purchasing power. Given</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">our inability to predict the degree of exchange rate fluctuations, we cannot estimate the effect these fluctuations may have upon future reported results, product pricing or our overall financial condition. Further, to date we have not attempted to reduce our exposure to short-term exchange rate fluctuations by using foreign currency exchange contracts.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;">Inflation Risk</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We do not believe that inflation has had a material effect on our business, financial condition or results of operations.  If our costs were to become subject to significant inflationary pressures, we might not be able to fully offset such higher costs through price increases.  Our inability or failure to do so could harm our business, financial condition and results of operations. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s5C69928E3CCD58E6A6FD4FB6E754B796"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. CONTROLS AND PROCEDURES</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management, with the participation of the Company&#8217;s principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including the Company&#8217;s principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, the principal executive officer and principal financial officer concluded that, as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no changes in internal control over financial reporting that occurred during the fiscal quarter ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB386BDC638A850858002BFB7DEEA4091"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II &#8212; OTHER INFORMATION</span></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sC632A3E02B3B5BD8B65086AEE2D95CA6"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1. LEGAL PROCEEDINGS</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, two putative securities class action complaints were filed against us and our top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;">, Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against Natural Health Trends Corp., and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the &#8220;Individual Defendants&#8221;), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. We moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants&#8217; motion to dismiss on December 5, 2016. On February 17, 2017, we filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.&#160; If approved, the proposed settlement will be fully funded by our insurers. Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the &#8220;Derivative Complaints&#8221;). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of our officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed us and our assets. The Derivative Complaints allege, inter alia, that we made materially false and misleading statements regarding the legality of our business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> action pending conclusion of the related federal class action in the United States District Court for the Central District of California:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Li v. Natural Health Trends Corp</span><span style="font-family:inherit;font-size:10pt;">. A nearly identical stipulated stay was entered in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> case on February 28, 2017. We believe that these claims are without merit and intend to vigorously defend against them.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s69571EBE31A156348F6CB86F3EB715C8"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A. RISK FACTORS</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2016, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common stock.  There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended December 31, 2016.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="s4FC4B5BD240551269A50732B281DD54E"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s4B60F855CF6052FB8AFB8F3E7CF6A597"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div><a id="s316AB8A1A50151199159D38A03C415F9"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. MINE SAFETY DISCLOSURES</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div><a id="sA6E767A16B3E5E4F9C0B6EBB843650C5"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. OTHER INFORMATION</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div><a id="s4A5EC12823975A2DBD04A12538155A46"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. EXHIBITS</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Number</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.INS</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.SCH</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Schema</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.CAL</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Calculation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.DEF</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Definition</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.LAB</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Labels</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.PRE</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Presentation</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAD535F987ECE546CA30D6280844C6094"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:35%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">NATURAL HEALTH TRENDS CORP.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: August&#160;2, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ Timothy S. Davidson</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Timothy S. Davidson</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4F8EB39873A25638B0C9DAF2BA9F0290"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</span></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:85%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Number</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Exhibit Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.INS</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.SCH</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Schema</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.CAL</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Calculation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.DEF</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Definition</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.LAB</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Labels</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">101.PRE</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">XBRL Taxonomy Extension Presentation</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s47A355FA895B582AB74EBBC32729E22F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Chris T. Sharng, certify that:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.  I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. &#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:35%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;2, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Chris T. Sharng</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chris T. Sharng</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s27E5BCB3940B565F8849921A07461A10"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Timothy S. Davidson, certify that:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.  I have reviewed this Quarterly Report on Form 10-Q of Natural Health Trends Corp.;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4. &#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">c)&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">d)&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a)&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">b)&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:35%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;2, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Timothy S. Davidson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Timothy S. Davidson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4F94C18E38415AB5A9B026B5C7EE6416"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATIONS PURSUANT TO</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Quarterly Report of Natural Health Trends Corp. (the &#8220;Company&#8221;) on Form 10-Q for the period ended </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, Chris T. Sharng, the Principal Executive Officer, and Timothy S. Davidson, the Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:35%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;2, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Chris T. Sharng</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chris T. Sharng</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: August&#160;2, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Timothy S. Davidson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Timothy S. Davidson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>nhtc-20170630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.naturalhealthtrendscorp.com/20170630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nhtc="http://www.naturalhealthtrendscorp.com/20170630" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nhtc-20170630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nhtc-20170630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nhtc-20170630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nhtc-20170630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccountingPronouncementsAccountingPronouncements" roleURI="http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements">
        <link:definition>2207200 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsBalanceSheetComponents" roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents">
        <link:definition>2110100 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsBalanceSheetComponentsDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails">
        <link:definition>2410402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsBalanceSheetComponentsTables" roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables">
        <link:definition>2310301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies">
        <link:definition>2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets">
        <link:definition>1002000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeUnaudited" roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsUnaudited" roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails">
        <link:definition>2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNotes" roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes">
        <link:definition>2111100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsPolicies" roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies">
        <link:definition>2211201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables">
        <link:definition>2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxes" roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes">
        <link:definition>2113100 - Disclosure - INCOME TAXES INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2413401 - Disclosure - INCOME TAXES NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfOperationsAndBasisOfPresentation" roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation">
        <link:definition>2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation">
        <link:definition>2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerCommonShareNetIncomePerCommonShare" roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare">
        <link:definition>2108100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerCommonShareNetIncomePerCommonShareDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails">
        <link:definition>2408403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerCommonShareNetIncomePerCommonSharePolicies" roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies">
        <link:definition>2208201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerCommonShareNetIncomePerCommonShareTables" roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables">
        <link:definition>2308302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions">
        <link:definition>2115100 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetail" roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail">
        <link:definition>2415401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquity">
        <link:definition>2112100 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2412406 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAccumulatedOtherComprehensiveLossTables" roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables">
        <link:definition>2312302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDividendsTables" roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables">
        <link:definition>2312303 - Disclosure - STOCKHOLDERS' EQUITY Dividends (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2412404 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockActivityDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails">
        <link:definition>2412405 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockActivityTables" roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables">
        <link:definition>2312301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEvent">
        <link:definition>2116100 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventNarrativeDetails" roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails">
        <link:definition>2416401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="nhtc_AccruedSalesReturns" name="AccruedSalesReturns" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="nhtc_AccruedWarehousingAndInventoryRelatedExpense" name="AccruedWarehousingAndInventoryRelatedExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="nhtc_AccumulatedOtherComprehensiveLossAbstract" name="AccumulatedOtherComprehensiveLossAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_BalanceSheetComponentsAbstract" name="BalanceSheetComponentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_BroadyHealthSciencesMember" name="BroadyHealthSciencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nhtc_CommonStockSpecialDividendsPerShareDeclared" name="CommonStockSpecialDividendsPerShareDeclared" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome" name="CumulativeTranslationAdjustmentRealizedInNetIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_EquityIncentive2016PlanMember" name="EquityIncentive2016PlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_FinancialInstitutionInstrumentsMember" name="FinancialInstitutionInstrumentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_INCOMETAXESAbstract" name="INCOMETAXESAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_MunicipalBondsAndNotesMember" name="MunicipalBondsAndNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nhtc_NumberOfDaysTerminationNotice" name="NumberOfDaysTerminationNotice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_ReStoreMember" name="ReStoreMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="nhtc_RoyaltyRate" name="RoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock" name="ScheduleofAdditionalBalanceSheetComponentsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_SecuritiesClassActionMember" name="SecuritiesClassActionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="nhtc_SootheMember" name="SootheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>nhtc-20170630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements" xlink:href="nhtc-20170630.xsd#AccountingPronouncementsAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" xlink:href="nhtc-20170630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="nhtc-20170630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" xlink:href="nhtc-20170630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="nhtc-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" xlink:href="nhtc-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" xlink:href="nhtc-20170630.xsd#IncomeTaxesIncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" xlink:href="nhtc-20170630.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:href="nhtc-20170630.xsd#NatureOfOperationsAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:href="nhtc-20170630.xsd#NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" xlink:href="nhtc-20170630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" xlink:href="nhtc-20170630.xsd#RelatedPartyTransactionsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" xlink:href="nhtc-20170630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityDividendsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityRestrictedStockActivityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" xlink:href="nhtc-20170630.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" xlink:href="nhtc-20170630.xsd#SubsequentEventNarrativeDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccountsPayableCurrent_222239a2-3ddd-5e4f-4ae1-b11c60b29d92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0ff25fd8-f6de-e7fa-c6c3-85d94f17f57b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_567bfdaf-7a71-0a8c-e33e-b9f7b4096843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_cd1623dd-4d7a-16b7-05d7-1ab0d4540c5c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_cd1623dd-4d7a-16b7-05d7-1ab0d4540c5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherDeferredCreditsCurrent" xlink:label="loc_us-gaap_OtherDeferredCreditsCurrent_5036ca61-95ce-7272-c6c4-dc88fee1d0ea" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherDeferredCreditsCurrent_5036ca61-95ce-7272-c6c4-dc88fee1d0ea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b18b100-5c23-de0c-2b69-6ea7677a5a64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a859bb84-8118-88ec-5136-83fdb14e8f32" xlink:to="loc_us-gaap_DeferredRevenueCurrent_2e84b53d-95cb-56a2-a5b5-1d31836c02d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_3b38d8c3-335c-53c8-5510-f59766fb81d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_bf36f21c-b9bb-d452-716e-f633b46110b9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_6d3ec995-5062-ef92-dd72-b570c1eafdc8" xlink:to="loc_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_bf36f21c-b9bb-d452-716e-f633b46110b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_TreasuryStockValue_d36dfcc8-b62a-1868-1a67-2bd77655103a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f759e73e-9f4f-941e-1138-49bc44f6b118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aeb1020a-508a-a8c1-f34c-bafff16c26cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_CommonStockValue_d53388e7-4c8c-4e6d-6e90-7a6e0a100b74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_AdditionalPaidInCapital_27e98f68-fe6c-3420-5b5a-861a4dc60800" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2644da13-7baa-0a2f-63e0-0906a691ba01" xlink:to="loc_us-gaap_PreferredStockValue_3c8f3df4-466c-f78c-b021-17337fc4a147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_04e17fb3-9b77-1c98-f460-7f5dd0c01008" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49d65a66-0444-b198-9d28-5c0811b1bdf3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68e7c3c1-9b8d-84fe-3a5c-d69c15dfe7a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_OtherAssetsCurrent_fdb77e30-ba68-0e41-abc1-70858b11de5b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_InventoryNet_a5201305-cb63-d1e5-f4e7-e25409fb5d3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_dbbeeff9-fd43-6151-195d-0532728ac216" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ec544f28-9c7b-137c-e428-9ae47c2375fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f9aa892-872a-217e-f4da-55b8bc195d22" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3f9aa892-872a-217e-f4da-55b8bc195d22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_Goodwill_d723083e-f7a3-6d89-9926-32afaa010d8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_08bee809-e27e-48c3-da2d-5d52948eb470" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e6ade192-0839-bdd8-d08b-20387a0e8201" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_9f72449f-62f6-71b1-0128-c7088f4f3527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_68bb4e9b-b5d4-7dc0-9a05-eb9f19c0c826" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_991d89e2-25f7-1061-f5f8-86acc91f176b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fc2ca57d-dc62-7ce6-b2c4-25896bddd1fc" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_fc2ca57d-dc62-7ce6-b2c4-25896bddd1fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_4605b555-adcd-113a-c33e-54bbeff72938" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0c0b26d1-4272-9f3a-27c6-649ac191d259" xlink:to="loc_us-gaap_PaymentsOfDividends_4605b555-adcd-113a-c33e-54bbeff72938" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_104af714-3829-5d79-3fb3-059f86c366da" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_b6c36e3f-ea84-a440-1267-34444a0f8e78" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_Depreciation_b6c36e3f-ea84-a440-1267-34444a0f8e78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_ShareBasedCompensation_432488d8-28ca-5b8d-679b-29be120957b5" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome" xlink:label="loc_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_e8baf4ce-1a51-f63e-4e75-59e44f6fdef1" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_e8baf4ce-1a51-f63e-4e75-59e44f6fdef1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bae7c33e-3fd3-413e-0f2e-aaa9daaa49d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_71d33c1e-c7fc-97d1-1bc4-a959482e606f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_71d33c1e-c7fc-97d1-1bc4-a959482e606f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7c8a7ed5-e324-f4d1-e0f2-1bef47015198" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_7c8a7ed5-e324-f4d1-e0f2-1bef47015198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503015f3-ea26-0d7a-c655-6d6aff0c5fab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7141899e-1a56-24a9-9015-497ee51d7b39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce728eee-c863-e8aa-a864-1d7a3b12d862" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_5660c678-1ac2-3f6e-3460-25ef32ea7507" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_5660c678-1ac2-3f6e-3460-25ef32ea7507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_38bb77ff-9a71-da5a-ae9a-8c89f84c6b01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_e557f5e5-37d9-5e0e-da29-aaf52a44f959" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_e557f5e5-37d9-5e0e-da29-aaf52a44f959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_071e32b9-2ae1-0fdb-f801-d54af8ad45c0" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_071e32b9-2ae1-0fdb-f801-d54af8ad45c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_36e55ee5-04cd-2301-ca0c-e92757ba5e08" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_8ab9b509-cc81-9912-329b-3866a58ee72a" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_36e55ee5-04cd-2301-ca0c-e92757ba5e08" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_045a7791-44b8-d416-a735-af6ac83e7eb3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_663a641c-b103-1e10-d3ec-c078ec7a031b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_7263cb18-5b58-9955-8575-e8eaa5dac989" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9b166675-b7b2-1067-1806-03b1ee0126f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8baf87d5-5f2f-7d0d-cb85-b9f249bae0c5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b936f21a-1a1f-465e-d82c-5e014c9c5399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2b73f435-08bc-014c-4845-03f6580194a0" xlink:to="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b0d6e80b-2a71-4b3d-5167-6e414c6a123b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_33158828-aa18-5ead-beab-c284c08cb606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees_cee4da39-28f7-209c-e4bc-61f421b5939c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8018a1c5-8b31-881d-1f35-ba7ca791bffa" xlink:to="loc_us-gaap_SalesCommissionsAndFees_cee4da39-28f7-209c-e4bc-61f421b5939c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_800dbb3e-0416-e0ab-a30e-cfaeb17b8c4c" xlink:to="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_CostOfGoodsSold_758fda00-4ec6-2a1a-3601-b22661c1a7ff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1fd2c3b5-12a4-0f06-9816-c6d97d4ac6df" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_dec93aa4-b03e-3954-a272-eeb250ead290" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>nhtc-20170630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements" xlink:href="nhtc-20170630.xsd#AccountingPronouncementsAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" xlink:href="nhtc-20170630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="nhtc-20170630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" xlink:href="nhtc-20170630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="nhtc-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" xlink:href="nhtc-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" xlink:href="nhtc-20170630.xsd#IncomeTaxesIncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" xlink:href="nhtc-20170630.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:href="nhtc-20170630.xsd#NatureOfOperationsAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:href="nhtc-20170630.xsd#NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" xlink:href="nhtc-20170630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" xlink:href="nhtc-20170630.xsd#RelatedPartyTransactionsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" xlink:href="nhtc-20170630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityDividendsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityRestrictedStockActivityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" xlink:href="nhtc-20170630.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" xlink:href="nhtc-20170630.xsd#SubsequentEventNarrativeDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedBalanceSheetStatementTable" xlink:label="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_176F1F751FB868545BB43CF232DBF4BB_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_176F1F751FB868545BB43CF232DBF4BB_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:to="loc_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:to="loc_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccruedSalesReturns" xlink:label="loc_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccruedWarehousingAndInventoryRelatedExpense" xlink:label="loc_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:to="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2232302D574D7717B384A1C613A51165_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2232302D574D7717B384A1C613A51165_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:to="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_D8168CBF6DC4D812B133A1C613A62738_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_D8168CBF6DC4D812B133A1C613A62738_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_SecuritiesClassActionMember" xlink:label="loc_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:to="loc_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:to="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_3B9143A8A7514FB62FB30BB24FB3B758_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_3B9143A8A7514FB62FB30BB24FB3B758_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_MunicipalBondsAndNotesMember" xlink:label="loc_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:to="loc_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_FinancialInstitutionInstrumentsMember" xlink:label="loc_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:to="loc_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="loc_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:to="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:to="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_BroadyHealthSciencesMember" xlink:label="loc_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:to="loc_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:to="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:to="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:to="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_SootheMember" xlink:label="loc_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:to="loc_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_ReStoreMember" xlink:label="loc_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:to="loc_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_RoyaltyRate" xlink:label="loc_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="loc_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="loc_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_NumberOfDaysTerminationNotice" xlink:label="loc_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="loc_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_FAB74226F8B855B8839EC868DD882CD0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_214A51AD2D665BC49F0AF67078595655" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_FAB74226F8B855B8839EC868DD882CD0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_214A51AD2D665BC49F0AF67078595655" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_080064A0C80E5F63A476CBF67D73FAF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_214A51AD2D665BC49F0AF67078595655" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_080064A0C80E5F63A476CBF67D73FAF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_AB8E25001DA6A957AA7CA6E23BC5E7D5_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_080064A0C80E5F63A476CBF67D73FAF8" xlink:to="loc_us-gaap_EquityComponentDomain_AB8E25001DA6A957AA7CA6E23BC5E7D5_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_080064A0C80E5F63A476CBF67D73FAF8" xlink:to="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_FAB74226F8B855B8839EC868DD882CD0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0ACE8DB187D54C37B84B0BB041369946_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:to="loc_us-gaap_EquityComponentDomain_0ACE8DB187D54C37B84B0BB041369946_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:to="loc_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0A923D32F135D00A4F318AECBBD91FD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:to="loc_us-gaap_PlanNameAxis_0A923D32F135D00A4F318AECBBD91FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0A923D32F135D00A4F318AECBBD91FD4" xlink:to="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0A923D32F135D00A4F318AECBBD91FD4" xlink:to="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_EquityIncentive2016PlanMember" xlink:label="loc_nhtc_EquityIncentive2016PlanMember_4AC4DFD42FE9397808448AECBBDFAB91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F" xlink:to="loc_nhtc_EquityIncentive2016PlanMember_4AC4DFD42FE9397808448AECBBDFAB91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CF12B6CB8657B0BC45D98AECBBDFEE5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:to="loc_us-gaap_AwardTypeAxis_CF12B6CB8657B0BC45D98AECBBDFEE5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_CF12B6CB8657B0BC45D98AECBBDFEE5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_CF12B6CB8657B0BC45D98AECBBDFEE5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4C9DFD23ADC7C8DA3EA18AECBBDFE72C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6" xlink:to="loc_us-gaap_RestrictedStockMember_4C9DFD23ADC7C8DA3EA18AECBBDFE72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40240A61B25923C6884B8AECBBDF2E5C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40240A61B25923C6884B8AECBBDF2E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40240A61B25923C6884B8AECBBDF2E5C" xlink:to="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40240A61B25923C6884B8AECBBDF2E5C" xlink:to="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A" xlink:to="loc_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_BBDFC3F92664357EB3FF8AECBBE061C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_BBDFC3F92664357EB3FF8AECBBE061C4" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CommonStockSpecialDividendsPerShareDeclared" xlink:label="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_ED5B06892488DEC0551A8AECBBE00B52" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_ED5B06892488DEC0551A8AECBBE00B52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCash" xlink:label="loc_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_627AD75645AA466F92898AECBBE193C3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_627AD75645AA466F92898AECBBE193C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:to="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:to="loc_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:to="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:to="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:to="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_EquityIncentive2016PlanMember" xlink:label="loc_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:to="loc_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:to="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_AD0FE8D8E73FDBCC58F9F23963604341_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_AD0FE8D8E73FDBCC58F9F23963604341_01C153F5EB9F55DCBB0F3C70A9127F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:to="loc_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CommonStockSpecialDividendsPerShareDeclared" xlink:label="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:to="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nhtc-20170630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2BFCDBFC9FAE9B1D1D760BB24BE9B215_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_CDA12FFEBD2E58E39449E8BF3289622F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CDA12FFEBD2E58E39449E8BF3289622F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CDA12FFEBD2E58E39449E8BF3289622F" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_CDA12FFEBD2E58E39449E8BF3289622F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_27FF69CDD3B89A16E3DF0CA8998DB4FB_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0496EE04DFBD5CA4ADD8F020D348934A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_27FF69CDD3B89A16E3DF0CA8998DB4FB_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0496EE04DFBD5CA4ADD8F020D348934A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0496EE04DFBD5CA4ADD8F020D348934A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0496EE04DFBD5CA4ADD8F020D348934A" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0496EE04DFBD5CA4ADD8F020D348934A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9CF9E0394EE4AC8DBA730BB24BE922D6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_302D6021E70350E1B9820C8ECFB6B299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9CF9E0394EE4AC8DBA730BB24BE922D6_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_302D6021E70350E1B9820C8ECFB6B299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_302D6021E70350E1B9820C8ECFB6B299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_302D6021E70350E1B9820C8ECFB6B299" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_302D6021E70350E1B9820C8ECFB6B299" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_C712A63E95C7773B9A750C8EBB64AAE6_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_094C9C506A945C0BB7099011F0B9BA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_094C9C506A945C0BB7099011F0B9BA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_094C9C506A945C0BB7099011F0B9BA4C" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_094C9C506A945C0BB7099011F0B9BA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BB4A9402BC14242E6E60C8EBB66B02C_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_A3A1149CB25250F495D7CBF8EB89FFDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued and Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7BB4A9402BC14242E6E60C8EBB66B02C_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_A3A1149CB25250F495D7CBF8EB89FFDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_A3A1149CB25250F495D7CBF8EB89FFDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_A3A1149CB25250F495D7CBF8EB89FFDD" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_A3A1149CB25250F495D7CBF8EB89FFDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2C1F810890F876CAC88CA1C6146D1921_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_3DD88159ADF4A1B77A8EA1C6146DD748_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_AA1BAE6A3DC15F918FB10FE23B4AD2F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3DD88159ADF4A1B77A8EA1C6146DD748_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_AA1BAE6A3DC15F918FB10FE23B4AD2F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AA1BAE6A3DC15F918FB10FE23B4AD2F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_AA1BAE6A3DC15F918FB10FE23B4AD2F5" xlink:to="lab_us-gaap_NetIncomeLoss_AA1BAE6A3DC15F918FB10FE23B4AD2F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5D8B4548CF9C79DB35E4A1C6146D9EB3_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_5D8B4548CF9C79DB35E4A1C6146D9EB3_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_004FAFA4628148D9F8F3A1C6146D045F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_776325B7B51C5C97B95ABEC3E008A899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_004FAFA4628148D9F8F3A1C6146D045F_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_776325B7B51C5C97B95ABEC3E008A899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_776325B7B51C5C97B95ABEC3E008A899" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_776325B7B51C5C97B95ABEC3E008A899" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_776325B7B51C5C97B95ABEC3E008A899" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_661EB96E7B25D560CEEAA1C6146EEDA7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70998BD69D8E563EB3D333FA9EE370B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_661EB96E7B25D560CEEAA1C6146EEDA7_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70998BD69D8E563EB3D333FA9EE370B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70998BD69D8E563EB3D333FA9EE370B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70998BD69D8E563EB3D333FA9EE370B9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70998BD69D8E563EB3D333FA9EE370B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2C6DC0CC55D1F98D02C3A1C6146E6942_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49D2B7CA645B5646A9B6456234E8F80C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2C6DC0CC55D1F98D02C3A1C6146E6942_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49D2B7CA645B5646A9B6456234E8F80C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49D2B7CA645B5646A9B6456234E8F80C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49D2B7CA645B5646A9B6456234E8F80C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49D2B7CA645B5646A9B6456234E8F80C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9A3DADD149DF06DFDD0AA1C6146E57BF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_068A295BF3135FE284F7F367A578CB0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (losses) gains on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9A3DADD149DF06DFDD0AA1C6146E57BF_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_068A295BF3135FE284F7F367A578CB0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_068A295BF3135FE284F7F367A578CB0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_068A295BF3135FE284F7F367A578CB0E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_068A295BF3135FE284F7F367A578CB0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0BA7DDA5A9E529F611F5A1C6146F79F4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_336FB31D4B5851AC884A7020444F6443" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0BA7DDA5A9E529F611F5A1C6146F79F4_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_336FB31D4B5851AC884A7020444F6443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_336FB31D4B5851AC884A7020444F6443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_336FB31D4B5851AC884A7020444F6443" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_336FB31D4B5851AC884A7020444F6443" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6931723A1CCF518D47D6FD821488BB24_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_4AC5E7F5B5B65D4B8896D917A578A16D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6931723A1CCF518D47D6FD821488BB24_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_4AC5E7F5B5B65D4B8896D917A578A16D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4AC5E7F5B5B65D4B8896D917A578A16D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_4AC5E7F5B5B65D4B8896D917A578A16D" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_4AC5E7F5B5B65D4B8896D917A578A16D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EE87156744A8D14D66B7FD7AC7D6CD0D_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E06612B7E9C156C5A571D939579FD5AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E06612B7E9C156C5A571D939579FD5AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E06612B7E9C156C5A571D939579FD5AC" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E06612B7E9C156C5A571D939579FD5AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_22FB43702CB411CA5A14FD7AC7DC994E_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_1DEE5D7C8A19550BA4ED65423551F54B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_22FB43702CB411CA5A14FD7AC7DC994E_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_1DEE5D7C8A19550BA4ED65423551F54B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1DEE5D7C8A19550BA4ED65423551F54B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_1DEE5D7C8A19550BA4ED65423551F54B" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_1DEE5D7C8A19550BA4ED65423551F54B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_449F6BD88B12D4C9C992A6D05936175C_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8211AF535E4D5BAB9D1DB57CC35091DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8211AF535E4D5BAB9D1DB57CC35091DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8211AF535E4D5BAB9D1DB57CC35091DA" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8211AF535E4D5BAB9D1DB57CC35091DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_357E1752D50C00CBD49DA6D0593719B0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C40118AAB7758788A96539F5E32BE21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_357E1752D50C00CBD49DA6D0593719B0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C40118AAB7758788A96539F5E32BE21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C40118AAB7758788A96539F5E32BE21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C40118AAB7758788A96539F5E32BE21" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C40118AAB7758788A96539F5E32BE21" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F2EF6FFC84532AE3474D6B110E5BC781_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6236F40556B65DF2BE71D629A5CF29C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6236F40556B65DF2BE71D629A5CF29C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6236F40556B65DF2BE71D629A5CF29C8" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6236F40556B65DF2BE71D629A5CF29C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD0148514F41B1E2B8796B110E5B9D6F_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08AD977F79F25E4C9A9B4FD00E4A084A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_DD0148514F41B1E2B8796B110E5B9D6F_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08AD977F79F25E4C9A9B4FD00E4A084A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08AD977F79F25E4C9A9B4FD00E4A084A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08AD977F79F25E4C9A9B4FD00E4A084A" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08AD977F79F25E4C9A9B4FD00E4A084A" xlink:type="arc" />
    <link:label id="lab_nhtc_AccumulatedOtherComprehensiveLossAbstract_9456953286EA60B6B8ED0BB03FC6BA04_label_en-US" xlink:label="lab_nhtc_AccumulatedOtherComprehensiveLossAbstract_C8AA3DEE61325E948CCA2A218C53D6CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss [Abstract]</link:label>
    <link:label id="lab_nhtc_AccumulatedOtherComprehensiveLossAbstract_9456953286EA60B6B8ED0BB03FC6BA04_documentation_en-US" xlink:label="lab_nhtc_AccumulatedOtherComprehensiveLossAbstract_C8AA3DEE61325E948CCA2A218C53D6CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss [Abstract]</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccumulatedOtherComprehensiveLossAbstract" xlink:label="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_C8AA3DEE61325E948CCA2A218C53D6CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_C8AA3DEE61325E948CCA2A218C53D6CA" xlink:to="lab_nhtc_AccumulatedOtherComprehensiveLossAbstract_C8AA3DEE61325E948CCA2A218C53D6CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8FC74F54311C2D65B3950BB041362539_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_8FC74F54311C2D65B3950BB041362539_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_FE7272F990AB81A5FF500BB04136E3A3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_FE7272F990AB81A5FF500BB04136E3A3_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_0ACE8DB187D54C37B84B0BB041369946_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_0ACE8DB187D54C37B84B0BB041369946_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:to="lab_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_55082381192D6E81E61A0BB04136AA92_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_55082381192D6E81E61A0BB04136AA92_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F2F3792D837AAFD5F5050BB041366598_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_F2F3792D837AAFD5F5050BB041366598_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8BA53CD9BC4138901A16FD852540F236_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_928EE5E8A2D15CE28CA1CE739E95E4A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_8BA53CD9BC4138901A16FD852540F236_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_928EE5E8A2D15CE28CA1CE739E95E4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_928EE5E8A2D15CE28CA1CE739E95E4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_928EE5E8A2D15CE28CA1CE739E95E4A6" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_928EE5E8A2D15CE28CA1CE739E95E4A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="lab_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46" xlink:to="lab_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3" xlink:to="lab_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_EA5B6EB51C6DBFDD1E6AA6E23BC65259_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_EA5B6EB51C6DBFDD1E6AA6E23BC65259_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9F1DFEB9722BFCF84C36A6E23BC69A32_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9F1DFEB9722BFCF84C36A6E23BC69A32_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_EF7D20178CA31E4531ADA6E23BC645C8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_EF7D20178CA31E4531ADA6E23BC645C8_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_308990048265E560BBCFA6E23BC7A2E3_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_308990048265E560BBCFA6E23BC7A2E3_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99EE07201308E557E182A6E23BC76117_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, December 31, 2016</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_99EE07201308E557E182A6E23BC76117_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A790D7B400C68FC6AC2DA6E23BC72BA9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A790D7B400C68FC6AC2DA6E23BC72BA9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0B34CF3F8838782D6C8AA6E23BC7712F_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0B34CF3F8838782D6C8AA6E23BC7712F_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9B2F1EDD8172086B6AE1A70F196194D6_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F004C0E72F6D55A0806B82269087349B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, March 31, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F004C0E72F6D55A0806B82269087349B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F004C0E72F6D55A0806B82269087349B" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F004C0E72F6D55A0806B82269087349B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:to="lab_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:to="lab_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788_label_en-US" xlink:label="lab_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788" xlink:to="lab_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72" xlink:to="lab_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C" xlink:to="lab_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD_label_en-US" xlink:label="lab_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD" xlink:to="lab_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD_label_en-US" xlink:label="lab_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD" xlink:to="lab_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:to="lab_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E" xlink:to="lab_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63" xlink:to="lab_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amounts held in eWallets</link:label>
    <link:label id="lab_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4_label_en-US" xlink:label="lab_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Deferred Credits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherDeferredCreditsCurrent" xlink:label="loc_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4" xlink:to="lab_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4" xlink:to="lab_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0" xlink:to="lab_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F_label_en-US" xlink:label="lab_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F" xlink:to="lab_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4" xlink:to="lab_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="lab_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28" xlink:to="lab_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F" xlink:to="lab_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE" xlink:to="lab_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CA191586FC5081E1294EEEB3BF07C41A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CA191586FC5081E1294EEEB3BF07C41A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CA191586FC5081E1294EEEB3BF07C41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CA191586FC5081E1294EEEB3BF07C41A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CA191586FC5081E1294EEEB3BF07C41A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD" xlink:to="lab_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088" xlink:to="lab_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_C3FF2D815A2EF85D0864917925F7B19A_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_6973F858E4D954C7937C4A763B3E7C62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_C3FF2D815A2EF85D0864917925F7B19A_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_6973F858E4D954C7937C4A763B3E7C62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6973F858E4D954C7937C4A763B3E7C62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_6973F858E4D954C7937C4A763B3E7C62" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_6973F858E4D954C7937C4A763B3E7C62" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6FAB9CC4634D275731980BB24FB3F7EB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6FAB9CC4634D275731980BB24FB3F7EB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_A7AB7E5A05F197FBBA7C0BB24FB366D3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_A7AB7E5A05F197FBBA7C0BB24FB366D3_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:to="lab_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_3B9143A8A7514FB62FB30BB24FB3B758_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_3B9143A8A7514FB62FB30BB24FB3B758_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:type="arc" />
    <link:label id="lab_nhtc_MunicipalBondsAndNotesMember_781E0FDAB7A05F456E240BB24FB328DF_terseLabel_en-US" xlink:label="lab_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal Bonds and Notes [Member]</link:label>
    <link:label id="lab_nhtc_MunicipalBondsAndNotesMember_781E0FDAB7A05F456E240BB24FB328DF_label_en-US" xlink:label="lab_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds and Notes [Member]</link:label>
    <link:label id="lab_nhtc_MunicipalBondsAndNotesMember_781E0FDAB7A05F456E240BB24FB328DF_documentation_en-US" xlink:label="lab_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_MunicipalBondsAndNotesMember" xlink:label="loc_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:to="lab_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_073049D6207F23BE4EBC0BB24FB3B634_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_073049D6207F23BE4EBC0BB24FB3B634_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:type="arc" />
    <link:label id="lab_nhtc_FinancialInstitutionInstrumentsMember_72369F052211756BF4880BB24FB3E079_terseLabel_en-US" xlink:label="lab_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Institution Instruments [Member]</link:label>
    <link:label id="lab_nhtc_FinancialInstitutionInstrumentsMember_72369F052211756BF4880BB24FB3E079_label_en-US" xlink:label="lab_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Institution Instruments [Member]</link:label>
    <link:label id="lab_nhtc_FinancialInstitutionInstrumentsMember_72369F052211756BF4880BB24FB3E079_documentation_en-US" xlink:label="lab_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to financial institution instruments.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_FinancialInstitutionInstrumentsMember" xlink:label="loc_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:to="lab_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_725904AD58010EE6131E0BB24FB32FAC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_725904AD58010EE6131E0BB24FB32FAC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B07C206143E8D2D873E90BB24FB3233D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_B07C206143E8D2D873E90BB24FB3233D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_C16CD354F2CB8530D8E60BB24FB3EAC1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_C16CD354F2CB8530D8E60BB24FB3EAC1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_215603739C759029F1870BB24FB398B1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_215603739C759029F1870BB24FB398B1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:to="lab_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EE13E7A83EE4FAB7EA13FD7A03409D16_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_520822D136755ABDA95E523C5770C0E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EE13E7A83EE4FAB7EA13FD7A03409D16_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_520822D136755ABDA95E523C5770C0E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_520822D136755ABDA95E523C5770C0E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_520822D136755ABDA95E523C5770C0E2" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_520822D136755ABDA95E523C5770C0E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_7CDCBEF5C368AD4AB770A1C613A51CE2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_7CDCBEF5C368AD4AB770A1C613A51CE2_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:to="lab_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_C1F0632B009A66A0317AA1C613A51E74_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_C1F0632B009A66A0317AA1C613A51E74_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2232302D574D7717B384A1C613A51165_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2232302D574D7717B384A1C613A51165_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseAxis_D2C66D10F0FEA1B9A02DA1C613A62474_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseAxis_D2C66D10F0FEA1B9A02DA1C613A62474_label_en-US" xlink:label="lab_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:to="lab_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_D8168CBF6DC4D812B133A1C613A62738_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationCaseTypeDomain_D8168CBF6DC4D812B133A1C613A62738_label_en-US" xlink:label="lab_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:to="lab_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:type="arc" />
    <link:label id="lab_nhtc_SecuritiesClassActionMember_92B9ED6C16CDB8F037C1A1C613A6C3CC_terseLabel_en-US" xlink:label="lab_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Class Action</link:label>
    <link:label id="lab_nhtc_SecuritiesClassActionMember_92B9ED6C16CDB8F037C1A1C613A6C3CC_label_en-US" xlink:label="lab_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Class Action [Member]</link:label>
    <link:label id="lab_nhtc_SecuritiesClassActionMember_92B9ED6C16CDB8F037C1A1C613A6C3CC_documentation_en-US" xlink:label="lab_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Securities Class Action [Member]</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_SecuritiesClassActionMember" xlink:label="loc_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:to="lab_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_48E9580BDCC78DE2EE90A1C613A6BB5D_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_48E9580BDCC78DE2EE90A1C613A6BB5D_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:to="lab_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_5E466C5125C12071641BA1C613A6BB1A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of complaints</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_5E466C5125C12071641BA1C613A6BB1A_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:type="arc" />
    <link:label id="lab_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8_label_en-US" xlink:label="lab_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INCOME TAXES [Abstract]</link:label>
    <link:label id="lab_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8_documentation_en-US" xlink:label="lab_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INCOME TAXES [Abstract]</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_INCOMETAXESAbstract" xlink:label="loc_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8" xlink:to="lab_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58" xlink:type="arc" />
    <link:label id="lab_nhtc_DocumentAndEntityInformation_8C5EB712D1AB1069C045E98FD0882C96_label_en-US" xlink:label="lab_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:label id="lab_nhtc_DocumentAndEntityInformation_8C5EB712D1AB1069C045E98FD0882C96_documentation_en-US" xlink:label="lab_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_DocumentAndEntityInformation" xlink:label="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="lab_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_3FBDEA15F9D4FAAA5B12E98FD088F12C_terseLabel_en-US" xlink:label="lab_dei_DocumentType_518A8BBDB3E25A1CB15014FE3A79F4BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_3FBDEA15F9D4FAAA5B12E98FD088F12C_label_en-US" xlink:label="lab_dei_DocumentType_518A8BBDB3E25A1CB15014FE3A79F4BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_518A8BBDB3E25A1CB15014FE3A79F4BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_518A8BBDB3E25A1CB15014FE3A79F4BA" xlink:to="lab_dei_DocumentType_518A8BBDB3E25A1CB15014FE3A79F4BA" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_931380C64C7F20B817B0E98FD088AC5D_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F3685BA318BF5311AA642672EBAE053C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_931380C64C7F20B817B0E98FD088AC5D_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_F3685BA318BF5311AA642672EBAE053C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F3685BA318BF5311AA642672EBAE053C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_F3685BA318BF5311AA642672EBAE053C" xlink:to="lab_dei_DocumentPeriodEndDate_F3685BA318BF5311AA642672EBAE053C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_BEB98D305A699C0F95F8E98FD088ED44_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_8E2515838D9D54E49A3BF9E83A202FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_BEB98D305A699C0F95F8E98FD088ED44_label_en-US" xlink:label="lab_dei_EntityRegistrantName_8E2515838D9D54E49A3BF9E83A202FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8E2515838D9D54E49A3BF9E83A202FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_8E2515838D9D54E49A3BF9E83A202FB2" xlink:to="lab_dei_EntityRegistrantName_8E2515838D9D54E49A3BF9E83A202FB2" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_6FFCCC6E557B405FA9A7E98FD0884F27_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_8A4B6EFD8A8053A480D40E355E090646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_6FFCCC6E557B405FA9A7E98FD0884F27_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_8A4B6EFD8A8053A480D40E355E090646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8A4B6EFD8A8053A480D40E355E090646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_8A4B6EFD8A8053A480D40E355E090646" xlink:to="lab_dei_EntityCentralIndexKey_8A4B6EFD8A8053A480D40E355E090646" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F4DB94F14C8E766C601AE98FD088FB33_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_73ADF30A08EB52C5A287C5DC3AA9A4B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_F4DB94F14C8E766C601AE98FD088FB33_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_73ADF30A08EB52C5A287C5DC3AA9A4B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_73ADF30A08EB52C5A287C5DC3AA9A4B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_73ADF30A08EB52C5A287C5DC3AA9A4B6" xlink:to="lab_dei_CurrentFiscalYearEndDate_73ADF30A08EB52C5A287C5DC3AA9A4B6" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_119B1DAF7A94549EDDCCE98FD088AC97_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_84CAD9FA0E4B53D2AD0AB306CADF4DC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_119B1DAF7A94549EDDCCE98FD088AC97_label_en-US" xlink:label="lab_dei_EntityFilerCategory_84CAD9FA0E4B53D2AD0AB306CADF4DC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_84CAD9FA0E4B53D2AD0AB306CADF4DC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_84CAD9FA0E4B53D2AD0AB306CADF4DC5" xlink:to="lab_dei_EntityFilerCategory_84CAD9FA0E4B53D2AD0AB306CADF4DC5" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_EC1C285EB691D37C2234E98FD0887F63_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_18BFE5690AF5531F8F9BE5FF200A2631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_EC1C285EB691D37C2234E98FD0887F63_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_18BFE5690AF5531F8F9BE5FF200A2631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_18BFE5690AF5531F8F9BE5FF200A2631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_18BFE5690AF5531F8F9BE5FF200A2631" xlink:to="lab_dei_EntityCurrentReportingStatus_18BFE5690AF5531F8F9BE5FF200A2631" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E18825711A0702E70B10E98FD089B717_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_532CAC0F5A395A08956C3B8F6E793B11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E18825711A0702E70B10E98FD089B717_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_532CAC0F5A395A08956C3B8F6E793B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_532CAC0F5A395A08956C3B8F6E793B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_532CAC0F5A395A08956C3B8F6E793B11" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_532CAC0F5A395A08956C3B8F6E793B11" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_8992D4093A1D534A0129E98FD089E496_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9D2D5FF3EBC159ACA40C294B6951B1F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8992D4093A1D534A0129E98FD089E496_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9D2D5FF3EBC159ACA40C294B6951B1F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9D2D5FF3EBC159ACA40C294B6951B1F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_9D2D5FF3EBC159ACA40C294B6951B1F9" xlink:to="lab_dei_DocumentFiscalYearFocus_9D2D5FF3EBC159ACA40C294B6951B1F9" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7B00DF4A1AC1FA4C3125E98FD0894A32_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C949124D9A4F5044A53774F3DE3A253B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7B00DF4A1AC1FA4C3125E98FD0894A32_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_C949124D9A4F5044A53774F3DE3A253B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C949124D9A4F5044A53774F3DE3A253B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_C949124D9A4F5044A53774F3DE3A253B" xlink:to="lab_dei_DocumentFiscalPeriodFocus_C949124D9A4F5044A53774F3DE3A253B" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_0C3EE9758C6E94B544EAE98FD08950F7_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_6B8F4D323DAD5F89B2A1265521EEEEB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_0C3EE9758C6E94B544EAE98FD08950F7_label_en-US" xlink:label="lab_dei_AmendmentFlag_6B8F4D323DAD5F89B2A1265521EEEEB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6B8F4D323DAD5F89B2A1265521EEEEB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_6B8F4D323DAD5F89B2A1265521EEEEB4" xlink:to="lab_dei_AmendmentFlag_6B8F4D323DAD5F89B2A1265521EEEEB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_905880A2453FB3EEC223917926B6E5D2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_9B50F80685E65AB38C853BCBD9F006B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_905880A2453FB3EEC223917926B6E5D2_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_9B50F80685E65AB38C853BCBD9F006B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9B50F80685E65AB38C853BCBD9F006B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_9B50F80685E65AB38C853BCBD9F006B9" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_9B50F80685E65AB38C853BCBD9F006B9" xlink:type="arc" />
    <link:label id="lab_nhtc_BalanceSheetComponentsAbstract_6F9690C9DCF27C2B35CD3CF22DED4384_label_en-US" xlink:label="lab_nhtc_BalanceSheetComponentsAbstract_F0D22294957755B1A22251AEE274FB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:label id="lab_nhtc_BalanceSheetComponentsAbstract_6F9690C9DCF27C2B35CD3CF22DED4384_documentation_en-US" xlink:label="lab_nhtc_BalanceSheetComponentsAbstract_F0D22294957755B1A22251AEE274FB0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Sheet Components [Abstract]</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_BalanceSheetComponentsAbstract" xlink:label="loc_nhtc_BalanceSheetComponentsAbstract_F0D22294957755B1A22251AEE274FB0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_BalanceSheetComponentsAbstract_F0D22294957755B1A22251AEE274FB0D" xlink:to="lab_nhtc_BalanceSheetComponentsAbstract_F0D22294957755B1A22251AEE274FB0D" xlink:type="arc" />
    <link:label id="lab_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_6ED8104F87D732D7B5143CEC8CF05DC7_terseLabel_en-US" xlink:label="lab_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Additional Balance Sheet Components [Table Text Block]</link:label>
    <link:label id="lab_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_6ED8104F87D732D7B5143CEC8CF05DC7_label_en-US" xlink:label="lab_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Additional Balance Sheet Components [Table Text Block]</link:label>
    <link:label id="lab_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_6ED8104F87D732D7B5143CEC8CF05DC7_documentation_en-US" xlink:label="lab_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Additional Balance Sheet Components [Table Text Block]</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock" xlink:label="loc_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:to="lab_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_9C69A31156571EC392826B110E6FBC10_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_075D3EC36BEB58C59EE5F8079E1A470E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_075D3EC36BEB58C59EE5F8079E1A470E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_075D3EC36BEB58C59EE5F8079E1A470E" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_075D3EC36BEB58C59EE5F8079E1A470E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3A293430E3505CE91AC96B110E6FB0C7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81582BAE07785DAAB57131030DAC2457" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_3A293430E3505CE91AC96B110E6FB0C7_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81582BAE07785DAAB57131030DAC2457" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81582BAE07785DAAB57131030DAC2457" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81582BAE07785DAAB57131030DAC2457" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81582BAE07785DAAB57131030DAC2457" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_A385BF63E4BD1383F7FC0BA1B6F1D433_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_54F1E754CDCD5B87BE8B94019AEE28F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_A385BF63E4BD1383F7FC0BA1B6F1D433_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_54F1E754CDCD5B87BE8B94019AEE28F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_54F1E754CDCD5B87BE8B94019AEE28F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_54F1E754CDCD5B87BE8B94019AEE28F9" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_54F1E754CDCD5B87BE8B94019AEE28F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7F7D2240F19AEFC13AF5A6D69EE6BD4A_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B0628198E0D2B8EB1A3A6D69EE71385_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B0628198E0D2B8EB1A3A6D69EE71385_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_10B89DFCD46574D1A1C5A6D69EE72D04_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1E593A9540C85BBA8F0461CFB44263DA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1E593A9540C85BBA8F0461CFB44263DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1E593A9540C85BBA8F0461CFB44263DA" xlink:to="lab_us-gaap_NetIncomeLoss_1E593A9540C85BBA8F0461CFB44263DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_098B7CB94E23F9ED2B9CA6D69EE8E643_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_098B7CB94E23F9ED2B9CA6D69EE8E643_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_E6870D5A6874EB015E43A6D69EE8D4EC_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_64203F477B805F14831E60AD86F865E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_E6870D5A6874EB015E43A6D69EE8D4EC_label_en-US" xlink:label="lab_us-gaap_Depreciation_64203F477B805F14831E60AD86F865E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_64203F477B805F14831E60AD86F865E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_64203F477B805F14831E60AD86F865E9" xlink:to="lab_us-gaap_Depreciation_64203F477B805F14831E60AD86F865E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_884D4B3F7DAC3BD703A0A6D69EE9D454_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A3A7CAD971765628BAA2B974515DE700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_884D4B3F7DAC3BD703A0A6D69EE9D454_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_A3A7CAD971765628BAA2B974515DE700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A3A7CAD971765628BAA2B974515DE700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_A3A7CAD971765628BAA2B974515DE700" xlink:to="lab_us-gaap_ShareBasedCompensation_A3A7CAD971765628BAA2B974515DE700" xlink:type="arc" />
    <link:label id="lab_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_1B242798A08DFCF6CAF7A6D69EE9F210_negatedTerseLabel_en-US" xlink:label="lab_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Translation Adjustment Realized In Net Income</link:label>
    <link:label id="lab_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_1B242798A08DFCF6CAF7A6D69EE9F210_label_en-US" xlink:label="lab_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Translation Adjustment Realized In Net Income</link:label>
    <link:label id="lab_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_1B242798A08DFCF6CAF7A6D69EE9F210_documentation_en-US" xlink:label="lab_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents cumulative translation adjustment realized in net income.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome" xlink:label="loc_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:to="lab_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FB24D959D0F25F8EE22DA6D69EE9D973_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_FB24D959D0F25F8EE22DA6D69EE9D973_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_C92E8BE919ABA7F8DAF0A6D69EE97942_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5449EC5C6C415C3ABCF188CF8B6A1F46" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_C92E8BE919ABA7F8DAF0A6D69EE97942_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_5449EC5C6C415C3ABCF188CF8B6A1F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5449EC5C6C415C3ABCF188CF8B6A1F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_5449EC5C6C415C3ABCF188CF8B6A1F46" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_5449EC5C6C415C3ABCF188CF8B6A1F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_A9885F1F990BAE4102B1A6D69EE9961B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_74E3115531DF5D6DB4D368CB9842FB80" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_A9885F1F990BAE4102B1A6D69EE9961B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_74E3115531DF5D6DB4D368CB9842FB80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_74E3115531DF5D6DB4D368CB9842FB80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_74E3115531DF5D6DB4D368CB9842FB80" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_74E3115531DF5D6DB4D368CB9842FB80" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_857D3883CDAB44A665E3A6D69EEAEE80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47773647C3F852BE979267EA7FCF057D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_857D3883CDAB44A665E3A6D69EEAEE80_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47773647C3F852BE979267EA7FCF057D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47773647C3F852BE979267EA7FCF057D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47773647C3F852BE979267EA7FCF057D" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47773647C3F852BE979267EA7FCF057D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EDAE06DB83D54980A361A6D69EEAFF5C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_212A8311356858819EEE3FECE164110B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_EDAE06DB83D54980A361A6D69EEAFF5C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_212A8311356858819EEE3FECE164110B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_212A8311356858819EEE3FECE164110B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_212A8311356858819EEE3FECE164110B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_212A8311356858819EEE3FECE164110B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A037B9D2BC4EEBF200A6D69EEAD7AB_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9E3FF6469E9157A48127435F8B1EF753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_12A037B9D2BC4EEBF200A6D69EEAD7AB_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9E3FF6469E9157A48127435F8B1EF753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9E3FF6469E9157A48127435F8B1EF753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9E3FF6469E9157A48127435F8B1EF753" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9E3FF6469E9157A48127435F8B1EF753" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7DD01D0569B88C04F5F5A6D69EEAAF09_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_87DF7278DA615515973262ED40114631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7DD01D0569B88C04F5F5A6D69EEAAF09_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_87DF7278DA615515973262ED40114631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_87DF7278DA615515973262ED40114631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_87DF7278DA615515973262ED40114631" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_87DF7278DA615515973262ED40114631" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_B21E8EE715067C532BE9A6D69EEABBA6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_192D3C2BE0235BF6A886119F358AB6B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_B21E8EE715067C532BE9A6D69EEABBA6_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_192D3C2BE0235BF6A886119F358AB6B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_192D3C2BE0235BF6A886119F358AB6B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_192D3C2BE0235BF6A886119F358AB6B9" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_192D3C2BE0235BF6A886119F358AB6B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_ED6241B280658EBFA889A6D69EEA2CC3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_449ADF92D18D55B9AED35ACFD2E82B03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_ED6241B280658EBFA889A6D69EEA2CC3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_449ADF92D18D55B9AED35ACFD2E82B03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_449ADF92D18D55B9AED35ACFD2E82B03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_449ADF92D18D55B9AED35ACFD2E82B03" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_449ADF92D18D55B9AED35ACFD2E82B03" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_3E647E3D5B5BBA133E65A6D69EEA87C8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_470B3A7A94D558308AFD1B3FEA5F9B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts held in eWallets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_3E647E3D5B5BBA133E65A6D69EEA87C8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_470B3A7A94D558308AFD1B3FEA5F9B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Customer Advances and Deposits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_470B3A7A94D558308AFD1B3FEA5F9B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_470B3A7A94D558308AFD1B3FEA5F9B8E" xlink:to="lab_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_470B3A7A94D558308AFD1B3FEA5F9B8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_6909953ABCFE0A33842DA6D69EEBA266_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99AC652E0C605DB3B9078E0B3FB6AD62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_6909953ABCFE0A33842DA6D69EEBA266_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99AC652E0C605DB3B9078E0B3FB6AD62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99AC652E0C605DB3B9078E0B3FB6AD62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99AC652E0C605DB3B9078E0B3FB6AD62" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99AC652E0C605DB3B9078E0B3FB6AD62" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCompensation_8BD75D0518753F032F56A6D69EEB0E9D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCompensation_C8FB417B3B275310B3B29F3157BF82E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term incentive</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCompensation_8BD75D0518753F032F56A6D69EEB0E9D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCompensation_C8FB417B3B275310B3B29F3157BF82E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_C8FB417B3B275310B3B29F3157BF82E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_C8FB417B3B275310B3B29F3157BF82E4" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCompensation_C8FB417B3B275310B3B29F3157BF82E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_112C3CFAD4249FCC59C4A6D69EEB8B27_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_467EDA569E135B878F26098CE1D6982A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_112C3CFAD4249FCC59C4A6D69EEB8B27_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_467EDA569E135B878F26098CE1D6982A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_467EDA569E135B878F26098CE1D6982A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_467EDA569E135B878F26098CE1D6982A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_467EDA569E135B878F26098CE1D6982A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_750769506D5C6E894DC2A6D69EEBB79E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_750769506D5C6E894DC2A6D69EEBB79E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_BC90F2FCFDF265076DECA6D69EEBFCA5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2F4F070C0C1F58C6A1A9437CEFD00164" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_BC90F2FCFDF265076DECA6D69EEBFCA5_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2F4F070C0C1F58C6A1A9437CEFD00164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2F4F070C0C1F58C6A1A9437CEFD00164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2F4F070C0C1F58C6A1A9437CEFD00164" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2F4F070C0C1F58C6A1A9437CEFD00164" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_AE437AE91936ED2F5D85A6D69EEB6377_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_98D3A3607414588186D700823B969AD4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_AE437AE91936ED2F5D85A6D69EEB6377_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_98D3A3607414588186D700823B969AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_98D3A3607414588186D700823B969AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_98D3A3607414588186D700823B969AD4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_98D3A3607414588186D700823B969AD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_67EF59E6ACE1D341A6BAA6D69EEB0241_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_67EF59E6ACE1D341A6BAA6D69EEB0241_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_784F008F541A724DCD71A6D69EECDB3F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_68164358F3315E23B28E0A128ABAF9E2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_784F008F541A724DCD71A6D69EECDB3F_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_68164358F3315E23B28E0A128ABAF9E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_68164358F3315E23B28E0A128ABAF9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_68164358F3315E23B28E0A128ABAF9E2" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_68164358F3315E23B28E0A128ABAF9E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDividends_6B786E89EC0ED7897EB4A6D69EEC6FAB_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_0CD90C09BBA15C6BA577F77FDF0BAD62" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_6B786E89EC0ED7897EB4A6D69EEC6FAB_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends_0CD90C09BBA15C6BA577F77FDF0BAD62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_0CD90C09BBA15C6BA577F77FDF0BAD62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends_0CD90C09BBA15C6BA577F77FDF0BAD62" xlink:to="lab_us-gaap_PaymentsOfDividends_0CD90C09BBA15C6BA577F77FDF0BAD62" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2EB587CA8DA6839F9C30A6D69EECEE1F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_33DC804CB34B53768F47E54F466DB2FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_2EB587CA8DA6839F9C30A6D69EECEE1F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_33DC804CB34B53768F47E54F466DB2FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_33DC804CB34B53768F47E54F466DB2FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_33DC804CB34B53768F47E54F466DB2FC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_33DC804CB34B53768F47E54F466DB2FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8B5079C01F38182D7F6BA6D69EEC0719_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2285727D0D3A5D299053C4837AC164FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_8B5079C01F38182D7F6BA6D69EEC0719_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2285727D0D3A5D299053C4837AC164FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2285727D0D3A5D299053C4837AC164FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2285727D0D3A5D299053C4837AC164FA" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2285727D0D3A5D299053C4837AC164FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FD9DCE06A94C6F213FAA6D69EECF10B_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_AB0DDFE9D90F5CA58F0833C3E471180E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7FD9DCE06A94C6F213FAA6D69EECF10B_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_AB0DDFE9D90F5CA58F0833C3E471180E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_AB0DDFE9D90F5CA58F0833C3E471180E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_AB0DDFE9D90F5CA58F0833C3E471180E" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_AB0DDFE9D90F5CA58F0833C3E471180E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CA50CBA592E0387206AA6D69EECA5EF_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_74D392D5A6EC53B7A39BA8BE1E1D6EA9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74D392D5A6EC53B7A39BA8BE1E1D6EA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74D392D5A6EC53B7A39BA8BE1E1D6EA9" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_74D392D5A6EC53B7A39BA8BE1E1D6EA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F9BD41F355D2C69159E7A6D69EEC3C08_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABD72448F5095B5A9F5D4C944CB05E03" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH AND CASH EQUIVALENTS, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABD72448F5095B5A9F5D4C944CB05E03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABD72448F5095B5A9F5D4C944CB05E03" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABD72448F5095B5A9F5D4C944CB05E03" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_933C71040B43797D7414A6D69EECBCC0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_933C71040B43797D7414A6D69EECBCC0_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssued1_9D387809AF32B4F26143A6D69EEC4E25_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1_9513A5C4A3985092876E4A518F374511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of treasury stock for employee awards, net</link:label>
    <link:label id="lab_us-gaap_StockIssued1_9D387809AF32B4F26143A6D69EEC4E25_label_en-US" xlink:label="lab_us-gaap_StockIssued1_9513A5C4A3985092876E4A518F374511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_9513A5C4A3985092876E4A518F374511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_9513A5C4A3985092876E4A518F374511" xlink:to="lab_us-gaap_StockIssued1_9513A5C4A3985092876E4A518F374511" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:to="lab_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:to="lab_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:to="lab_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:to="lab_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:type="arc" />
    <link:label id="lab_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F_terseLabel_en-US" xlink:label="lab_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2016</link:label>
    <link:label id="lab_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F_label_en-US" xlink:label="lab_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive 2016 Plan [Member]</link:label>
    <link:label id="lab_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F_documentation_en-US" xlink:label="lab_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive 2016 Plan</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_EquityIncentive2016PlanMember" xlink:label="loc_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:to="lab_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62D750DC223ACA9F220B8B02D82D8A0C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62D750DC223ACA9F220B8B02D82D8A0C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62D750DC223ACA9F220B8B02D82D8A0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62D750DC223ACA9F220B8B02D82D8A0C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62D750DC223ACA9F220B8B02D82D8A0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6A0BEDC845FFD51FE2508B02D82DB6FA_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6A0BEDC845FFD51FE2508B02D82DB6FA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6A0BEDC845FFD51FE2508B02D82DB6FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6A0BEDC845FFD51FE2508B02D82DB6FA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6A0BEDC845FFD51FE2508B02D82DB6FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_85CB027BC2D4B23BE88DF239636049A2_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_B1B820998E45528BB5A01A64EA93BE5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B1B820998E45528BB5A01A64EA93BE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B1B820998E45528BB5A01A64EA93BE5A" xlink:to="lab_us-gaap_SubsequentEventsAbstract_B1B820998E45528BB5A01A64EA93BE5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_60C56530513B42D4E221F2396360D5F4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_60C56530513B42D4E221F2396360D5F4_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:to="lab_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_08871DAE66E12408AE5EF2396360080B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_08871DAE66E12408AE5EF2396360080B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_AD0FE8D8E73FDBCC58F9F23963604341_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_AD0FE8D8E73FDBCC58F9F23963604341_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_ED969FE493A87A8918E3F23963602A56_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_ED969FE493A87A8918E3F23963602A56_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:to="lab_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_134C0C1EE557F1CE7C78F2396360D981_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_134C0C1EE557F1CE7C78F2396360D981_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:to="lab_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_C952C881B94321CBCCDBF239636068B6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_C952C881B94321CBCCDBF239636068B6_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:type="arc" />
    <link:label id="lab_nhtc_CommonStockSpecialDividendsPerShareDeclared_D1FA8F3E55708CF95107F2396360C67A_terseLabel_en-US" xlink:label="lab_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CommonStockSpecialDividendsPerShareDeclared</link:label>
    <link:label id="lab_nhtc_CommonStockSpecialDividendsPerShareDeclared_D1FA8F3E55708CF95107F2396360C67A_label_en-US" xlink:label="lab_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CommonStockSpecialDividendsPerShareDeclared</link:label>
    <link:label id="lab_nhtc_CommonStockSpecialDividendsPerShareDeclared_D1FA8F3E55708CF95107F2396360C67A_documentation_en-US" xlink:label="lab_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Special dividends declared during the period for each share of common stock outstanding.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CommonStockSpecialDividendsPerShareDeclared" xlink:label="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:to="lab_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_DAD0E45DDD81A473CC740CA98D756DBF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_051FD2DFF2CD5ED9915376E82AD44FD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_DAD0E45DDD81A473CC740CA98D756DBF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_051FD2DFF2CD5ED9915376E82AD44FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_051FD2DFF2CD5ED9915376E82AD44FD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_051FD2DFF2CD5ED9915376E82AD44FD3" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_051FD2DFF2CD5ED9915376E82AD44FD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:to="lab_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:to="lab_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends, Cash</link:label>
    <link:label id="lab_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8_label_en-US" xlink:label="lab_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCash" xlink:label="loc_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:to="lab_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition period for compensation costs not yet recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, amount authorized</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CondensedBalanceSheetStatementTable_F41DB64DFCF7CC97BD843CF231087F32_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</link:label>
    <link:label id="lab_us-gaap_CondensedBalanceSheetStatementTable_F41DB64DFCF7CC97BD843CF231087F32_label_en-US" xlink:label="lab_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedBalanceSheetStatementTable" xlink:label="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:to="lab_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_20AD594BA9F30034E9A23CF231CD0C6B_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_20AD594BA9F30034E9A23CF231CD0C6B_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_176F1F751FB868545BB43CF232DBF4BB_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_176F1F751FB868545BB43CF232DBF4BB_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsMember_7AA62DB9D8445B55927A3CF231E83971_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_7AA62DB9D8445B55927A3CF231E83971_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:to="lab_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashMember_D594A0E89365568440B03CF231DB45F9_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:label id="lab_us-gaap_CashMember_D594A0E89365568440B03CF231DB45F9_label_en-US" xlink:label="lab_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:to="lab_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:type="arc" />
    <link:label id="lab_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_848ED5EDA6278231044A3CF23117F84C_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_848ED5EDA6278231044A3CF23117F84C_label_en-US" xlink:label="lab_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="lab_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B0AB7B686B6EC74580C63CF2315EB73C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:type="arc" />
    <link:label id="lab_nhtc_AccruedSalesReturns_75C1D0325F0C7143CDDD3CF23181DBB0_terseLabel_en-US" xlink:label="lab_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:label id="lab_nhtc_AccruedSalesReturns_75C1D0325F0C7143CDDD3CF23181DBB0_label_en-US" xlink:label="lab_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:label id="lab_nhtc_AccruedSalesReturns_75C1D0325F0C7143CDDD3CF23181DBB0_documentation_en-US" xlink:label="lab_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Returns</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccruedSalesReturns" xlink:label="loc_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:to="lab_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_8E50C1FCD3A2F250DDB83CF231A3B420_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_8E50C1FCD3A2F250DDB83CF231A3B420_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:type="arc" />
    <link:label id="lab_nhtc_AccruedWarehousingAndInventoryRelatedExpense_60648CC91024C71369C83CF231B788E2_terseLabel_en-US" xlink:label="lab_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Warehousing And Inventory Related Expense</link:label>
    <link:label id="lab_nhtc_AccruedWarehousingAndInventoryRelatedExpense_60648CC91024C71369C83CF231B788E2_label_en-US" xlink:label="lab_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Warehousing And Inventory Related Expense</link:label>
    <link:label id="lab_nhtc_AccruedWarehousingAndInventoryRelatedExpense_60648CC91024C71369C83CF231B788E2_documentation_en-US" xlink:label="lab_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Warehousing And Inventory Related Expense</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccruedWarehousingAndInventoryRelatedExpense" xlink:label="loc_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:to="lab_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_391ED9FE9135A70B05553CF231C2C2CF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_63E89D6355B4CDE540FF6B110F0B449E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B80C97222AC55E3BBB4841F254665AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENT</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_63E89D6355B4CDE540FF6B110F0B449E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_B80C97222AC55E3BBB4841F254665AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B80C97222AC55E3BBB4841F254665AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_B80C97222AC55E3BBB4841F254665AA0" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_B80C97222AC55E3BBB4841F254665AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:to="lab_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:type="arc" />
    <link:label id="lab_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE_terseLabel_en-US" xlink:label="lab_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Broady Health Sciences</link:label>
    <link:label id="lab_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE_label_en-US" xlink:label="lab_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Broady Health Sciences [Member]</link:label>
    <link:label id="lab_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE_documentation_en-US" xlink:label="lab_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Broady Health Sciences.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_BroadyHealthSciencesMember" xlink:label="loc_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:to="lab_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA_terseLabel_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA_label_en-US" xlink:label="lab_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:to="lab_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096_terseLabel_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096_label_en-US" xlink:label="lab_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:to="lab_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:type="arc" />
    <link:label id="lab_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB_terseLabel_en-US" xlink:label="lab_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soothe</link:label>
    <link:label id="lab_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB_label_en-US" xlink:label="lab_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soothe [Member]</link:label>
    <link:label id="lab_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB_documentation_en-US" xlink:label="lab_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Soothe.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_SootheMember" xlink:label="loc_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:to="lab_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:type="arc" />
    <link:label id="lab_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF_terseLabel_en-US" xlink:label="lab_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ReStore</link:label>
    <link:label id="lab_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF_label_en-US" xlink:label="lab_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ReStore [Member]</link:label>
    <link:label id="lab_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF_documentation_en-US" xlink:label="lab_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a product called ReStore&#8482;.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_ReStoreMember" xlink:label="loc_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:to="lab_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:type="arc" />
    <link:label id="lab_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387_terseLabel_en-US" xlink:label="lab_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387_label_en-US" xlink:label="lab_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Rate</link:label>
    <link:label id="lab_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387_documentation_en-US" xlink:label="lab_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty rate.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_RoyaltyRate" xlink:label="loc_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:to="lab_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:to="lab_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:type="arc" />
    <link:label id="lab_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053_terseLabel_en-US" xlink:label="lab_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of days for termination notice</link:label>
    <link:label id="lab_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053_label_en-US" xlink:label="lab_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days Termination Notice</link:label>
    <link:label id="lab_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053_documentation_en-US" xlink:label="lab_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents number of days termination notice.</link:label>
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_NumberOfDaysTerminationNotice" xlink:label="loc_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:to="lab_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsAbstract_26048746CC16BB6DD5E0F4782E261C4C_label_en-US" xlink:label="lab_us-gaap_DividendsAbstract_26048746CC16BB6DD5E0F4782E261C4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsAbstract" xlink:label="loc_us-gaap_DividendsAbstract_26048746CC16BB6DD5E0F4782E261C4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAbstract_26048746CC16BB6DD5E0F4782E261C4C" xlink:to="lab_us-gaap_DividendsAbstract_26048746CC16BB6DD5E0F4782E261C4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_835F44260798797660786B110F03E846_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3C53F528075A5473A499F19E462F81B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_835F44260798797660786B110F03E846_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3C53F528075A5473A499F19E462F81B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3C53F528075A5473A499F19E462F81B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3C53F528075A5473A499F19E462F81B9" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3C53F528075A5473A499F19E462F81B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_11D67DB9ADE44AA6801E6B110F042813_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_D9FBFAD758275182AF9A930343437592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_11D67DB9ADE44AA6801E6B110F042813_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_D9FBFAD758275182AF9A930343437592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_D9FBFAD758275182AF9A930343437592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_D9FBFAD758275182AF9A930343437592" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_D9FBFAD758275182AF9A930343437592" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_C59E6C3E19320DE16D096B110F043B68_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_ECF8DAF8D9A15E80AC83D83943E0BAEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_C59E6C3E19320DE16D096B110F043B68_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_ECF8DAF8D9A15E80AC83D83943E0BAEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ECF8DAF8D9A15E80AC83D83943E0BAEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_ECF8DAF8D9A15E80AC83D83943E0BAEB" xlink:to="lab_us-gaap_PreferredStockSharesIssued_ECF8DAF8D9A15E80AC83D83943E0BAEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3293BBE3D92F8759F5F76B110F042DD1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_7641BC74FEC75F5192B1D8AB4ACE00CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3293BBE3D92F8759F5F76B110F042DD1_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_7641BC74FEC75F5192B1D8AB4ACE00CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7641BC74FEC75F5192B1D8AB4ACE00CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_7641BC74FEC75F5192B1D8AB4ACE00CC" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_7641BC74FEC75F5192B1D8AB4ACE00CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_65F5AC0B7CB744B59C186B110F04F15A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2DB446301E735AB2B61643FD110D8B37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_65F5AC0B7CB744B59C186B110F04F15A_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2DB446301E735AB2B61643FD110D8B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2DB446301E735AB2B61643FD110D8B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_2DB446301E735AB2B61643FD110D8B37" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2DB446301E735AB2B61643FD110D8B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_CFBB9C587DDF3FC2223D6B110F04896A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_20CAE0ECA7FD5ED5AFD4F6C3DF675F5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_CFBB9C587DDF3FC2223D6B110F04896A_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_20CAE0ECA7FD5ED5AFD4F6C3DF675F5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20CAE0ECA7FD5ED5AFD4F6C3DF675F5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_20CAE0ECA7FD5ED5AFD4F6C3DF675F5B" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_20CAE0ECA7FD5ED5AFD4F6C3DF675F5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_860B014225743B5C83806B110F047837_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D0540094D940542F84A4FA696706E7B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_860B014225743B5C83806B110F047837_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D0540094D940542F84A4FA696706E7B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D0540094D940542F84A4FA696706E7B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_D0540094D940542F84A4FA696706E7B2" xlink:to="lab_us-gaap_CommonStockSharesIssued_D0540094D940542F84A4FA696706E7B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_2F732047F37E94D8FD436B110F0406BE_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_EAB0E1976DEC50E09227B242985FD8DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_2F732047F37E94D8FD436B110F0406BE_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_EAB0E1976DEC50E09227B242985FD8DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_EAB0E1976DEC50E09227B242985FD8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_EAB0E1976DEC50E09227B242985FD8DA" xlink:to="lab_us-gaap_TreasuryStockShares_EAB0E1976DEC50E09227B242985FD8DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_60A4F578D14B2CA3F31291C088925D6B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="lab_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_19626B6FA77BAA5DACD791C088923A7E_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_3946FFF8B1B459A6BB0130A6C21DEC3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net sales</link:label>
    <link:label id="lab_us-gaap_SalesRevenueGoodsNet_19626B6FA77BAA5DACD791C088923A7E_label_en-US" xlink:label="lab_us-gaap_SalesRevenueGoodsNet_3946FFF8B1B459A6BB0130A6C21DEC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Goods, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_3946FFF8B1B459A6BB0130A6C21DEC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueGoodsNet_3946FFF8B1B459A6BB0130A6C21DEC3E" xlink:to="lab_us-gaap_SalesRevenueGoodsNet_3946FFF8B1B459A6BB0130A6C21DEC3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsSold_A577D5E40924F2DDA1B491C08892704B_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_576509BB32B854749CAB512A963D282B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsSold_A577D5E40924F2DDA1B491C08892704B_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsSold_576509BB32B854749CAB512A963D282B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_576509BB32B854749CAB512A963D282B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsSold_576509BB32B854749CAB512A963D282B" xlink:to="lab_us-gaap_CostOfGoodsSold_576509BB32B854749CAB512A963D282B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_77D0DA59DEE5908FD9C191C088928E7D_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_C409E96291BF5740B6A64C5D7CE47572" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_77D0DA59DEE5908FD9C191C088928E7D_label_en-US" xlink:label="lab_us-gaap_GrossProfit_C409E96291BF5740B6A64C5D7CE47572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C409E96291BF5740B6A64C5D7CE47572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_C409E96291BF5740B6A64C5D7CE47572" xlink:to="lab_us-gaap_GrossProfit_C409E96291BF5740B6A64C5D7CE47572" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3FBBF63D518EFAE4C73A91C088926CC4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_3FBBF63D518EFAE4C73A91C088926CC4_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:to="lab_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesCommissionsAndFees_863E34A3566820973D3E91C08892B49C_terseLabel_en-US" xlink:label="lab_us-gaap_SalesCommissionsAndFees_7D57C45C68D5554B9B62C567B2FF45FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commissions expense</link:label>
    <link:label id="lab_us-gaap_SalesCommissionsAndFees_863E34A3566820973D3E91C08892B49C_label_en-US" xlink:label="lab_us-gaap_SalesCommissionsAndFees_7D57C45C68D5554B9B62C567B2FF45FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Commissions and Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees_7D57C45C68D5554B9B62C567B2FF45FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesCommissionsAndFees_7D57C45C68D5554B9B62C567B2FF45FE" xlink:to="lab_us-gaap_SalesCommissionsAndFees_7D57C45C68D5554B9B62C567B2FF45FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5EAC0BBAFC6EB3AD9FC091C088929ADE_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E884DDB3DCE859BFAF1A8D8AF6611039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5EAC0BBAFC6EB3AD9FC091C088929ADE_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E884DDB3DCE859BFAF1A8D8AF6611039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E884DDB3DCE859BFAF1A8D8AF6611039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E884DDB3DCE859BFAF1A8D8AF6611039" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E884DDB3DCE859BFAF1A8D8AF6611039" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_B26E59340712D539E04C91C088923A41_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_88E203B4A7AE5FCB9753A4401C42D175" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_B26E59340712D539E04C91C088923A41_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_88E203B4A7AE5FCB9753A4401C42D175" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_88E203B4A7AE5FCB9753A4401C42D175" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_88E203B4A7AE5FCB9753A4401C42D175" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_88E203B4A7AE5FCB9753A4401C42D175" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_DB8855DE3660B36F744691C088926CA7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_150FBB064E575BA9B55678EAE0DC0BBC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_DB8855DE3660B36F744691C088926CA7_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_150FBB064E575BA9B55678EAE0DC0BBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_150FBB064E575BA9B55678EAE0DC0BBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_150FBB064E575BA9B55678EAE0DC0BBC" xlink:to="lab_us-gaap_OperatingExpenses_150FBB064E575BA9B55678EAE0DC0BBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2A82E58D9B3B45D3AA6891C088926E00_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_6EBDE195EE9251258A0E3197E9DD6060" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_2A82E58D9B3B45D3AA6891C088926E00_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_6EBDE195EE9251258A0E3197E9DD6060" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6EBDE195EE9251258A0E3197E9DD6060" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_6EBDE195EE9251258A0E3197E9DD6060" xlink:to="lab_us-gaap_OperatingIncomeLoss_6EBDE195EE9251258A0E3197E9DD6060" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B65C06D042E24826C12491C088923B67_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C025FC318BC75658AD54719256365D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_B65C06D042E24826C12491C088923B67_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_C025FC318BC75658AD54719256365D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C025FC318BC75658AD54719256365D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_C025FC318BC75658AD54719256365D51" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_C025FC318BC75658AD54719256365D51" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E7804A3EED02ABB1973F91C088920AB8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_FF27BE12776F54E59A06AE8BD0CF306C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E7804A3EED02ABB1973F91C088920AB8_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_FF27BE12776F54E59A06AE8BD0CF306C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_FF27BE12776F54E59A06AE8BD0CF306C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_FF27BE12776F54E59A06AE8BD0CF306C" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_FF27BE12776F54E59A06AE8BD0CF306C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_45C59EBC139141D7924291C08892C7E0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_755EE851C71856F0825FC1666D37E3E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_45C59EBC139141D7924291C08892C7E0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_755EE851C71856F0825FC1666D37E3E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_755EE851C71856F0825FC1666D37E3E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_755EE851C71856F0825FC1666D37E3E1" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_755EE851C71856F0825FC1666D37E3E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_1972430510C4BBD391E391C088923948_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income per common share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:to="lab_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_F2306230BFED01512D7A91C08892CD37_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_79932CE809D756878101E8F500A0FAE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_79932CE809D756878101E8F500A0FAE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_79932CE809D756878101E8F500A0FAE3" xlink:to="lab_us-gaap_EarningsPerShareBasic_79932CE809D756878101E8F500A0FAE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AAC4C3A64F409FCAC32991C08892BD4F_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AAC4C3A64F409FCAC32991C08892BD4F_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4FC02246482D0D1B8F0091C08892D18F_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCE3ED5DCE3950B3BFCCD0D88D637B13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCE3ED5DCE3950B3BFCCD0D88D637B13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCE3ED5DCE3950B3BFCCD0D88D637B13" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCE3ED5DCE3950B3BFCCD0D88D637B13" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C7FC72903E4DE784D9BB91C088927BC0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84908856DE315F44941A46297F7BBACD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84908856DE315F44941A46297F7BBACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84908856DE315F44941A46297F7BBACD" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84908856DE315F44941A46297F7BBACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsAbstract_1680CF8780CFAED8896991C08892C1AA_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsAbstract_C924C664AC7D5870B4EC16294621DEA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends declared per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsAbstract" xlink:label="loc_us-gaap_DividendsAbstract_C924C664AC7D5870B4EC16294621DEA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAbstract_C924C664AC7D5870B4EC16294621DEA7" xlink:to="lab_us-gaap_DividendsAbstract_C924C664AC7D5870B4EC16294621DEA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_7986BF161B66E102AD2C91C08892618D_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_A9801C9D2BE354D0887C04A51803629A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_A9801C9D2BE354D0887C04A51803629A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared_A9801C9D2BE354D0887C04A51803629A" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared_A9801C9D2BE354D0887C04A51803629A" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nhtc-20170630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements" xlink:href="nhtc-20170630.xsd#AccountingPronouncementsAccountingPronouncements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" xlink:href="nhtc-20170630.xsd#BalanceSheetComponentsBalanceSheetComponentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" xlink:href="nhtc-20170630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="nhtc-20170630.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" xlink:href="nhtc-20170630.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="nhtc-20170630.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:href="nhtc-20170630.xsd#ConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" xlink:href="nhtc-20170630.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" xlink:href="nhtc-20170630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" xlink:href="nhtc-20170630.xsd#IncomeTaxesIncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" xlink:href="nhtc-20170630.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:href="nhtc-20170630.xsd#NatureOfOperationsAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:href="nhtc-20170630.xsd#NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:href="nhtc-20170630.xsd#NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" xlink:href="nhtc-20170630.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" xlink:href="nhtc-20170630.xsd#RelatedPartyTransactionsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" xlink:href="nhtc-20170630.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityDividendsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:href="nhtc-20170630.xsd#StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" xlink:href="nhtc-20170630.xsd#StockholdersEquityRestrictedStockActivityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" xlink:href="nhtc-20170630.xsd#SubsequentEvent" xlink:type="simple" />
  <link:roleRef roleURI="http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" xlink:href="nhtc-20170630.xsd#SubsequentEventNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_094C9C506A945C0BB7099011F0B9BA4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_A3A1149CB25250F495D7CBF8EB89FFDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_094C9C506A945C0BB7099011F0B9BA4C" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_A3A1149CB25250F495D7CBF8EB89FFDD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponents" xlink:type="extended" />
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_BalanceSheetComponentsAbstract" xlink:label="loc_nhtc_BalanceSheetComponentsAbstract_5117F7632B4C55ABB3B9BE68B46C92F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedBalanceSheetStatementTable" xlink:label="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_BalanceSheetComponentsAbstract_5117F7632B4C55ABB3B9BE68B46C92F8" xlink:to="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_154A68DB3C2F51D1BD213351900C8311" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:label="loc_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:to="loc_us-gaap_CashEquivalentsMember_ECC5751037B4546EB5B898B171C4B096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashMember" xlink:label="loc_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_AC6F11D41B40582BA9CDC49C17184F5B" xlink:to="loc_us-gaap_CashMember_A3B87C4597065A76B4C02D4E9AE89335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:label="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementTable_9DF26589015450AF9D484929022A68FA" xlink:to="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6488E4FD092E5EBFB52AFD37F25B5A13" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccruedSalesReturns" xlink:label="loc_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_nhtc_AccruedSalesReturns_46AF9E074BE953F0AF9B030151D5F878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_DA1D28D698E15ABE92F715D927717F61" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccruedWarehousingAndInventoryRelatedExpense" xlink:label="loc_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_nhtc_AccruedWarehousingAndInventoryRelatedExpense_DF49EAF00F1C5EBD98647B6534FFBD7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems_D16227D6BD3859FCB9BEA48955E85FE2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_DF5CC0C24E0F5A15A3DBFF465F26E718" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_BalanceSheetComponentsAbstract" xlink:label="loc_nhtc_BalanceSheetComponentsAbstract_B962D811D2855526ACEB836F0E7632B4" xlink:type="locator" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock" xlink:label="loc_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_BalanceSheetComponentsAbstract_B962D811D2855526ACEB836F0E7632B4" xlink:to="loc_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock_4C6B334A3DFB542A9DE5E3CC98E3BA04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6236F40556B65DF2BE71D629A5CF29C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08AD977F79F25E4C9A9B4FD00E4A084A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6236F40556B65DF2BE71D629A5CF29C8" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_08AD977F79F25E4C9A9B4FD00E4A084A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BF05D67DF6865B1D821A9E1B487EE620" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_BF05D67DF6865B1D821A9E1B487EE620" xlink:to="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_9842DE60FF225F37A2188DABA3BA46A3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5C861AF548175042AFDFB13722B08C4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:to="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseAxis_242B2D3C08425F3F923F30B7228A8A6C" xlink:to="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_SecuritiesClassActionMember" xlink:label="loc_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationCaseTypeDomain_A547CDA43662541ABEE3A37F83C8CF54" xlink:to="loc_nhtc_SecuritiesClassActionMember_C241F073FF075691B11D5F200846BDF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3A982D4642D05640B10F75CA6C771ECC" xlink:to="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_CCDB7265BBD4541AB98350964B45C6F9" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_E170074293B553E7BD6BCA091C1A76C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90" xlink:to="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:to="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_E172E6BA30771C1F22C4EEB3BF0346C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:to="loc_us-gaap_InventoryNet_0EF4FB1CFC378EBF62A5EEB3BF036788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:to="loc_us-gaap_OtherAssetsCurrent_6F39156C49C7B29975F4EEB3BF03BF72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_86CBEE240EC41671454BEEB3BF0315F2" xlink:to="loc_us-gaap_AssetsCurrent_83007F5FDFA8EDA0CDFBEEB3BF044A9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_35B1A7BE7B78FB652079EEB3BF049C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:to="loc_us-gaap_Goodwill_0C51F11FB5FE29DE920EEEB3BF0406BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_EEC0355C35EAE326DEE7EEB3BF0467A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_63ABD42591B43823FC70EEB3BF04AAA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8968A067E3B60E9AF1FBEEB3BF038123" xlink:to="loc_us-gaap_Assets_600FD67682C907FB2E80EEB3BF04C2AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_17939DE743BB2EFE171DEEB3BF034D90" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:to="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_AccountsPayableCurrent_FE48A95B37ECCC955E86EEB3BF05C56E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_903A41ED9692F69A04C3EEB3BF050DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4535460CFF4499A54DABEEB3BF05E8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7094555CC09D78DDD043EEB3BF05EAEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_DeferredRevenueCurrent_DC3D2FF6D2CC74BACA96EEB3BF05FB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherDeferredCreditsCurrent" xlink:label="loc_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_OtherDeferredCreditsCurrent_C1024D37F0F606B757CFEEB3BF0520E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_A602552B1816C45EB0FEEEB3BF0650DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9227557809C407CEB234EEB3BF056A96" xlink:to="loc_us-gaap_LiabilitiesCurrent_9ECEA8985D07002A641DEEB3BF060BB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_D4A2CA0B37DC13943D8CEEB3BF06887C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:to="loc_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent_FDB7ABD01B80F8C22B36EEB3BF0607A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_19703AED2A1A6AF15B87EEB3BF044074" xlink:to="loc_us-gaap_Liabilities_69FA4E7D1B57EDBDE6E6EEB3BF06201F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:to="loc_us-gaap_CommitmentsAndContingencies_10A8E003B3F3B71C1C1DEEB3BF06AFC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:to="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="loc_us-gaap_PreferredStockValue_6D74E74FE74FE838B4BFEEB3BF065E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="loc_us-gaap_CommonStockValue_6988E26A6394777A146EEEB3BF060C9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="loc_us-gaap_AdditionalPaidInCapital_86AD9398B038ACD481C8EEB3BF067EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_58F98A03C57EB1B86522EEB3BF060970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CA191586FC5081E1294EEEB3BF07C41A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_CA191586FC5081E1294EEEB3BF07C41A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="loc_us-gaap_TreasuryStockValue_87380E42625B79081ED2EEB3BF0710CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F64E08460AAA15231195EEB3BF06AF66" xlink:to="loc_us-gaap_StockholdersEquity_68543831FF8540ED16E9EEB3BF073088" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_E2E523007D2C21BF02D3EEB3BF04FD5A" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_FC3EB9C09B697A1DCC0CEEB3BF07F2B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3C53F528075A5473A499F19E462F81B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3C53F528075A5473A499F19E462F81B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_D9FBFAD758275182AF9A930343437592" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_D9FBFAD758275182AF9A930343437592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ECF8DAF8D9A15E80AC83D83943E0BAEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ECF8DAF8D9A15E80AC83D83943E0BAEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7641BC74FEC75F5192B1D8AB4ACE00CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7641BC74FEC75F5192B1D8AB4ACE00CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2DB446301E735AB2B61643FD110D8B37" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2DB446301E735AB2B61643FD110D8B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20CAE0ECA7FD5ED5AFD4F6C3DF675F5B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20CAE0ECA7FD5ED5AFD4F6C3DF675F5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D0540094D940542F84A4FA696706E7B2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_CommonStockSharesIssued_D0540094D940542F84A4FA696706E7B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_EAB0E1976DEC50E09227B242985FD8DA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80404602E15C5FF486554733D879E0A4" xlink:to="loc_us-gaap_TreasuryStockShares_EAB0E1976DEC50E09227B242985FD8DA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1E593A9540C85BBA8F0461CFB44263DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:to="loc_us-gaap_NetIncomeLoss_1E593A9540C85BBA8F0461CFB44263DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_64203F477B805F14831E60AD86F865E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:to="loc_us-gaap_Depreciation_64203F477B805F14831E60AD86F865E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_A3A7CAD971765628BAA2B974515DE700" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:to="loc_us-gaap_ShareBasedCompensation_A3A7CAD971765628BAA2B974515DE700" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome" xlink:label="loc_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:to="loc_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome_0B3B307521F950FF8DA556CAF30EE410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4EE1483097C55E068146B90B8F8297EE" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_5449EC5C6C415C3ABCF188CF8B6A1F46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_5449EC5C6C415C3ABCF188CF8B6A1F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_74E3115531DF5D6DB4D368CB9842FB80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_74E3115531DF5D6DB4D368CB9842FB80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47773647C3F852BE979267EA7FCF057D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_47773647C3F852BE979267EA7FCF057D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_212A8311356858819EEE3FECE164110B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_212A8311356858819EEE3FECE164110B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9E3FF6469E9157A48127435F8B1EF753" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9E3FF6469E9157A48127435F8B1EF753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_87DF7278DA615515973262ED40114631" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_87DF7278DA615515973262ED40114631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_192D3C2BE0235BF6A886119F358AB6B9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_192D3C2BE0235BF6A886119F358AB6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_449ADF92D18D55B9AED35ACFD2E82B03" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_449ADF92D18D55B9AED35ACFD2E82B03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_470B3A7A94D558308AFD1B3FEA5F9B8E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits_470B3A7A94D558308AFD1B3FEA5F9B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99AC652E0C605DB3B9078E0B3FB6AD62" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_99AC652E0C605DB3B9078E0B3FB6AD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_C8FB417B3B275310B3B29F3157BF82E4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_B714D67C26085A129E62BA8FED1F2778" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_C8FB417B3B275310B3B29F3157BF82E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_467EDA569E135B878F26098CE1D6982A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7B9A1BE0B6235D7B8546C75A4180FF57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_467EDA569E135B878F26098CE1D6982A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2F4F070C0C1F58C6A1A9437CEFD00164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2F4F070C0C1F58C6A1A9437CEFD00164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_98D3A3607414588186D700823B969AD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_59A6CBE3CCBE54DA83FF1F59012084F6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_98D3A3607414588186D700823B969AD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_68164358F3315E23B28E0A128ABAF9E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_68164358F3315E23B28E0A128ABAF9E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfDividends" xlink:label="loc_us-gaap_PaymentsOfDividends_0CD90C09BBA15C6BA577F77FDF0BAD62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:to="loc_us-gaap_PaymentsOfDividends_0CD90C09BBA15C6BA577F77FDF0BAD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_33DC804CB34B53768F47E54F466DB2FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_88AC2BB7E78B52C0AC321708CD65F527" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_33DC804CB34B53768F47E54F466DB2FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2285727D0D3A5D299053C4837AC164FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_2285727D0D3A5D299053C4837AC164FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_AB0DDFE9D90F5CA58F0833C3E471180E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_AB0DDFE9D90F5CA58F0833C3E471180E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74D392D5A6EC53B7A39BA8BE1E1D6EA9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_74D392D5A6EC53B7A39BA8BE1E1D6EA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABD72448F5095B5A9F5D4C944CB05E03" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ABD72448F5095B5A9F5D4C944CB05E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6AAA0AF96B915224812C6E39B5E79252" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_9513A5C4A3985092876E4A518F374511" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_FB23E3D50C22545882ABE0D50A5C3124" xlink:to="loc_us-gaap_StockIssued1_9513A5C4A3985092876E4A518F374511" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_AA1BAE6A3DC15F918FB10FE23B4AD2F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:to="loc_us-gaap_NetIncomeLoss_AA1BAE6A3DC15F918FB10FE23B4AD2F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_776325B7B51C5C97B95ABEC3E008A899" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_776325B7B51C5C97B95ABEC3E008A899" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70998BD69D8E563EB3D333FA9EE370B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_70998BD69D8E563EB3D333FA9EE370B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49D2B7CA645B5646A9B6456234E8F80C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49D2B7CA645B5646A9B6456234E8F80C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_068A295BF3135FE284F7F367A578CB0E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_A3E30ED6B55957C7BEA2D20405755C24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_068A295BF3135FE284F7F367A578CB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_336FB31D4B5851AC884A7020444F6443" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_94E6A5251D305F749D4FF8517D055E4E" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_336FB31D4B5851AC884A7020444F6443" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_3946FFF8B1B459A6BB0130A6C21DEC3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_3946FFF8B1B459A6BB0130A6C21DEC3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_576509BB32B854749CAB512A963D282B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_CostOfGoodsSold_576509BB32B854749CAB512A963D282B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C409E96291BF5740B6A64C5D7CE47572" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_GrossProfit_C409E96291BF5740B6A64C5D7CE47572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesCommissionsAndFees" xlink:label="loc_us-gaap_SalesCommissionsAndFees_7D57C45C68D5554B9B62C567B2FF45FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:to="loc_us-gaap_SalesCommissionsAndFees_7D57C45C68D5554B9B62C567B2FF45FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E884DDB3DCE859BFAF1A8D8AF6611039" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E884DDB3DCE859BFAF1A8D8AF6611039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_88E203B4A7AE5FCB9753A4401C42D175" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_88E203B4A7AE5FCB9753A4401C42D175" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_150FBB064E575BA9B55678EAE0DC0BBC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4682B50EA469551CB4CCC24AACB3DF02" xlink:to="loc_us-gaap_OperatingExpenses_150FBB064E575BA9B55678EAE0DC0BBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6EBDE195EE9251258A0E3197E9DD6060" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_OperatingIncomeLoss_6EBDE195EE9251258A0E3197E9DD6060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_C025FC318BC75658AD54719256365D51" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_C025FC318BC75658AD54719256365D51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_FF27BE12776F54E59A06AE8BD0CF306C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_FF27BE12776F54E59A06AE8BD0CF306C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_755EE851C71856F0825FC1666D37E3E1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_755EE851C71856F0825FC1666D37E3E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5A27886332145746AE714CFE91D7A710" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_NetIncomeLoss_5A27886332145746AE714CFE91D7A710" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_79932CE809D756878101E8F500A0FAE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:to="loc_us-gaap_EarningsPerShareBasic_79932CE809D756878101E8F500A0FAE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_478DD2D18D815A989A6D76088A4191FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ED47D2E24C4F5317B8289F5A4ADB25DC" xlink:to="loc_us-gaap_EarningsPerShareDiluted_478DD2D18D815A989A6D76088A4191FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCE3ED5DCE3950B3BFCCD0D88D637B13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_DCE3ED5DCE3950B3BFCCD0D88D637B13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84908856DE315F44941A46297F7BBACD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_AE615A99B32F5FA6B1D5C4AA4BA631CA" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_84908856DE315F44941A46297F7BBACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsAbstract" xlink:label="loc_us-gaap_DividendsAbstract_C924C664AC7D5870B4EC16294621DEA7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1FCC6617D2C0565190F225C2167AAFE1" xlink:to="loc_us-gaap_DividendsAbstract_C924C664AC7D5870B4EC16294621DEA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_A9801C9D2BE354D0887C04A51803629A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_C924C664AC7D5870B4EC16294621DEA7" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_A9801C9D2BE354D0887C04A51803629A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_DocumentAndEntityInformation" xlink:label="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_518A8BBDB3E25A1CB15014FE3A79F4BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_DocumentType_518A8BBDB3E25A1CB15014FE3A79F4BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_F3685BA318BF5311AA642672EBAE053C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_DocumentPeriodEndDate_F3685BA318BF5311AA642672EBAE053C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_8E2515838D9D54E49A3BF9E83A202FB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_EntityRegistrantName_8E2515838D9D54E49A3BF9E83A202FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_8A4B6EFD8A8053A480D40E355E090646" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_EntityCentralIndexKey_8A4B6EFD8A8053A480D40E355E090646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_73ADF30A08EB52C5A287C5DC3AA9A4B6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_CurrentFiscalYearEndDate_73ADF30A08EB52C5A287C5DC3AA9A4B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_84CAD9FA0E4B53D2AD0AB306CADF4DC5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_EntityFilerCategory_84CAD9FA0E4B53D2AD0AB306CADF4DC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_18BFE5690AF5531F8F9BE5FF200A2631" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_EntityCurrentReportingStatus_18BFE5690AF5531F8F9BE5FF200A2631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_532CAC0F5A395A08956C3B8F6E793B11" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_532CAC0F5A395A08956C3B8F6E793B11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9D2D5FF3EBC159ACA40C294B6951B1F9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_DocumentFiscalYearFocus_9D2D5FF3EBC159ACA40C294B6951B1F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_C949124D9A4F5044A53774F3DE3A253B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_C949124D9A4F5044A53774F3DE3A253B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6B8F4D323DAD5F89B2A1265521EEEEB4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_DocumentAndEntityInformation_8DAB0B0D7DE3580B884777B273116FA0" xlink:to="loc_dei_AmendmentFlag_6B8F4D323DAD5F89B2A1265521EEEEB4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccumulatedOtherComprehensiveLossAbstract" xlink:label="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_9891469FA61E5419B30D0F7344AB04AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_9891469FA61E5419B30D0F7344AB04AE" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:to="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4F73A5F97F7B56A7ADD62A26CAEB9ED3" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_MunicipalBondsAndNotesMember" xlink:label="loc_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:to="loc_nhtc_MunicipalBondsAndNotesMember_078FDCBF981F5C0F9F28D7E4EF0EE44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_52A458479D9A5E719C6B6FFAE9C6401B" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_FinancialInstitutionInstrumentsMember" xlink:label="loc_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_AA25C7B70CC057768C54C8312A65FFF6" xlink:to="loc_nhtc_FinancialInstitutionInstrumentsMember_CF9EA5BD25B8595B82CB38B8F6DAB828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_12B5445827FB52CBBCCFC88C5EC9B0B2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_16FAFC34FB21593BAC96B52592DA5D2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax_61AB595FEA805F7DA3672ED105AE79FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_DEA7D7F9B7A45C2F82AF7361840DB8D9" xlink:to="loc_us-gaap_AvailableForSaleSecurities_AAB43D21FC6C5680BA2EE89E1F48F134" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_578762EE86AA591A9B6124BDA02D8F74" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4AC5E7F5B5B65D4B8896D917A578A16D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_578762EE86AA591A9B6124BDA02D8F74" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4AC5E7F5B5B65D4B8896D917A578A16D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_CDA12FFEBD2E58E39449E8BF3289622F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0496EE04DFBD5CA4ADD8F020D348934A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CDA12FFEBD2E58E39449E8BF3289622F" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0496EE04DFBD5CA4ADD8F020D348934A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_302D6021E70350E1B9820C8ECFB6B299" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_CDA12FFEBD2E58E39449E8BF3289622F" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_302D6021E70350E1B9820C8ECFB6B299" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_05865467B33A5D0FAF3C6AC8A90BF29A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_928EE5E8A2D15CE28CA1CE739E95E4A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_05865467B33A5D0FAF3C6AC8A90BF29A" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_928EE5E8A2D15CE28CA1CE739E95E4A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_INCOMETAXESAbstract" xlink:label="loc_nhtc_INCOMETAXESAbstract_529E0C36ACEC5FC49D6E120511904C9F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_051FD2DFF2CD5ED9915376E82AD44FD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_INCOMETAXESAbstract_529E0C36ACEC5FC49D6E120511904C9F" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_051FD2DFF2CD5ED9915376E82AD44FD3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_INCOMETAXESAbstract" xlink:label="loc_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_INCOMETAXESAbstract_D65F599E2CF3125F46978B2013C43AB8" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_1C5CD28C083E6A441D528B2014114E58" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9DED833F1372539EACD7AE35BF5453A3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_520822D136755ABDA95E523C5770C0E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9DED833F1372539EACD7AE35BF5453A3" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_520822D136755ABDA95E523C5770C0E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E06612B7E9C156C5A571D939579FD5AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1DEE5D7C8A19550BA4ED65423551F54B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E06612B7E9C156C5A571D939579FD5AC" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1DEE5D7C8A19550BA4ED65423551F54B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3EE72492692550909F32257A5D8C6D09" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_FE94843114DC5425B47EFA55452F4B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3EE72492692550909F32257A5D8C6D09" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_FE94843114DC5425B47EFA55452F4B8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_54C89EC9D61358B58323EEB3F3403FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7BC82FC67F7543384B3FEEB3F340008D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="loc_us-gaap_EarningsPerShareBasic_78000A345B17F0781441EEB3F340EA46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_F4515BA18C1C6D50A6CAEEB3F340DA6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_125EDB44ECA5F2B60207EEB3F341D779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F0BF5FE394180367DD7BEEB3F341A5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84E498786381D8CFD008EEB3F33F8163" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3797A66E060A66AD0F20EEB3F341EAA3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2F25A4658C885A3FAF4DDF367326A017" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6973F858E4D954C7937C4A763B3E7C62" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2F25A4658C885A3FAF4DDF367326A017" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_6973F858E4D954C7937C4A763B3E7C62" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_214A0D4B855E517E9C6C7E3E2F72A30C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_9B50F80685E65AB38C853BCBD9F006B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_214A0D4B855E517E9C6C7E3E2F72A30C" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_9B50F80685E65AB38C853BCBD9F006B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_075D3EC36BEB58C59EE5F8079E1A470E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81582BAE07785DAAB57131030DAC2457" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_075D3EC36BEB58C59EE5F8079E1A470E" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_81582BAE07785DAAB57131030DAC2457" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_A729F33BECCEBD2EE8628B06F378B752" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_A729F33BECCEBD2EE8628B06F378B752" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_49A9B09C9AC6EA70F4BC8B06F379247C" xlink:to="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_BroadyHealthSciencesMember" xlink:label="loc_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_91F77DB1902E133C80E38B06F379850D" xlink:to="loc_nhtc_BroadyHealthSciencesMember_0AA59DB622F1AEF121798B06F3798CDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:to="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductOrServiceAxis_DBAFFC5EBBA483590F468B06F37928BA" xlink:to="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_SootheMember" xlink:label="loc_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:to="loc_nhtc_SootheMember_3BF32307EE5D5586986A8B06F379CEBB" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_ReStoreMember" xlink:label="loc_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductsAndServicesDomain_183C1CDCE064ACD328DE8B06F3794096" xlink:to="loc_nhtc_ReStoreMember_0D114167D4A182E251028B06F37A0DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_7B522BDA03CC1C6A5E618B06F378539F" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_RoyaltyRate" xlink:label="loc_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="loc_nhtc_RoyaltyRate_84EBCD7E0E38536569D38B06F37AB387" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="loc_us-gaap_RoyaltyExpense_22DB24CC250F64D387C18B06F37A2631" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_NumberOfDaysTerminationNotice" xlink:label="loc_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_25D9A419308634DBDB938B06F37AFF38" xlink:to="loc_nhtc_NumberOfDaysTerminationNotice_2D5362AD5D0339E49BB38B06F37AC053" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8211AF535E4D5BAB9D1DB57CC35091DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C40118AAB7758788A96539F5E32BE21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8211AF535E4D5BAB9D1DB57CC35091DA" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7C40118AAB7758788A96539F5E32BE21" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccumulatedOtherComprehensiveLossAbstract" xlink:label="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_4779FBE30BF85D129A78D7F550FFC772" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_214A51AD2D665BC49F0AF67078595655" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_4779FBE30BF85D129A78D7F550FFC772" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_214A51AD2D665BC49F0AF67078595655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_080064A0C80E5F63A476CBF67D73FAF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_214A51AD2D665BC49F0AF67078595655" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_080064A0C80E5F63A476CBF67D73FAF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_080064A0C80E5F63A476CBF67D73FAF8" xlink:to="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_92A89301A1D7545EA6855EA6FF5A34DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_E46C5E48DE8F5C1D84A233EC261D964A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_FD1FBC2575A95F0E82C5748A0DF832F3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_50B63B6C51685E6EB23279E037F85F62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_FAB74226F8B855B8839EC868DD882CD0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_214A51AD2D665BC49F0AF67078595655" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_FAB74226F8B855B8839EC868DD882CD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_FAB74226F8B855B8839EC868DD882CD0" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_C8DC59F2745A51498C604AA03E7DED39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_73B4199890BC51E7B25D702CE8E40DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_D22DA14194EF58CFBEF868E0702D3910" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F004C0E72F6D55A0806B82269087349B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_07AEE930148F541D974D71644EE4753E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_F004C0E72F6D55A0806B82269087349B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_AccumulatedOtherComprehensiveLossAbstract" xlink:label="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_C8AA3DEE61325E948CCA2A218C53D6CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_nhtc_AccumulatedOtherComprehensiveLossAbstract_C8AA3DEE61325E948CCA2A218C53D6CA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_A5B446292CCD5C8ABA04136E83DB079D" xlink:to="loc_us-gaap_EquityComponentDomain_337ACB53C2785F08B4E42783D9A05B34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_96EBDD50BE5454E0AC8BD27E7461CEA9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_61FA3725B23655A8A762A009B1E0EDF8" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3A0A6BF43CCB529D9EC2A4384BE4529B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsAbstract" xlink:label="loc_us-gaap_DividendsAbstract_26048746CC16BB6DD5E0F4782E261C4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_26048746CC16BB6DD5E0F4782E261C4C" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_30DB52A9632542DBAF61F4782E2D8AAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CD9D414856F81CC578C38AECBBD5B611" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CD9D414856F81CC578C38AECBBD5B611" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0A923D32F135D00A4F318AECBBD91FD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:to="loc_us-gaap_PlanNameAxis_0A923D32F135D00A4F318AECBBD91FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0A923D32F135D00A4F318AECBBD91FD4" xlink:to="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_EquityIncentive2016PlanMember" xlink:label="loc_nhtc_EquityIncentive2016PlanMember_4AC4DFD42FE9397808448AECBBDFAB91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_379DCF686F17F644EF2A8AECBBDFFA4F" xlink:to="loc_nhtc_EquityIncentive2016PlanMember_4AC4DFD42FE9397808448AECBBDFAB91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_CF12B6CB8657B0BC45D98AECBBDFEE5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:to="loc_us-gaap_AwardTypeAxis_CF12B6CB8657B0BC45D98AECBBDFEE5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_CF12B6CB8657B0BC45D98AECBBDFEE5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4C9DFD23ADC7C8DA3EA18AECBBDFE72C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2849B43CC71AB2D90F938AECBBDF6FC6" xlink:to="loc_us-gaap_RestrictedStockMember_4C9DFD23ADC7C8DA3EA18AECBBDFE72C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40240A61B25923C6884B8AECBBDF2E5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40240A61B25923C6884B8AECBBDF2E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40240A61B25923C6884B8AECBBDF2E5C" xlink:to="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4302E2C732EB7FCDC5B18AECBBE0360A" xlink:to="loc_us-gaap_CommonStockMember_9D5DE345075FC3B475018AECBBE067BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63A1ADAA8634EF43469C8AECBBD8BCF2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_BBDFC3F92664357EB3FF8AECBBE061C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_BBDFC3F92664357EB3FF8AECBBE061C4" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CommonStockSpecialDividendsPerShareDeclared" xlink:label="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_ED5B06892488DEC0551A8AECBBE00B52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_ED5B06892488DEC0551A8AECBBE00B52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_DividendsCommonStockCash_D538E8B21F059A3C66FF8AECBBE01DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DividendsCash" xlink:label="loc_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_DividendsCash_1632252D7CE8F4937B178AECBBE0E5C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_00F7FDBB1D41A49B8CAF8AECBBE0D771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_8217898F0CE3FF4DFBF18AECBBE12EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8577E8B2D6B27EDCBC428AECBBE1048B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_627AD75645AA466F92898AECBBE193C3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_627AD75645AA466F92898AECBBE193C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B1A9E35CD6049D6168988AECBBE14359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_7F41888E0FB0FAE2D4158AECBBE1A676" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1A89505694C8FDFC9E908AECBBE15609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8BE9DE7512F791CE99EC8AECBBE24F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_C718FEA9D886E03AD2608AECBBE23E6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareCashPaid" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_604E7A1AB9E998A8C5B88AECBBE063CB" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_C6C45699930F4B2614828AECBBE2E41E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C06970154017894DCF3A8B02D8267268" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C06970154017894DCF3A8B02D8267268" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:to="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7A930B1A603E57A088CE8B02D82C467B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4AF9E7CE0536CB9A3FEC8B02D82C2E31" xlink:to="loc_us-gaap_RestrictedStockMember_392D5136BFCB1B0705BC8B02D82CB23F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:to="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0FE3D4B3BD3A168D50F28B02D82CEF9C" xlink:to="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_EquityIncentive2016PlanMember" xlink:label="loc_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_592808BEA7BEFE4EB9248B02D82C54C4" xlink:to="loc_nhtc_EquityIncentive2016PlanMember_F88B61F202B0B95735018B02D82CF55F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DCBD71DBDAB3FABD4D748B02D82BB856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_703919691139C3145E6B8B02D82C3758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1309026D1F6EA4CABA848B02D82CF6CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D5F8BBF76C85CB911CBE8B02D82DCF02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CE0F523DA90FAEEB64D58B02D82D41B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D2ABC607A001411E4F2C8B02D82DCC2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62D750DC223ACA9F220B8B02D82D8A0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_05AA87FA6C41527B21AD8B02D82CFE2A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_62D750DC223ACA9F220B8B02D82D8A0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1098FD8DCBA70839FBA48B02D82D1F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CC89BE97C16AF717D03E8B02D82DF825" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E907AF653C914E872E728B02D82D8D7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF9C106888374EC251268B02D82D5972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6A0BEDC845FFD51FE2508B02D82DB6FA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_B83D98A19E3B61B76A7E8B02D82D1FC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6A0BEDC845FFD51FE2508B02D82DB6FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_BEF43DDB0587E7738A988B02D82CA39E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_868DCD97686DC987D7A38B02D82D3410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C06970154017894DCF3A8B02D8267268" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_10858A83642953DD57868B02D84A15BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D83AB1E3A2B35FBAAF4A780C1682CFD1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_54F1E754CDCD5B87BE8B94019AEE28F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D83AB1E3A2B35FBAAF4A780C1682CFD1" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_54F1E754CDCD5B87BE8B94019AEE28F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_BC454526E72E5710A0609C76D5014113" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_B80C97222AC55E3BBB4841F254665AA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_BC454526E72E5710A0609C76D5014113" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_B80C97222AC55E3BBB4841F254665AA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B1B820998E45528BB5A01A64EA93BE5A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B1B820998E45528BB5A01A64EA93BE5A" xlink:to="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1EA752E6D56E5534A54DCBA28EEDF5FE" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_F2FB2AABAE41552DB65645507DDE3780" xlink:to="loc_us-gaap_SubsequentEventMember_853586014560524CA910BD07238C3876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_21B8838F0F8B52FCB2A478E3FB942ACF" xlink:to="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_D990838789725B76B4D803EC8D30245F" xlink:type="arc" />
    <link:loc xlink:href="nhtc-20170630.xsd#nhtc_CommonStockSpecialDividendsPerShareDeclared" xlink:label="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_C7D86298338959A18D4FA34B3C6D42DF" xlink:to="loc_nhtc_CommonStockSpecialDividendsPerShareDeclared_108D2C4AA3E956738DC753E0229C3C94" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>nhtc20170802_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nhtc="http://www.naturalhealthtrendscorp.com/20170630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nhtc-20170630.xsd" xlink:type="simple"/>
    <context id="FD2017Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:MunicipalBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:MunicipalBondsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:FinancialInstitutionInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">nhtc:FinancialInstitutionInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="I2017Q3jul28-jul28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2017-07-28</instant>
        </period>
    </context>
    <context id="FD2017Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="FI2017Q1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="I2016Q2Apr07_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-07</instant>
        </period>
    </context>
    <context id="D2016Q2Apr08-Apr08_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-08</startDate>
            <endDate>2016-04-08</endDate>
        </period>
    </context>
    <context id="I2015Q3Jul28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2015-07-28</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q1jan24-jan24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2017-01-24</startDate>
            <endDate>2017-01-24</endDate>
        </period>
    </context>
    <context id="I2016Q1Jan12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2016-01-12</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="D2017Q2Apr24-Apr24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2017-04-24</startDate>
            <endDate>2017-04-24</endDate>
        </period>
    </context>
    <context id="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nhtc:EquityIncentive2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2017Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2016Q1QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">nhtc:SecuritiesClassActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FD2016Q2YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-02-01</startDate>
            <endDate>2013-02-28</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:ReStoreMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-29</startDate>
            <endDate>2015-04-29</endDate>
        </period>
    </context>
    <context id="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">nhtc:SootheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">nhtc:BroadyHealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-31</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="FD2016Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <startDate>2017-04-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="FI2016Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="FI2015Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000912061</identifier>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="complaint">
        <measure>nhtc:complaint</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2017Q2YTD"
      id="Fact-C699FAD9E9C753A6AD131EA191678B22-wk-Fact-C699FAD9E9C753A6AD131EA191678B22">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2017Q2YTD"
      id="Fact-6B8C77B1AE2E53F2989C0F4036FC1F08-wk-Fact-6B8C77B1AE2E53F2989C0F4036FC1F08">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2017Q2YTD"
      id="Fact-C62A7C9619D05BBFADF7504F79B94C58-wk-Fact-C62A7C9619D05BBFADF7504F79B94C58">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2017Q2YTD"
      id="Fact-763FDFA098E55234A07EA913A5654B58-wk-Fact-763FDFA098E55234A07EA913A5654B58">2017</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2017Q2YTD"
      id="Fact-7138BBCD6AE35CA09E4385B565A7CB8E-wk-Fact-7138BBCD6AE35CA09E4385B565A7CB8E">0000912061</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2017Q2YTD"
      id="Fact-6453A0EDC18F5D7280F62870F7A7348E-wk-Fact-6453A0EDC18F5D7280F62870F7A7348E">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory
      contextRef="FD2017Q2YTD"
      id="Fact-DA59C20086A657D6B78924C8AE909A68-wk-Fact-DA59C20086A657D6B78924C8AE909A68">Accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-C6B348288D7453FFAD01757FE2FEB5FA-wk-Fact-C6B348288D7453FFAD01757FE2FEB5FA"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-5C628AADC2EC591AB1B647DFCFCCECFC-wk-Fact-5C628AADC2EC591AB1B647DFCFCCECFC"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-DDCC2E5DAD2853C6A38668D3B7B49766-wk-Fact-DDCC2E5DAD2853C6A38668D3B7B49766"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-652A6975F7CD5EC3891D8BDADB634755-wk-Fact-652A6975F7CD5EC3891D8BDADB634755"
      unitRef="shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-2723FD60FEF25491B7840621001DD570-wk-Fact-2723FD60FEF25491B7840621001DD570"
      unitRef="shares">12979414</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-2F05C60051DC56678DCD5D7602BEC761-wk-Fact-2F05C60051DC56678DCD5D7602BEC761"
      unitRef="shares">12979414</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-29DFE6C8D6015A049C61FE7FBF29E902-wk-Fact-29DFE6C8D6015A049C61FE7FBF29E902"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-5372D56CFF4752869E4B19D5A4F58D59-wk-Fact-5372D56CFF4752869E4B19D5A4F58D59"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-9F3BECED263E569B89C87060F95A5AAD-wk-Fact-9F3BECED263E569B89C87060F95A5AAD"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-8E28A08DFB95526DBEE8EFE82A6D9237-wk-Fact-8E28A08DFB95526DBEE8EFE82A6D9237"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-11CB6C4AA1F45EB984064FACA08BEACA-wk-Fact-11CB6C4AA1F45EB984064FACA08BEACA"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-49A839F4F1265C7C98CF72620B409640-wk-Fact-49A839F4F1265C7C98CF72620B409640"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-764D0CEE7B085412B27E2AC5B72156E5-wk-Fact-764D0CEE7B085412B27E2AC5B72156E5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-835E0D5FD9445209BF14DF67B4237412-wk-Fact-835E0D5FD9445209BF14DF67B4237412"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="D2016Q2Apr08-Apr08_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      id="Fact-7FDAA9058813378A24658B0B22CE1D7C-wk-Fact-7FDAA9058813378A24658B0B22CE1D7C">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:TreasuryStockShares
      contextRef="FI2016Q4"
      decimals="INF"
      id="Fact-D46EC1FFD59F593FAC078ADAE260AB76-wk-Fact-D46EC1FFD59F593FAC078ADAE260AB76"
      unitRef="shares">1692218</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="FI2017Q2"
      decimals="INF"
      id="Fact-B13112F0353E52AB832B9353CDD981FC-wk-Fact-B13112F0353E52AB832B9353CDD981FC"
      unitRef="shares">1637524</us-gaap:TreasuryStockShares>
    <dei:DocumentType
      contextRef="FD2017Q2YTD"
      id="d140105964e333-wk-Fact-CC935D88AB7C5EAAB87E4B17208D2DFF">10-Q</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="FD2017Q2YTD"
      id="d140105964e369-wk-Fact-7F008383D95E577AB90E6473978DD8AB">2017-06-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="FD2017Q2YTD"
      id="d140105964e410-wk-Fact-5898EDAC997057C5A024EB1AF5B90E66">NATURAL HEALTH TRENDS CORP.</dei:EntityRegistrantName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2017Q3jul28-jul28"
      decimals="INF"
      id="d140105964e584-wk-Fact-47742066D4C05B6E9346B5A19EE38B24"
      unitRef="shares">11341890</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e523-wk-Fact-3AA82854F4645D1AB8EF2F2C66F367FA"
      unitRef="usd">136261000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e542-wk-Fact-A2AA8FBEA98E5148B2B2DF86BC44772E"
      unitRef="usd">125921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InventoryNet
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e557-wk-Fact-C3892C3D315C53C6B25F942DE2609AED"
      unitRef="usd">9804000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e576-wk-Fact-CA40D84676FE51C69BEF362012C658B4"
      unitRef="usd">11257000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e596-wk-Fact-1AF2A66C40DD53968850E52A749E9E7E"
      unitRef="usd">3638000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e615-wk-Fact-E9F8DD8F7D9757A8B232DD4FA64E5062"
      unitRef="usd">4066000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e635-wk-Fact-A11727D52D005F0EA2256E34BFD26876"
      unitRef="usd">149703000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e654-wk-Fact-1992C72F5A96537AA85B2B606760B9E1"
      unitRef="usd">141244000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e674-wk-Fact-8833098BC9D4566AADBAA98CD898225D"
      unitRef="usd">1292000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e693-wk-Fact-3E0D4410D6A3573AB73FADD5487DE8FC"
      unitRef="usd">1388000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e713-wk-Fact-1FBD9C55DAED56359FC74F25A0D735F2"
      unitRef="usd">1764000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e732-wk-Fact-293E31DB5FD250CD855D78EBA2264D53"
      unitRef="usd">1764000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e752-wk-Fact-2380E4EE1D47588C8F8CDAB7A188B700"
      unitRef="usd">3039000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e771-wk-Fact-CEBD8310F93B521FBAD3C2D46179B4BE"
      unitRef="usd">2963000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e792-wk-Fact-C1DDE47B74975713BE0A5C63480AA60D"
      unitRef="usd">768000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e811-wk-Fact-2CF98BCCEAF75E8386826D9F88AD1D16"
      unitRef="usd">692000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e836-wk-Fact-8513E9E21B745A1FB997624E2EF10F66"
      unitRef="usd">156566000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e855-wk-Fact-7EB1190A4B635A1A85F18337885A834C"
      unitRef="usd">148051000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e957-wk-Fact-1C9365259CC859659838F14C0D408B4C"
      unitRef="usd">2371000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e976-wk-Fact-A4F687A68956522894DB87C2ECB4A426"
      unitRef="usd">2145000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e991-wk-Fact-910DC38D62CA5AF4862F98088CF510EC"
      unitRef="usd">4971000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1010-wk-Fact-01BD7D4DF303542190CFC58185DA6A0B"
      unitRef="usd">663000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1030-wk-Fact-27463135780C5AB095B3C44C998B5370"
      unitRef="usd">12666000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1049-wk-Fact-2FF0793CA2A75B7A978C31604D0EC9FA"
      unitRef="usd">13611000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1069-wk-Fact-359548B1D77C57B684BDEA3F8F35201F"
      unitRef="usd">10366000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1088-wk-Fact-8C9710A778E9599096A351B362BA4521"
      unitRef="usd">14989000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1108-wk-Fact-9D3CAF31D16A588DA7F9C3244ABDBF2B"
      unitRef="usd">3994000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1127-wk-Fact-AD2E7EA24D6B541E8BED8AA07A7F5C98"
      unitRef="usd">4948000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherDeferredCreditsCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1147-wk-Fact-E18824088544586B858EA6B0088E03A3"
      unitRef="usd">18713000</us-gaap:OtherDeferredCreditsCurrent>
    <us-gaap:OtherDeferredCreditsCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1166-wk-Fact-788AA76BE68A57509100D6352810F0DB"
      unitRef="usd">19165000</us-gaap:OtherDeferredCreditsCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1186-wk-Fact-96C2F0CD2DA7579C8771A832B058DBDD"
      unitRef="usd">1622000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1205-wk-Fact-B5F8DC4ECF9358B98F2F733C7599A61E"
      unitRef="usd">1633000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1226-wk-Fact-9B92F8B30E2A537DA9CD736BCC157131"
      unitRef="usd">54703000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1245-wk-Fact-2A5BEBF47A545C35A27CDEA2FB634FA7"
      unitRef="usd">57154000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1265-wk-Fact-93C34655C1CA5982955975E545E73B07"
      unitRef="usd">285000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxLiabilitiesNoncurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1284-wk-Fact-5EBCE7D251265DDA9C08DF60F553F9EE"
      unitRef="usd">268000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1304-wk-Fact-EAAF18B446C0578BB4CB70E36667D353"
      unitRef="usd">7179000</us-gaap:DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1323-wk-Fact-5409876514B55214AFD303879D5AD5D3"
      unitRef="usd">8190000</us-gaap:DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1343-wk-Fact-9CE69A9F8BE95B8792A8674ADAF54918"
      unitRef="usd">62167000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1362-wk-Fact-11150E6FF15559F19AB72F8F5C620007"
      unitRef="usd">65612000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2017Q2"
      id="d140108584e1382-wk-Fact-A4159D55600159A2B5F07DA371703F6C"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2016Q4"
      id="d140108584e1401-wk-Fact-C42933BABE8C53DCA84F486D1AB65BB6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1462-wk-Fact-7C2CEFD47A705A74AC812689C1D51ECE"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1481-wk-Fact-F3B0BB396A4C5022A0A186D5BE127855"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1501-wk-Fact-9BCEA8069B3550CCB11FE6F256AC7E48"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1520-wk-Fact-4ECECC92B2CA546597F0990DD76F4FD8"
      unitRef="usd">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1540-wk-Fact-F2FF25620A2B5CDBBDAB799B9724275E"
      unitRef="usd">86665000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1559-wk-Fact-622ECBFCDDE65C9C89AFCA24BAB4F4A1"
      unitRef="usd">86574000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1579-wk-Fact-11598074D26C5835BAB6C0D2CB1F7405"
      unitRef="usd">49198000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1598-wk-Fact-D75755ED70BA55FE882785BB151726A8"
      unitRef="usd">38548000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1618-wk-Fact-30B39A386426516DB0029ACA843E2490"
      unitRef="usd">-907000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1638-wk-Fact-94ADD82D1FF754DC991BE04AB2AF63A8"
      unitRef="usd">-807000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1660-wk-Fact-395E2A4DB30C588DB36098BA5203F1DF"
      unitRef="usd">40570000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1680-wk-Fact-90E3E830EF0F592B83745CFC011F5C94"
      unitRef="usd">41889000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1701-wk-Fact-D09DE923BA2758AFA3BCEB4BBDC1C702"
      unitRef="usd">94399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1720-wk-Fact-05A423782CD25002B98C997AB4803800"
      unitRef="usd">82439000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140108584e1745-wk-Fact-34C94BCF069B5AB5B0713CFF2FDD1667"
      unitRef="usd">156566000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140108584e1764-wk-Fact-3FDB436DB9CE58C18CE48E1955E10167"
      unitRef="usd">148051000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e530-wk-Fact-19EDD3862600543FAA77FE93F6DE68F8"
      unitRef="usd">51465000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e549-wk-Fact-118DB6B34C9D580B877EF776E4066E90"
      unitRef="usd">80391000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e568-wk-Fact-10703331B9675673A80158339141914E"
      unitRef="usd">111339000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:SalesRevenueGoodsNet
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e588-wk-Fact-AC707A81DB3E58A8A0E3CA19E072D3D4"
      unitRef="usd">154737000</us-gaap:SalesRevenueGoodsNet>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e603-wk-Fact-E1FBFDD077915042BB3F994736D63341"
      unitRef="usd">9793000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e622-wk-Fact-6BEAAD2188445DD68F8670A0BDE5B977"
      unitRef="usd">15059000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e641-wk-Fact-9625AC4DB0B5582B82DF4CB2C2639F8C"
      unitRef="usd">21038000</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e661-wk-Fact-88EF8E76940153B38CA4712BB088D742"
      unitRef="usd">29339000</us-gaap:CostOfGoodsSold>
    <us-gaap:GrossProfit
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e681-wk-Fact-18F52E88BF63541C95E521118495BDA2"
      unitRef="usd">41672000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e700-wk-Fact-52F0CE528A035024AF67A9413ED2713D"
      unitRef="usd">65332000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e719-wk-Fact-7436575141CC50EE85B1339013A72172"
      unitRef="usd">90301000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e739-wk-Fact-FD34310F69D750D39AE42602530ABD68"
      unitRef="usd">125398000</us-gaap:GrossProfit>
    <us-gaap:SalesCommissionsAndFees
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e841-wk-Fact-2126BD95B22E522598652CF2D2B10F46"
      unitRef="usd">22075000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e860-wk-Fact-CEE2B304A0B15A11A84A33F19309D1E6"
      unitRef="usd">37883000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e879-wk-Fact-CFA7559DEB095EE68F507BBC9CFDFEBF"
      unitRef="usd">48040000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SalesCommissionsAndFees
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e899-wk-Fact-64F1FB144EA85820B4D8D062ACE1C5BA"
      unitRef="usd">72969000</us-gaap:SalesCommissionsAndFees>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e919-wk-Fact-B8480EEB3EC85D189D9172077E33958B"
      unitRef="usd">6590000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e938-wk-Fact-EE91CB9297E25C279B2381BF288CF876"
      unitRef="usd">12431000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e957-wk-Fact-09BBDF58479F59EC84495EAABC5F260A"
      unitRef="usd">16126000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e977-wk-Fact-7ED76C85FEAC5BCEB59D8F3DFBB1BB44"
      unitRef="usd">23335000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e997-wk-Fact-7E70A531D35A5E58A2B942B2132A172E"
      unitRef="usd">140000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1016-wk-Fact-C93ED2AEC9475C3B93AF402B6089E934"
      unitRef="usd">91000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1035-wk-Fact-67EB13EF9DA659DF95DD03879711A654"
      unitRef="usd">276000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1055-wk-Fact-56E27883658B5E1F898F4EE0BBF3FBA4"
      unitRef="usd">180000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1075-wk-Fact-18E8D481BD815D41A45D5DC94DA7CD8E"
      unitRef="usd">28805000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1094-wk-Fact-078B151574A4508296DAC94FC8294F7D"
      unitRef="usd">50405000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1113-wk-Fact-DCF123B4894152BA9D108B22E1D5798F"
      unitRef="usd">64442000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1133-wk-Fact-4E7BB785C18653BCA053ACA154C55E9B"
      unitRef="usd">96484000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1153-wk-Fact-3A195B7F7B705C2BB7895F4B2BDDE2B5"
      unitRef="usd">12867000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1172-wk-Fact-7E915E69CFCB561381959593BBCBB024"
      unitRef="usd">14927000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1191-wk-Fact-3881E0529B4654419030175D014B2853"
      unitRef="usd">25859000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1211-wk-Fact-6AB128F1DCC35C15A3D57D90EF21E64F"
      unitRef="usd">28914000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1232-wk-Fact-434FE4CAFB1A55E290DBFF644851F2CF"
      unitRef="usd">80000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1251-wk-Fact-FC4F361559C755B5B466E30C78235DDF"
      unitRef="usd">16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1270-wk-Fact-BC5C58595419554BB014B8247D720764"
      unitRef="usd">236000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1290-wk-Fact-D70B273BA14E594090337860B52BC45F"
      unitRef="usd">-8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1311-wk-Fact-B1CE882C14F552F783B81577281E564A"
      unitRef="usd">12947000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1330-wk-Fact-4F9BC74FD8065CD8A602ACA28839C438"
      unitRef="usd">14943000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1349-wk-Fact-B0886BC91812547AA43B90AB2C888261"
      unitRef="usd">26095000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1369-wk-Fact-6248EE52061853FD9441BEBC2D57D061"
      unitRef="usd">28906000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1389-wk-Fact-DD9A1FF729135378B790097B57C86BAA"
      unitRef="usd">2644000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1408-wk-Fact-2452C9E617655DF996BACC121FC8E5B2"
      unitRef="usd">2742000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1427-wk-Fact-4EFFE706DCDB5C14BF042C7587221669"
      unitRef="usd">5367000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1447-wk-Fact-6E50736E919850FD9D380DD0B1213BCC"
      unitRef="usd">5425000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1472-wk-Fact-D61402E6386B5C61B3849B9F0DCF9F22"
      unitRef="usd">10303000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1491-wk-Fact-DF72591BFB29537FBDB5F63B4DBCACB5"
      unitRef="usd">12201000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1510-wk-Fact-FDB9EDA593AA50B180B5D35A4B8A57FF"
      unitRef="usd">20728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1530-wk-Fact-6F6E769DCE635A8CABA8AA041D956C79"
      unitRef="usd">23481000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q2QTD"
      decimals="2"
      id="d140110624e1632-wk-Fact-FBACBE76C19E51CC99DB4928E995AF32"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2016Q2QTD"
      decimals="2"
      id="d140110624e1651-wk-Fact-AAD38C082ED154B7B796EF0670C263F2"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q2YTD"
      decimals="2"
      id="d140110624e1670-wk-Fact-38443D75E9DD543F99E829329809E8F9"
      unitRef="usdPerShare">1.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2016Q2YTD"
      decimals="2"
      id="d140110624e1690-wk-Fact-7C6568F703C05D17AF158FD73D17F193"
      unitRef="usdPerShare">2.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q2QTD"
      decimals="2"
      id="d140110624e1710-wk-Fact-8668D6CDF5025FE3BA7A8F58844DA616"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2016Q2QTD"
      decimals="2"
      id="d140110624e1729-wk-Fact-C2A89157206D5BE09D1792A84B8FF350"
      unitRef="usdPerShare">1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q2YTD"
      decimals="2"
      id="d140110624e1748-wk-Fact-4AEEBC57085E50509438D69D785C316E"
      unitRef="usdPerShare">1.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2016Q2YTD"
      decimals="2"
      id="d140110624e1768-wk-Fact-1F89FCF28B465D52937865903C7BDE05"
      unitRef="usdPerShare">2.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1865-wk-Fact-F27EE613B03C529FAA1DA48DDEF41D21"
      unitRef="shares">11243000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1884-wk-Fact-9D22B566BD3259B6B981DB468373FAE5"
      unitRef="shares">11333000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1903-wk-Fact-319773D3A7055A938DC73A32DEA77711"
      unitRef="shares">11236000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e1923-wk-Fact-08CEF2868AB95027B651C8C44CF023A1"
      unitRef="shares">11553000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140110624e1943-wk-Fact-B47A8C791E6D53959FE8EA71B94B688D"
      unitRef="shares">11274000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140110624e1962-wk-Fact-6D49C0B279A75205BFE9396C6E3F858C"
      unitRef="shares">11359000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140110624e1981-wk-Fact-710C76C6816A567E9C9D7E636DA87F20"
      unitRef="shares">11264000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140110624e2001-wk-Fact-3729BD5585A35D6E93600443EC04AA33"
      unitRef="shares">11579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="FD2017Q2QTD"
      decimals="INF"
      id="d140110624e2026-wk-Fact-67B0D700CD8658428C195857773236B5"
      unitRef="usdPerShare">0.45</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="FD2016Q2QTD"
      decimals="INF"
      id="d140110624e2045-wk-Fact-C513F47104A353FA904F998ABE9042B2"
      unitRef="usdPerShare">0.06</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="FD2017Q2YTD"
      decimals="INF"
      id="d140110624e2064-wk-Fact-CFA2588D329857EFA585E012C0FB94AC"
      unitRef="usdPerShare">0.89</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="FD2016Q2YTD"
      decimals="INF"
      id="d140110624e2084-wk-Fact-98AFEC15B83E5F2FA8548FC6AC5C2849"
      unitRef="usdPerShare">0.11</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140108581e531-wk-Fact-D61402E6386B5C61B3849B9F0DCF9F22"
      unitRef="usd">10303000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140108581e550-wk-Fact-DF72591BFB29537FBDB5F63B4DBCACB5"
      unitRef="usd">12201000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140108581e569-wk-Fact-FDB9EDA593AA50B180B5D35A4B8A57FF"
      unitRef="usd">20728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140108581e589-wk-Fact-6F6E769DCE635A8CABA8AA041D956C79"
      unitRef="usd">23481000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140108581e686-wk-Fact-5AAED4E89C9955548441660101032048"
      unitRef="usd">87000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140108581e705-wk-Fact-E9CD31AF417B5EC08DC63FD505AF90EA"
      unitRef="usd">-327000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140108581e725-wk-Fact-C380429C12C551CDADB0C6A5E68B1D1F"
      unitRef="usd">163000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140108581e745-wk-Fact-F12C496D555F524FA738A86F3C84D07E"
      unitRef="usd">-275000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140108581e766-wk-Fact-FF1C6573449A52A2B7876263BB3F01C6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140108581e785-wk-Fact-03325943F3D95B42BFC2F1D337EC76A0"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140108581e804-wk-Fact-ED56B829A9D35F7886D2C9002FE046FF"
      unitRef="usd">258000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140108581e825-wk-Fact-DB0876E2F40859B6B7E94D2C683DB55D"
      unitRef="usd">-132000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140108581e845-wk-Fact-55D14D5384525744B349B6193EC6D1A8"
      unitRef="usd">87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140108581e864-wk-Fact-4CBB89A5539C564AA5AF3819B210493F"
      unitRef="usd">-195000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140108581e884-wk-Fact-209134B29D2C513891537F098AF98088"
      unitRef="usd">-95000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140108581e905-wk-Fact-A6E2A9CE019F5B42885D332B8DEF104B"
      unitRef="usd">-143000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140108581e926-wk-Fact-99EF4E60B0A45C4FB960914662E3D925"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140108581e945-wk-Fact-61A24CED9D0E547D81D05EB12DA76E96"
      unitRef="usd">-1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140108581e965-wk-Fact-BC76D84C67E154E6B4EB0000DCE0C785"
      unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140108581e986-wk-Fact-04105E7E589F594C8D40471C3710DD4E"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140108581e1011-wk-Fact-184AC27D51995C8CA70B9C0465F6BE8B"
      unitRef="usd">10392000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140108581e1030-wk-Fact-BAE98B2FCCD05DBC85C369645C34B9C2"
      unitRef="usd">12005000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140108581e1049-wk-Fact-617095AFD85155128F3F81E467564CF3"
      unitRef="usd">20628000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140108581e1069-wk-Fact-4D92E2A167275EB3A5922F3F6090AD6E"
      unitRef="usd">23345000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e481-wk-Fact-FDB9EDA593AA50B180B5D35A4B8A57FF"
      unitRef="usd">20728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e500-wk-Fact-6F6E769DCE635A8CABA8AA041D956C79"
      unitRef="usd">23481000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e556-wk-Fact-C3CB49480FE151DC97AC4DFBFD783BB7"
      unitRef="usd">276000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e575-wk-Fact-C17A1553321B58C79B2BA2BF3CF91B88"
      unitRef="usd">180000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e595-wk-Fact-AAA7961F57765A88B04EFF2CEBA840E6"
      unitRef="usd">17000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e614-wk-Fact-C7DFCDD33A645CD3824820C753A4CF83"
      unitRef="usd">84000</us-gaap:ShareBasedCompensation>
    <nhtc:CumulativeTranslationAdjustmentRealizedInNetIncome
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e634-wk-Fact-F945138E37575EEDAD1CA72DA410796F"
      unitRef="usd">258000</nhtc:CumulativeTranslationAdjustmentRealizedInNetIncome>
    <nhtc:CumulativeTranslationAdjustmentRealizedInNetIncome
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e654-wk-Fact-2E5D94AD790352318D518A538E87F598"
      unitRef="usd">-132000</nhtc:CumulativeTranslationAdjustmentRealizedInNetIncome>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e715-wk-Fact-72F923B26BE9501C87CE352A642C96BC"
      unitRef="usd">-1388000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e734-wk-Fact-D5A31F3103FA522FA0E5F7D09A55A490"
      unitRef="usd">1865000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e755-wk-Fact-CDFC399539A853B5A362CBEC51516CB7"
      unitRef="usd">-489000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e774-wk-Fact-929C61A92C475D9DA3D1C9E5C26941A1"
      unitRef="usd">612000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e796-wk-Fact-1E1D68D2BCF254AB973B284711948415"
      unitRef="usd">58000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e816-wk-Fact-8C0F9FBAFDA152E0AB09172E7B6487FD"
      unitRef="usd">-2000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e836-wk-Fact-F285910711FB579A957F7E6536FBF3B9"
      unitRef="usd">226000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e855-wk-Fact-1C9C4875BD9858E2B2F8991DA1EB795B"
      unitRef="usd">665000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e875-wk-Fact-F3BE8BEADB085710884D61CE1FC3838B"
      unitRef="usd">4304000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e894-wk-Fact-91AF54D9286952C9BD6C760B35E6757A"
      unitRef="usd">487000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e914-wk-Fact-86CC265A893550C9818D8B4AFAFB7340"
      unitRef="usd">-915000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e934-wk-Fact-9AF36A05478D5487A8867D5E9A8E9D32"
      unitRef="usd">-989000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e955-wk-Fact-5FEDBA088C3D53F78D2AD850E47F726A"
      unitRef="usd">-3229000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e975-wk-Fact-2A20AA77717E5E2094EE5EE062F5CC00"
      unitRef="usd">2597000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e995-wk-Fact-1D08560749DC5675B96017C7E214BDDB"
      unitRef="usd">-939000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1015-wk-Fact-D1F2E0EB290C5121B8587D9CCD17031A"
      unitRef="usd">4816000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1035-wk-Fact-C34EB581A27458BF9C33AAC6E47CCDCC"
      unitRef="usd">-327000</us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits>
    <us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1055-wk-Fact-A8435CDC47BD53E9B278F436896E775E"
      unitRef="usd">1759000</us-gaap:IncreaseDecreaseInCustomerAdvancesAndDeposits>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1075-wk-Fact-5FB7D006114B58D9A7812549CF934F6E"
      unitRef="usd">-24000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1095-wk-Fact-33089CDC7DDD5E65B5E325EA516792F8"
      unitRef="usd">203000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1115-wk-Fact-5CDD1F30565252EC8672206F2DB14A94"
      unitRef="usd">-1049000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1135-wk-Fact-E137E5BD41595B8C841A534433FF2FD8"
      unitRef="usd">-506000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1156-wk-Fact-F2F7F3EE976D56BCB6948530AD2E3701"
      unitRef="usd">20629000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1175-wk-Fact-C4ECC46C7F1F5284886183304ADAAF01"
      unitRef="usd">30434000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1237-wk-Fact-72876B38D29358E5ABEC2A52CD579EC6"
      unitRef="usd">170000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1257-wk-Fact-BAAC0AA05D275110B9595E79C7356BCB"
      unitRef="usd">524000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1278-wk-Fact-D134BF3E0BFA518F88969A63928990D1"
      unitRef="usd">-170000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1298-wk-Fact-AD38695C86BA5394A7F1677F04BFCC34"
      unitRef="usd">-524000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1360-wk-Fact-1ACB4BCD50F7542EBDAAD42383BECD69"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1379-wk-Fact-6B5C0D1193295197A18A777B1A06F932"
      unitRef="usd">23704000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1400-wk-Fact-45938F983B8D51FE919F635605AE926B"
      unitRef="usd">10078000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1420-wk-Fact-C8390782BC735C8BA5ABED202F93B35E"
      unitRef="usd">1262000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1441-wk-Fact-7A9BEB25595857B68B2B65071C3CC84E"
      unitRef="usd">-10078000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1461-wk-Fact-EF8559A2C9C55B94BBFD38A4006AF330"
      unitRef="usd">-24966000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1482-wk-Fact-C43A56C3A05D528EB3E2F20203D7F1CF"
      unitRef="usd">-41000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1502-wk-Fact-109F3D16D34D509C899D2F2CCAF1A741"
      unitRef="usd">-209000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1523-wk-Fact-9F87D6EFA2CF56F5918CACC311FB5012"
      unitRef="usd">10340000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1542-wk-Fact-84AB090FF3D75EF9824209052D7EB57D"
      unitRef="usd">4735000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140112316e1562-wk-Fact-A2AA8FBEA98E5148B2B2DF86BC44772E"
      unitRef="usd">125921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2015Q4"
      decimals="-3"
      id="d140112316e1581-wk-Fact-F7C88DE6505C5CFEA429FF8C91B8F8C2"
      unitRef="usd">104914000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140112316e1606-wk-Fact-3AA82854F4645D1AB8EF2F2C66F367FA"
      unitRef="usd">136261000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q2"
      decimals="-3"
      id="d140112316e1625-wk-Fact-DA660D4D08295F82824AF5E6E84A52C7"
      unitRef="usd">109649000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:StockIssued1
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140112316e1687-wk-Fact-521233C58CC5551BABBB52031E6A7B2F"
      unitRef="usd">1393000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140112316e1706-wk-Fact-042E2971234050B7A9FB5E55D3B179E0"
      unitRef="usd">1741000</us-gaap:StockIssued1>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-AA3CD9FEA0BC5C9188030139D4819B2F-0-wk-Fact-1CBC66B36C075730AED2041C52CA6F3F">NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Nature of Operations&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Natural Health Trends Corp. (the &#x201c;Company&#x201d;), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and &#x201c;quality of life&#x201d; products under the &#x201c;NHT Global&#x201d; brand.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The Company&#x2019;s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company&#x2019;s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company&#x2019;s 2016 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-4F7FC6D8F39F56DDA1313E30E71232EA-0-wk-Fact-149BA93DD0FE55FA824FDA7F97856BD0">Principles of Consolidation&lt;div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-970EBE6DE1925947925A0ADE4C66387A-0-wk-Fact-85B499B7BBB95CDC945976F2687EF554">ACCOUNTING PRONOUNCEMENTS&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-18, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Statement of Cash Flows - Restricted Cash&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, that requires organizations that lease assets, referred to as &#x201c;lessees&#x201d;, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification of Deferred Taxes&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the FASB issued ASU No. 2015-11,&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#160;Inventory: Simplifying the Measurement of Inventory.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.&#160; Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.&#160; The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company&#x2019;s consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue From Contracts With Customers&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#160; It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.&#160; Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.&#160; In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company&#x2019;s present or future financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-44CA2F81214A5DF4BC8E6BD2B47AB9FE-0-wk-Fact-F955B6DF3DC15ED7B52B388394A6AB7F">NET INCOME PER COMMON SHARE&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Numerator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Denominator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Per Share Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Numerator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Denominator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Per Share Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net income per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income available to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.08&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested restricted stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Diluted net income per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income available to common stockholders plus assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.07&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="22"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Numerator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Denominator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Per Share Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Income&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Numerator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Denominator)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Per Share Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Basic net income per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income available to common stockholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,553&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Non-vested restricted stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Diluted net income per common share:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Net income available to common stockholders plus assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;20,728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;23,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,579&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.03&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-D89389B3408B58DAA596932B18659D05-0-wk-Fact-B2CF69829DC8539A98401959A29089AF">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140114937e836-wk-Fact-D594914EC3AD52EB9E1CCD751FA111DA"
      unitRef="usd">10303000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140114937e850-wk-Fact-F27EE613B03C529FAA1DA48DDEF41D21"
      unitRef="shares">11243000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q2QTD"
      decimals="2"
      id="d140114937e869-wk-Fact-FBACBE76C19E51CC99DB4928E995AF32"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140114937e889-wk-Fact-4C15CCC8774259D38447FADF5992DE99"
      unitRef="usd">12201000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140114937e903-wk-Fact-9D22B566BD3259B6B981DB468373FAE5"
      unitRef="shares">11333000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2016Q2QTD"
      decimals="2"
      id="d140114937e922-wk-Fact-AAD38C082ED154B7B796EF0670C263F2"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140114937e1068-wk-Fact-BEAFAB226B1F52BE89D96EA917AC0E29"
      unitRef="shares">31000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140114937e1121-wk-Fact-5DC1361012865C95901EAD58101EF9E5"
      unitRef="shares">26000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140114937e1272-wk-Fact-6147BD709F6B536BB694AA7AC9205471"
      unitRef="usd">10303000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q2QTD"
      decimals="-3"
      id="d140114937e1286-wk-Fact-B47A8C791E6D53959FE8EA71B94B688D"
      unitRef="shares">11274000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q2QTD"
      decimals="2"
      id="d140114937e1305-wk-Fact-8668D6CDF5025FE3BA7A8F58844DA616"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140114937e1325-wk-Fact-6130B523B9685517868A341CA020B320"
      unitRef="usd">12201000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140114937e1339-wk-Fact-6D49C0B279A75205BFE9396C6E3F858C"
      unitRef="shares">11359000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2016Q2QTD"
      decimals="2"
      id="d140114937e1358-wk-Fact-C2A89157206D5BE09D1792A84B8FF350"
      unitRef="usdPerShare">1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140114937e1867-wk-Fact-1EA18075EDA0BEF30917F8DB94A49F51"
      unitRef="usd">20728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140114937e1881-wk-Fact-319773D3A7055A938DC73A32DEA77711"
      unitRef="shares">11236000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q2YTD"
      decimals="2"
      id="d140114937e1900-wk-Fact-38443D75E9DD543F99E829329809E8F9"
      unitRef="usdPerShare">1.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140114937e1920-wk-Fact-A5296EE4D907E0526C09F8DB945C5A1F"
      unitRef="usd">23481000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140114937e1934-wk-Fact-08CEF2868AB95027B651C8C44CF023A1"
      unitRef="shares">11553000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2016Q2YTD"
      decimals="2"
      id="d140114937e1953-wk-Fact-7C6568F703C05D17AF158FD73D17F193"
      unitRef="usdPerShare">2.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140114937e2099-wk-Fact-6B38254AB7F761EB4C0AF8DB94CC1A6A"
      unitRef="shares">28000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140114937e2152-wk-Fact-FA6F882A485954C1155EF8DB95AEDC9B"
      unitRef="shares">26000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140114937e2303-wk-Fact-B8FA38C05D3EA9E87D63F8DB9503B62A"
      unitRef="usd">20728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140114937e2317-wk-Fact-710C76C6816A567E9C9D7E636DA87F20"
      unitRef="shares">11264000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q2YTD"
      decimals="2"
      id="d140114937e2336-wk-Fact-4AEEBC57085E50509438D69D785C316E"
      unitRef="usdPerShare">1.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140114937e2356-wk-Fact-AC85A2865F77E1DBCBF9F8DB93FB4A7E"
      unitRef="usd">23481000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140114937e2370-wk-Fact-3729BD5585A35D6E93600443EC04AA33"
      unitRef="shares">11579000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2016Q2YTD"
      decimals="2"
      id="d140114937e2389-wk-Fact-1F89FCF28B465D52937865903C7BDE05"
      unitRef="usdPerShare">2.03</us-gaap:EarningsPerShareDiluted>
    <nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-49A4B293BADB5342948C20A6F2D13A65-0-wk-Fact-8EFB8A135F975C7D9CC69DA444076FB8">The components of certain balance sheet amounts are as follows (in thousands):&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;63,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;52,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;136,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;125,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Sales returns&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Employee-related&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;6,087&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Warehousing, inventory-related and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,978&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,816&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;14,989&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember"
      decimals="-3"
      id="d140115433e438-wk-Fact-ADD66E252E2459018E069B9B5258314B"
      unitRef="usd">63036000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashMember"
      decimals="-3"
      id="d140115433e457-wk-Fact-4161C8E13F295A6CACA27C42E3D7D5C4"
      unitRef="usd">52453000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q2_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d140115433e472-wk-Fact-5F79524428015B8BBB1C8E7B27534CF3"
      unitRef="usd">73225000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CashEquivalentsMember"
      decimals="-3"
      id="d140115433e491-wk-Fact-48778628390A52078FCA35C1D622DB7F"
      unitRef="usd">73468000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140115433e516-wk-Fact-3AA82854F4645D1AB8EF2F2C66F367FA"
      unitRef="usd">136261000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140115433e535-wk-Fact-A2AA8FBEA98E5148B2B2DF86BC44772E"
      unitRef="usd">125921000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <nhtc:AccruedSalesReturns
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140115433e596-wk-Fact-6E47884F95675448A6D92250AB43E1A4"
      unitRef="usd">2301000</nhtc:AccruedSalesReturns>
    <nhtc:AccruedSalesReturns
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140115433e615-wk-Fact-648A7E0F00A75F19880606B484BBD548"
      unitRef="usd">1632000</nhtc:AccruedSalesReturns>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140115433e630-wk-Fact-41F252402B2451F2ABD76FDE9933FBD1"
      unitRef="usd">6087000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140115433e649-wk-Fact-567EB8E2324C5654A9FDC02EF5911901"
      unitRef="usd">10541000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <nhtc:AccruedWarehousingAndInventoryRelatedExpense
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140115433e669-wk-Fact-C9A5272CEBD055FBB338407ED8CC44F3"
      unitRef="usd">1978000</nhtc:AccruedWarehousingAndInventoryRelatedExpense>
    <nhtc:AccruedWarehousingAndInventoryRelatedExpense
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140115433e688-wk-Fact-BF76E790B02A565F91C5D76A1D73D7E8"
      unitRef="usd">2816000</nhtc:AccruedWarehousingAndInventoryRelatedExpense>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140115433e713-wk-Fact-359548B1D77C57B684BDEA3F8F35201F"
      unitRef="usd">10366000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140115433e732-wk-Fact-8C9710A778E9599096A351B362BA4521"
      unitRef="usd">14989000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-CA8897956A1F5194ABF47EB547698EC0-0-wk-Fact-ABF49CB6010F51F8BDEB6692B8039CA4">FAIR VALUE MEASUREMENTS&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, cash and cash equivalents include the Company&#x2019;s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.&#160; Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments - Debt and Equity Securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As such, the Company determined its investments in debt securities held at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders&#x2019; equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.&#160; The Company has elected to not fair value existing eligible items.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjusted Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjusted Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds and notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financial institution instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-10C62694C78D525091877436ACA4F7C2-0-wk-Fact-96DE4352E52E5B91A87A74B25B7639E8">As of &lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, cash and cash equivalents include the Company&#x2019;s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.&#160; Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments - Debt and Equity Securities&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. As such, the Company determined its investments in debt securities held at &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt; should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders&#x2019; equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="FD2017Q2YTD"
      id="TextSelection-15A75ED0FE515E38A2FFAA72085FCB64-0-wk-Fact-8BAC3353B04458ADAC226DDE88EC6252">The carrying amounts of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-3997CC6C5EE75EDE9F5FBEEFD08BFBB5-0-wk-Fact-506B1EDF693F5668B7B4C062C3DD9E15">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:29%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;December&#160;31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjusted Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Adjusted Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Municipal bonds and notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;11,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;43,490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,312&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;16,303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,671&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Financial institution instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;45,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total available-for-sale investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,470&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;73,468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember"
      decimals="-3"
      id="d140116371e655-wk-Fact-995E53AC9C905B54B54CD0D641033F0C"
      unitRef="usd">11895000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember"
      decimals="-3"
      id="d140116371e674-wk-Fact-0E1D1C5BD82E51F2858351A60B4309EC"
      unitRef="usd">2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember"
      decimals="-3"
      id="d140116371e693-wk-Fact-80361866D9BE5E2599E0698F00752E19"
      unitRef="usd">11897000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember"
      decimals="-3"
      id="d140116371e713-wk-Fact-E9DF4E8C0B8F5377A874E4942F34337B"
      unitRef="usd">43490000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember"
      decimals="-3"
      id="d140116371e732-wk-Fact-4C4CAEF1D8B055BEA851119F95DF912B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_MunicipalBondsAndNotesMember"
      decimals="-3"
      id="d140116371e752-wk-Fact-95F5D842644B52C69AA4C98398F7650C"
      unitRef="usd">43490000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d140116371e767-wk-Fact-B73F3666CE465087ACA63BAA01A36117"
      unitRef="usd">16312000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d140116371e786-wk-Fact-EF3F21B501B550EEAE8E461B03A02FED"
      unitRef="usd">-9000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d140116371e806-wk-Fact-9A27E0C2A701570D8746169948E6AAC0"
      unitRef="usd">16303000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d140116371e826-wk-Fact-5AE684A50E5D53B4BA77FB28828A69B2"
      unitRef="usd">1673000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d140116371e845-wk-Fact-2F92F22DA426568B803081F264380A73"
      unitRef="usd">-2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="d140116371e865-wk-Fact-3A1A797C3AC357EC945D2260927C8153"
      unitRef="usd">1671000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember"
      decimals="-3"
      id="d140116371e886-wk-Fact-C9C8EF44DD4D5574A759D853938F9385"
      unitRef="usd">45025000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember"
      decimals="-3"
      id="d140116371e905-wk-Fact-C19E61808A3C5C64BC6245EE800334D9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2017Q2_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember"
      decimals="-3"
      id="d140116371e924-wk-Fact-704BE284139A50B08F9CC7F19B7EB981"
      unitRef="usd">45025000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember"
      decimals="-3"
      id="d140116371e944-wk-Fact-69DF516653D15EC3A0D913B7DF0E69CF"
      unitRef="usd">28307000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember"
      decimals="-3"
      id="d140116371e963-wk-Fact-13EBD4A2F32355A1B30D82C9577DFA62"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2016Q4_us-gaap_InvestmentTypeAxis_nhtc_FinancialInstitutionInstrumentsMember"
      decimals="-3"
      id="d140116371e982-wk-Fact-5466F584218A57C48DED3960F1A5A1CC"
      unitRef="usd">28307000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140116371e1008-wk-Fact-0F613783AC655526992F914358E837B0"
      unitRef="usd">73232000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140116371e1027-wk-Fact-94425517E9E35CC483D273269D150C33"
      unitRef="usd">-7000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2017Q2"
      decimals="-3"
      id="d140116371e1047-wk-Fact-AFC110069CDF5045A324B16BAE218D2A"
      unitRef="usd">73225000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140116371e1067-wk-Fact-23B2839937EA5FC79EA611EB8CCDDA34"
      unitRef="usd">73470000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140116371e1086-wk-Fact-AE9171DEB4EB57909FC2E685B2387038"
      unitRef="usd">-2000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax>
    <us-gaap:AvailableForSaleSecurities
      contextRef="FI2016Q4"
      decimals="-3"
      id="d140116371e1107-wk-Fact-A140FB09A5A259FCB6E8F93BF4BDA6AB"
      unitRef="usd">73468000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-3C3AAD096B3D5477AB3A51AEE25D5CD6-0-wk-Fact-BA57C4FAD99B51FDA37420A5F54275E7">. STOCKHOLDERS&#x2019; EQUITY&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&#x2019;s cash dividend activity for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Declaration Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Record Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 24, 2017 (special)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;9, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;19, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 24, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;9, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;19, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January 24, 2017 (special)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;February&#160;21, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;3, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January 24, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;February&#160;21, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;3, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payment of any future dividends on shares of common stock will be at the discretion of the Company&#x2019;s Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 12, 2016, the Board of Directors authorized an increase to the Company&#x2019;s stock repurchase program first approved on July 28, 2015 from &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$15.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. Repurchases are expected to be executed to the extent that the Company&#x2019;s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$32.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$70.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation expense totaled &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$8,600&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$10,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$17,300&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$84,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the six months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company&#x2019;s 2016 annual meeting of stockholders. The modification of the award resulted in an additional &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$64,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; in stock-based compensation expense for the three months ended March 31, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;At the Company&#x2019;s annual meeting of stockholders held on April 7, 2016, the Company&#x2019;s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company&#x2019;s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&#x2019;s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2,393,873&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares remained available for issuance under the 2016 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On January 24, 2017, the Company granted &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,260&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. The shares vest on a quarterly basis over &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; years and are subject to forfeiture in the event of the employee&#x2019;s termination of service to the Company under specified circumstances.  &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&#x2019;s restricted stock activity under the 2016 Plan:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Wtd. Avg. Price at Date of Issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at June 30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the Company&#x2019;s other restricted stock activity:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Wtd. Avg. Price at Date of Issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at June 30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, total unrecognized stock-based compensation expense related to non-vested restricted stock was &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$18,500&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, which is expected to be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.5 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;The changes in accumulated other comprehensive loss by component for the first &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months of 2017 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrealized Losses on Available-For-Sale Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified out of accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, June 30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-21E33DB3114DC1F205E9F4762D32EE35-0-wk-Fact-E94DB659DF27ED42403BF476DB9CAB6E">The following table summarizes the Company&#x2019;s cash dividend activity for the &lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (in thousands, except per share data):&lt;/span&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Declaration Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Record Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Payment Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 24, 2017 (special)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;9, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;19, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;April 24, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;9, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;May&#160;19, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January 24, 2017 (special)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;3,962&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;February&#160;21, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;3, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;January 24, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;1,019&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;February&#160;21, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;March&#160;3, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;0.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,078&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Payment of any future dividends on shares of common stock will be at the discretion of the Company&#x2019;s Board of Directors.</us-gaap:DividendsDeclaredTableTextBlock>
    <nhtc:CommonStockSpecialDividendsPerShareDeclared
      contextRef="D2017Q2Apr24-Apr24"
      decimals="2"
      id="d140117901e453-wk-Fact-7B27CEF701E829ED2BD7F47B37795F82"
      unitRef="usdPerShare">0.35</nhtc:CommonStockSpecialDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="D2017Q2Apr24-Apr24"
      decimals="-3"
      id="d140117901e472-wk-Fact-DEBF135DE69A86771020F47D0BD1139D"
      unitRef="usd">3964000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2017Q2Apr24-Apr24"
      decimals="INF"
      id="d140117901e513-wk-Fact-0117148D3D719A6BE967F47AB148E76E"
      unitRef="usdPerShare">0.10</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCash
      contextRef="D2017Q2Apr24-Apr24"
      decimals="-3"
      id="d140117901e532-wk-Fact-67385CD98D4F992BDAE4F47D0D5C90F4"
      unitRef="usd">1133000</us-gaap:DividendsCash>
    <nhtc:CommonStockSpecialDividendsPerShareDeclared
      contextRef="D2017Q1jan24-jan24"
      decimals="2"
      id="d140117901e578-wk-Fact-E51DFB4631FF0995C1B0F47A556330D6"
      unitRef="usdPerShare">0.35</nhtc:CommonStockSpecialDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="D2017Q1jan24-jan24"
      decimals="-3"
      id="d140117901e597-wk-Fact-B2F394276D2F8C9B159EF47D0F73680E"
      unitRef="usd">3962000</us-gaap:DividendsCommonStockCash>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2017Q1jan24-jan24"
      decimals="INF"
      id="d140117901e643-wk-Fact-DFF3F9A2B90D7D5A3637F47A28F36A4F"
      unitRef="usdPerShare">0.09</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCash
      contextRef="D2017Q1jan24-jan24"
      decimals="-3"
      id="d140117901e662-wk-Fact-491D3E207D1606453247F47D11443891"
      unitRef="usd">1019000</us-gaap:DividendsCash>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="FD2017Q2YTD"
      decimals="INF"
      id="d140117901e713-wk-Fact-7E011E9B459E01788D02F47CA66B0637"
      unitRef="usdPerShare">0.89</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCash
      contextRef="FD2017Q2YTD"
      decimals="-3"
      id="d140117901e732-wk-Fact-B78FDDCC25FAF53B215DF47D3E935553"
      unitRef="usd">10078000</us-gaap:DividendsCash>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2015Q3Jul28"
      decimals="-5"
      id="d140117901e776-wk-Fact-D3C00224E15C58E5BDABAE675A02E18D"
      unitRef="usd">15000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2016Q1Jan12"
      decimals="-5"
      id="d140117901e780-wk-Fact-1D5EFD2B18F15EB89FF05BCFF862D5D9"
      unitRef="usd">70000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="FI2017Q1"
      decimals="-5"
      id="d140117901e788-wk-Fact-34ACB83307545729BAE2776BB96A19CA"
      unitRef="usd">32000000.0</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2016Q1Jan12"
      decimals="-5"
      id="d140117901e792-wk-Fact-1D5EFD2B18F15EB89FF05BCFF862D5D9"
      unitRef="usd">70000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q2QTD"
      decimals="-2"
      id="d140117901e806-wk-Fact-ACEB555003CD5BA299BFB01A84232C98"
      unitRef="usd">8600</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q2QTD"
      decimals="-3"
      id="d140117901e810-wk-Fact-01FDC42BA45959FDAFDB4BA7BAA3ED91"
      unitRef="usd">10000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q2YTD"
      decimals="-2"
      id="d140117901e822-wk-Fact-D59F6E2181323C57370EEECBB260A40A"
      unitRef="usd">17300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2016Q2YTD"
      decimals="-3"
      id="d140117901e827-wk-Fact-1DABF51730BBB16C7A31EECC2C3BCDA1"
      unitRef="usd">84000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="FD2017Q1QTD"
      decimals="-3"
      id="d140117901e839-wk-Fact-FF5926FAADDF558FB33731E92E93BEB1"
      unitRef="usd">64000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="I2016Q2Apr07_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d140117901e848-wk-Fact-437C62F4CC9F5AB9A291F1B5D9C0D601"
      unitRef="shares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2017Q2"
      decimals="0"
      id="d140117901e856-wk-Fact-38158A305A615CEFAD9B270256B8CA36"
      unitRef="shares">2393873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D2016Q2Apr08-Apr08_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="d140117901e865-wk-Fact-BA9DD32F196B5B7FAE0205737A962C2F"
      unitRef="shares">56260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="D2017Q1jan24-jan24"
      decimals="-5"
      id="d140117901e869-wk-Fact-ED27019DCA7354C3852E456E562AD498"
      unitRef="usd">1400000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="INF"
      id="d140117901e943-wk-Fact-56EB344B39F6545499999B9D617EC6C0"
      unitRef="shares">38256</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="2"
      id="d140117901e962-wk-Fact-F24DC685DE1C5BEC86F5E80AE9A490C8"
      unitRef="usdPerShare">34.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="INF"
      id="d140117901e977-wk-Fact-C483CECEA26D5F3290BCF4DD3F8E3767"
      unitRef="shares">56260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="2"
      id="d140117901e991-wk-Fact-B348A5C91A8C553EABE7D814F4A89726"
      unitRef="usdPerShare">25.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="INF"
      id="d140117901e1011-wk-Fact-ADEF727F14E75C8BAC91F2DA43427602"
      unitRef="shares">17668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="2"
      id="d140117901e1026-wk-Fact-A8221C602D545AB8AFCDEC58C8399E95"
      unitRef="usdPerShare">29.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="0"
      id="d140117901e1046-wk-Fact-35BE3DB744105DDD9F67CC6741C5199B"
      unitRef="shares">1148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="2"
      id="d140117901e1061-wk-Fact-88AFC1319CD354CC92E47DD129CC8451"
      unitRef="usdPerShare">28.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="INF"
      id="d140117901e1081-wk-Fact-14BABB04612252D3BC3FEA3F9DAD9969"
      unitRef="shares">75700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_PlanNameAxis_nhtc_EquityIncentive2016PlanMember"
      decimals="2"
      id="d140117901e1095-wk-Fact-86EF8357F14F5B4DB5C4502C8A64B458"
      unitRef="usdPerShare">28.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-9980EA910A8D51E2BAC2F8316249E498-0-wk-Fact-09A739915ECF55CFA03081AC4F678059">The following table summarizes the Company&#x2019;s other restricted stock activity:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Wtd. Avg. Price at Date of Issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;22,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(10,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(418&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at June 30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;10,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;12.15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes the Company&#x2019;s restricted stock activity under the 2016 Plan:&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Wtd. Avg. Price at Date of Issuance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;38,256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;34.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;56,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;25.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(17,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;29.58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Nonvested at June 30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;75,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;28.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="0"
      id="d140117901e1174-wk-Fact-AF48513F717B5419ACC8B09C29F3B1F3"
      unitRef="shares">22348</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d140117901e1193-wk-Fact-64CEA29FCD9C50C2B3365F441E2DF962"
      unitRef="usdPerShare">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="0"
      id="d140117901e1208-wk-Fact-A24922CE68CC5586A8B66321788414DC"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d140117901e1222-wk-Fact-73934EA40DB75559A3772448CB3C9124"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="0"
      id="d140117901e1242-wk-Fact-0EA770EEBD375BD18D8E1E083DBACADD"
      unitRef="shares">10970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d140117901e1257-wk-Fact-BC4B55CECCA15178A1A87F0B9898EC41"
      unitRef="usdPerShare">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="0"
      id="d140117901e1277-wk-Fact-2194322C18A851F58F0625CBC7B444A9"
      unitRef="shares">418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d140117901e1292-wk-Fact-88102746948E570F9C2A9799D5E4A2E3"
      unitRef="usdPerShare">12.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="0"
      id="d140117901e1312-wk-Fact-406316C7399C5306B9DC1409EFC0AE13"
      unitRef="shares">10960</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="2"
      id="d140117901e1326-wk-Fact-3C632D7676C25720A5BC76C724C3B3A9"
      unitRef="usdPerShare">12.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2017Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      decimals="INF"
      id="d140117901e1350-wk-Fact-78130CCAC3085C23B3E78F332BB7AD5B"
      unitRef="usd">18500</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2017Q2YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember"
      id="d140117901e1354-wk-Fact-EB2FB6F0DDCB520A9776A2FB7C0B1299">P0Y6M0D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-C2C23202DC395509B42D3711EE0EA731-0-wk-Fact-397FC8AD8AFE5DAFAB54898D3AE3689C">The changes in accumulated other comprehensive loss by component for the first &lt;span style="font-family:inherit;font-size:10pt;"&gt;six&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; months of 2017 were as follows (in thousands):&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Foreign Currency Translation Adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Unrealized Losses on Available-For-Sale Investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Amounts reclassified out of accumulated other comprehensive loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;Balance, June 30, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;(907&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d140117901e1473-wk-Fact-29546F7F32AE55D593C77D2FD3E24BD5"
      unitRef="usd">-805000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d140117901e1493-wk-Fact-EF1E2F7A117253A39082F7F054626D6E"
      unitRef="usd">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d140117901e1513-wk-Fact-4D5477BA04A657CEBEAB12FBFB5A9ABC"
      unitRef="usd">-807000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d140117901e1530-wk-Fact-0A5A61BF66E052ADB13F4A4F600CE3CD"
      unitRef="usd">163000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d140117901e1549-wk-Fact-F6F245C7DF475D98B2036784C5B76A88"
      unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d140117901e1569-wk-Fact-D6DDF706380D5A7DAF8AB792EEC839E9"
      unitRef="usd">158000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d140117901e1590-wk-Fact-BC3C37FAA79A5446AE9F7205AADF9722"
      unitRef="usd">-258000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d140117901e1610-wk-Fact-D813FB1249F95F829653203067B344FE"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="FD2017Q2YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d140117901e1629-wk-Fact-78DE1BC2837154A2A860BEC6AEF05957"
      unitRef="usd">-258000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-3"
      id="d140117901e1656-wk-Fact-06FD9962244E564B98AB2312E8F67DEE"
      unitRef="usd">-900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-3"
      id="d140117901e1676-wk-Fact-38041457CF5E549E88974A76310AA3C0"
      unitRef="usd">-7000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d140117901e1696-wk-Fact-3341CE0E42FC5E9BA941BF6690F2CF9A"
      unitRef="usd">-907000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-18D663A331DA504EACEF78127BC74993-0-wk-Fact-F2391EE38DE458328D32743D4C6B46EB">INCOME TAXES&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries.  The Company repatriated &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$19.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses.  Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced.  The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings.  The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Company has accrued tax liabilities for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="FD2016Q1QTD"
      decimals="-5"
      id="d140117982e328-wk-Fact-EEB747A7041742C2F65E8B1FC8588408"
      unitRef="usd">19800000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-81C6DCA2EEAA5A17A6397C2E9EB706F2-0-wk-Fact-B733E047AAE9500CB6CBABDBD19F6F51">COMMITMENTS AND CONTINGENCIES&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Securities Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In January 2016, &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Ford v. Natural Health Trends Corp.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp;amp; Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the &#x201c;Individual Defendants&#x201d;), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants&#x2019; motion to dismiss on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.&#160; If approved, the proposed settlement will be fully funded by the Company&#x2019;s insurers.&#160; Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Shareholder Derivative Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Zhou v. Sharng&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Kleinfeldt v. Sharng&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; (collectively the &#x201c;Derivative Complaints&#x201d;). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company&#x2019;s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Zhou&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; action pending conclusion of the related federal class action in the United States District Court for the Central District of California:&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Ford v. Natural Health Trends Corp.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Li v. Natural Health Trends Corp&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;. A nearly identical stipulated stay was entered in the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Kleinfeldt&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; case on February 8, 2017.  The Company believes that these claims are without merit and intends to vigorously defend against them.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;The consolidated class action, if a settlement is not finalized and approved by the Court, and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company&#x2019;s operating results and financial condition.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember"
      decimals="INF"
      id="d140118085e334-wk-Fact-3E01F93EA344532A8E843F872D7B658F"
      unitRef="complaint">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-9BD14FBA91EA55CC9B7EBB786778493C-0-wk-Fact-987DE0B8801357D98B4C7E206817109D">RELATED PARTY TRANSACTIONS&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (&#x201c;BHS&#x201d;) regarding the manufacture and sale of a product called&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Soothe&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2122;.  George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS.  Under the agreement, the Company agreed to pay BHS a royalty of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide.  Royalties recognized for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$500&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$800&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$1,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$2,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120 days&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2019; notice.  Otherwise, the agreement terminates March 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called&#160;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ReStor&#x2122;.&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160; Under the agreement, the Company agreed to pay BHS a royalty of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;2.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue.  Such provision was effective retroactively to January 1, 2015.  Such royalties were &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$86,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$141,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the three months ended &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$177,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$280,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;six months ended&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;June&#160;30, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;120 days&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#x2019; notice or, under certain circumstances, with &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;no&lt;/span&gt; notice.  Otherwise, the agreement terminates March 31, 2020.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <nhtc:RoyaltyRate
      contextRef="D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="INF"
      id="d140118134e333-wk-Fact-9C24EF50BF74531FB880205A4C940A71"
      unitRef="number">0.025</nhtc:RoyaltyRate>
    <us-gaap:RoyaltyExpense
      contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="-2"
      id="d140118134e345-wk-Fact-0F0EBCBED1B25E3CA9F8C1846F439837"
      unitRef="usd">500</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="-2"
      id="d140118134e350-wk-Fact-E1208BA95B785C6EBBBD5D9329430B46"
      unitRef="usd">800</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="0"
      id="d140118134e354-wk-Fact-6B2937D627305401B3F1303EEE923725"
      unitRef="usd">1200</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="-2"
      id="d140118134e358-wk-Fact-96FCB73716D252819CC04DB32402ED1D"
      unitRef="usd">2000</us-gaap:RoyaltyExpense>
    <nhtc:NumberOfDaysTerminationNotice
      contextRef="D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      id="d140118134e375-wk-Fact-16F2E4AD11075BF78088A7DC92A22508">P120DT0H</nhtc:NumberOfDaysTerminationNotice>
    <nhtc:RoyaltyRate
      contextRef="D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="INF"
      id="d140118134e388-wk-Fact-801EA8A210B253B08B604D7DAAB2587D"
      unitRef="number">0.025</nhtc:RoyaltyRate>
    <us-gaap:RoyaltyExpense
      contextRef="FD2017Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="-3"
      id="d140118134e392-wk-Fact-8E26C7887D0951E493E48AD8BA88FA21"
      unitRef="usd">86000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2016Q2QTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="-3"
      id="d140118134e396-wk-Fact-C7D5DB04D12351C090EAC23358F84094"
      unitRef="usd">141000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2017Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="-3"
      id="d140118134e409-wk-Fact-07B77D1C7F9EE9DED00DEEE9D2D3D2A9"
      unitRef="usd">177000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2016Q2YTD_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      decimals="-3"
      id="d140118134e413-wk-Fact-A196ECCDECF732C7408BEEEA4A66BE6C"
      unitRef="usd">280000</us-gaap:RoyaltyExpense>
    <nhtc:NumberOfDaysTerminationNotice
      contextRef="D2013Q1Feb1-Feb28_us-gaap_ProductOrServiceAxis_nhtc_ReStoreMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember"
      id="d140118134e430-wk-Fact-7B7D16FCAEA3502FBEC92804F4D88900">P120DT0H</nhtc:NumberOfDaysTerminationNotice>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2017Q2YTD"
      id="TextSelection-4C42DCC7A3D55CF89B06834E15B2602B-0-wk-Fact-EB0C454083A35577B0BD1E8BA7AA8660">SUBSEQUENT EVENT&lt;div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;July&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;, the Board of Directors declared a quarterly cash dividend of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.11&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; and a special cash dividend of &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;span&gt;$0.25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; on each share of common stock outstanding. Such dividends are payable on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt; to stockholders of record on &lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;August&#160;21, 2017&lt;/span&gt;. Payment of any future dividends on shares of common stock will be at the discretion of the Company&#x2019;s Board of Directors.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d140118184e334-wk-Fact-1B6D4C0AB17D57EAA8160601D97FDFED"
      unitRef="usdPerShare">0.11</us-gaap:CommonStockDividendsPerShareDeclared>
    <nhtc:CommonStockSpecialDividendsPerShareDeclared
      contextRef="D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="2"
      id="d140118184e338-wk-Fact-844756D400EF581CB65659A18D740C7F"
      unitRef="usdPerShare">0.25</nhtc:CommonStockSpecialDividendsPerShareDeclared>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803261024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jul. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_DocumentAndEntityInformation', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NATURAL HEALTH TRENDS CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000912061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,341,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_DocumentAndEntityInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_DocumentAndEntityInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803828800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 136,261<span></span>
</td>
<td class="nump">$ 125,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">9,804<span></span>
</td>
<td class="nump">11,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,638<span></span>
</td>
<td class="nump">4,066<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">149,703<span></span>
</td>
<td class="nump">141,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">3,039<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">692<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">156,566<span></span>
</td>
<td class="nump">148,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,371<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">4,971<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued commissions</a></td>
<td class="nump">12,666<span></span>
</td>
<td class="nump">13,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">10,366<span></span>
</td>
<td class="nump">14,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">3,994<span></span>
</td>
<td class="nump">4,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDeferredCreditsCurrent', window );">Amounts held in eWallets</a></td>
<td class="nump">18,713<span></span>
</td>
<td class="nump">19,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">54,703<span></span>
</td>
<td class="nump">57,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred Tax Liabilities, Net, Noncurrent</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent', window );">Long-term incentive</a></td>
<td class="nump">7,179<span></span>
</td>
<td class="nump">8,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">62,167<span></span>
</td>
<td class="nump">65,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">86,665<span></span>
</td>
<td class="nump">86,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">49,198<span></span>
</td>
<td class="nump">38,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(907)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively</a></td>
<td class="num">(40,570)<span></span>
</td>
<td class="num">(41,889)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">94,399<span></span>
</td>
<td class="nump">82,439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 156,566<span></span>
</td>
<td class="nump">$ 148,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=64834752&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDeferredCreditsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unearned revenue or income classified as other, expected to be taken into income within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDeferredCreditsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803954864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">12,979,414<span></span>
</td>
<td class="nump">12,979,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">1,637,524<span></span>
</td>
<td class="nump">1,692,218<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803785520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net sales</a></td>
<td class="nump">$ 51,465<span></span>
</td>
<td class="nump">$ 80,391<span></span>
</td>
<td class="nump">$ 111,339<span></span>
</td>
<td class="nump">$ 154,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of sales</a></td>
<td class="nump">9,793<span></span>
</td>
<td class="nump">15,059<span></span>
</td>
<td class="nump">21,038<span></span>
</td>
<td class="nump">29,339<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">41,672<span></span>
</td>
<td class="nump">65,332<span></span>
</td>
<td class="nump">90,301<span></span>
</td>
<td class="nump">125,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesCommissionsAndFees', window );">Commissions expense</a></td>
<td class="nump">22,075<span></span>
</td>
<td class="nump">37,883<span></span>
</td>
<td class="nump">48,040<span></span>
</td>
<td class="nump">72,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">6,590<span></span>
</td>
<td class="nump">12,431<span></span>
</td>
<td class="nump">16,126<span></span>
</td>
<td class="nump">23,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">28,805<span></span>
</td>
<td class="nump">50,405<span></span>
</td>
<td class="nump">64,442<span></span>
</td>
<td class="nump">96,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">12,867<span></span>
</td>
<td class="nump">14,927<span></span>
</td>
<td class="nump">25,859<span></span>
</td>
<td class="nump">28,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">12,947<span></span>
</td>
<td class="nump">14,943<span></span>
</td>
<td class="nump">26,095<span></span>
</td>
<td class="nump">28,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">2,644<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
<td class="nump">5,367<span></span>
</td>
<td class="nump">5,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 10,303<span></span>
</td>
<td class="nump">$ 12,201<span></span>
</td>
<td class="nump">$ 20,728<span></span>
</td>
<td class="nump">$ 23,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">11,243<span></span>
</td>
<td class="nump">11,333<span></span>
</td>
<td class="nump">11,236<span></span>
</td>
<td class="nump">11,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">11,274<span></span>
</td>
<td class="nump">11,359<span></span>
</td>
<td class="nump">11,264<span></span>
</td>
<td class="nump">11,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Cash dividends declared per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common (in dollars per share)</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Income Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesCommissionsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesCommissionsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803352592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 10,303<span></span>
</td>
<td class="nump">$ 12,201<span></span>
</td>
<td class="nump">$ 20,728<span></span>
</td>
<td class="nump">$ 23,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">87<span></span>
</td>
<td class="num">(327)<span></span>
</td>
<td class="nump">163<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(132)<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</a></td>
<td class="nump">87<span></span>
</td>
<td class="num">(195)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (losses) gains on available-for-sale securities</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 10,392<span></span>
</td>
<td class="nump">$ 12,005<span></span>
</td>
<td class="nump">$ 20,628<span></span>
</td>
<td class="nump">$ 23,345<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32022-110900<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32157-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e709-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803609360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 20,728<span></span>
</td>
<td class="nump">$ 23,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome', window );">Cumulative Translation Adjustment Realized In Net Income</a></td>
<td class="num">(258)<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="num">(1,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">489<span></span>
</td>
<td class="num">(612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">4,304<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued commissions</a></td>
<td class="num">(915)<span></span>
</td>
<td class="num">(989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
<td class="num">(3,229)<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(939)<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits', window );">Amounts held in eWallets</a></td>
<td class="num">(327)<span></span>
</td>
<td class="nump">1,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Long-term incentive</a></td>
<td class="num">(1,049)<span></span>
</td>
<td class="num">(506)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by operating activities</a></td>
<td class="nump">20,629<span></span>
</td>
<td class="nump">30,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(170)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(10,078)<span></span>
</td>
<td class="num">(1,262)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash used in financing activities</a></td>
<td class="num">(10,078)<span></span>
</td>
<td class="num">(24,966)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">10,340<span></span>
</td>
<td class="nump">4,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, beginning of period</a></td>
<td class="nump">125,921<span></span>
</td>
<td class="nump">104,914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS, end of period</a></td>
<td class="nump">136,261<span></span>
</td>
<td class="nump">109,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of treasury stock for employee awards, net</a></td>
<td class="nump">$ 1,393<span></span>
</td>
<td class="nump">$ 1,741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents cumulative translation adjustment realized in net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6640880192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</a></td>
<td class="text">NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Nature of Operations</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Natural Health Trends Corp. (the &#8220;Company&#8221;), a Delaware corporation, is an international direct-selling and e-commerce company headquartered in Rolling Hills Estates, California. Subsidiaries controlled by the Company sell personal care, wellness, and &#8220;quality of life&#8221; products under the &#8220;NHT Global&#8221; brand.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company&#8217;s wholly-owned subsidiaries have an active physical presence in the following markets: the Americas, which consists of the United States, Canada, Cayman Islands, Mexico and Peru; Greater China, which consists of Hong Kong, Taiwan and China; Southeast Asia, which consists of Singapore, Malaysia and Vietnam; South Korea; Japan; and Europe. The Company also operates in Russia and Kazakhstan through an engagement with a local service provider.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</span><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. As a result, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company&#8217;s financial information for the interim periods presented. The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the fiscal year. These consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company&#8217;s 2016 Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 10, 2017.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Principles of Consolidation</span></div><div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794390688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">NET INCOME PER COMMON SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.92</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,274</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803682848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Notes)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company&#8217;s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.&#160; Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders&#8217; equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounting standards permit companies, at their option, to choose to measure many financial instruments and certain other items at fair value.&#160; The Company has elected to not fair value existing eligible items.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,897</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div>Financial institution instruments include instruments issued or managed by financial institutions such as money market fund deposits and time deposits.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13504-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794276640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">. STOCKHOLDERS&#8217; EQUITY<div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</span></div><div style="line-height:120%;text-align:left;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s cash dividend activity for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment of any future dividends on shares of common stock will be at the discretion of the Company&#8217;s Board of Directors.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Repurchases</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 12, 2016, the Board of Directors authorized an increase to the Company&#8217;s stock repurchase program first approved on July 28, 2015 from </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. Repurchases are expected to be executed to the extent that the Company&#8217;s earnings and cash-on-hand allow, and will be made in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Exchange Act. For all or a portion of the authorized repurchase amount, the Company may enter into one or more plans that are compliant with Rule 10b5-1 of the Exchange Act that are designed to facilitate these purchases. The stock repurchase program does not require the Company to acquire a specific number of shares, and may be suspended from time to time or discontinued. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$32.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$70.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> stock repurchase program approved on July 28, 2015 and increased on January 12, 2016 remained available for future purchases, inclusive of related estimated income tax.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$8,600</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$17,300</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$84,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the six months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively. During March 2016, the Company modified the vesting feature of an award granted to a director who decided to not stand for re-election at the Company&#8217;s 2016 annual meeting of stockholders. The modification of the award resulted in an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$64,000</span></span><span style="font-family:inherit;font-size:10pt;"> in stock-based compensation expense for the three months ended March 31, 2016.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the Company&#8217;s annual meeting of stockholders held on April 7, 2016, the Company&#8217;s stockholders approved the Natural Health Trends Corp. 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) to replace its 2007 Equity Incentive Plan. The 2016 Plan allows for the grant of various equity awards including incentive stock options, non-statutory options, stock, stock units, stock appreciation rights and other similar equity-based awards to the Company&#8217;s employees, officers, non-employee directors, contractors, consultants and advisors of the Company. Up to </span><span style="font-family:inherit;font-size:10pt;"><span>2,500,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock (subject to adjustment under certain circumstances) may be issued pursuant to awards granted. At </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>2,393,873</span></span><span style="font-family:inherit;font-size:10pt;"> shares remained available for issuance under the 2016 Plan. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 24, 2017, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span><span style="font-family:inherit;font-size:10pt;"> shares of restricted common stock under the 2016 Plan to certain employees for the purpose of further aligning their interest with those of its stockholders and settling fiscal 2016 performance incentives totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. The shares vest on a quarterly basis over </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;"> years and are subject to forfeiture in the event of the employee&#8217;s termination of service to the Company under specified circumstances.  </span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s restricted stock activity under the 2016 Plan:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company&#8217;s other restricted stock activity:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, total unrecognized stock-based compensation expense related to non-vested restricted stock was </span><span style="font-family:inherit;font-size:10pt;"><span>$18,500</span></span><span style="font-family:inherit;font-size:10pt;">, which is expected to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>0.5 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated Other Comprehensive Loss</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The changes in accumulated other comprehensive loss by component for the first </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of 2017 were as follows (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(907</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792424368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_INCOMETAXESAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text">INCOME TAXES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of capital return activities approved by the Board of Directors during the first quarter of 2016 and anticipated future capital return activities, the Company determined that a portion of its current undistributed foreign earnings are no longer deemed reinvested indefinitely by its non-U.S. subsidiaries.  The Company repatriated </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to the U.S. during the three months ended March 31, 2016, part of which was offset by U.S. net operating losses.  Accordingly, the deferred tax liability previously established for undistributed foreign earnings up to its existing U.S. net operating losses was reduced.  The excess amount repatriated during the year ended December 31, 2016 was generated from current foreign earnings.  The Company will continue to periodically reassess the needs of its foreign subsidiaries and update its indefinite reinvestment assertion as necessary. To the extent that additional foreign earnings are not deemed permanently reinvested, the Company expects to recognize additional income tax provision at the applicable U.S. corporate tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company has accrued tax liabilities for earnings that the Company plans to repatriate out of accumulated earnings in future periods. All undistributed earnings in excess of 50% of current earnings on an annual basis are intended to be reinvested indefinitely as of </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The Company and its subsidiaries file tax returns in the United States, California and Texas and various foreign jurisdictions. For federal income tax purposes, fiscal years 2007 through 2015 remain open for examination by tax authorities as a result of net operating loss carryovers from older years being used to offset income in recent tax years. The Company is no longer subject to state income tax examinations for years prior to 2011. No jurisdictions are currently examining any income tax returns of the Company or its subsidiaries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_INCOMETAXESAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>INCOME TAXES [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_INCOMETAXESAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794390688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Securities Class Action</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2016, </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> putative securities class action complaints were filed against the Company and its top executives in the United States District Court for the Central District of California. On March 29, 2016, the Court consolidated these actions under the caption </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;">, Case No. 2:16-cv-00255-TJH-AFMx, appointed two Lead Plaintiffs, Mahn Dao and Juan Wang, and appointed the Rosen Law Firm and Levi &amp; Korsinsky LLP as co-Lead Counsel for the purported class. Plaintiffs filed a consolidated complaint on April 29, 2016. The consolidated complaint purports to assert claims on behalf of all persons who purchased or otherwise acquired our common stock between March 6, 2015 and March 15, 2016 under (i) Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder against the Company and Chris T. Sharng, Timothy S. Davidson and George K. Broady (together, the &#8220;Individual Defendants&#8221;), and (ii) Section 20(a) of the Securities Exchange Act of 1934 against the Individual Defendants. The consolidated complaint alleges, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multilevel marketing business. The consolidated complaint seeks an indeterminate amount of damages, plus interest and costs. The Company moved to dismiss the consolidated complaint on June 15, 2016. After full briefing and a hearing, the Court denied defendants&#8217; motion to dismiss on December 5, 2016. On February 17, 2017, the Company filed an answer to the consolidated complaint. On April 14, 2017, the Court entered an order setting case management deadlines for the case, which include the conclusion of fact discovery in May 2018 and a final pretrial conference in August 2018. On July 10, 2017, the Court entered a stipulation between the parties, postponing all deadlines and staying the case for thirty days to allow the parties to engage in settlement discussions. On July 17, 2017, the parties reached an agreement in principle to settle the action. On July 18, 2017, the parties jointly filed a stipulation and proposed order with the Court, seeking to extend the stay for approximately sixty days to allow them an opportunity to negotiate the terms of a written settlement agreement and prepare and file the documentation necessary to obtain Court approval of the settlement. The Court entered the requested order on July 25, 2017, effecting a further stay of the case until September 25, 2017.&#160; If approved, the proposed settlement will be fully funded by the Company&#8217;s insurers.&#160; Defendants continue to believe that these claims are without merit and intend to vigorously defend against them if a settlement is not finalized and approved by the Court.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Claims</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, a purported shareholder derivative complaint was filed in the Superior Court of the State of California, County of Los Angeles: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou v. Sharng</span><span style="font-family:inherit;font-size:10pt;">. In March 2016, a purported shareholder derivative complaint was filed in the United States District Court for the Central District of California: </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt v. Sharng</span><span style="font-family:inherit;font-size:10pt;"> (collectively the &#8220;Derivative Complaints&#8221;). The Derivative Complaints purport to assert claims for breach of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement and corporate waste against certain of the Company&#8217;s officers and directors. The Derivative Complaints also purport to assert fiduciary duty claims based on alleged insider selling and conspiring to enter into several stock repurchase agreements, which allegedly harmed the Company and its assets. The Derivative Complaints allege, inter alia, that the Company made materially false and misleading statements regarding the legality of its business operations in China, including running an allegedly illegal multi-level marketing business, and that certain officers and directors sold common stock on the basis of this allegedly material, adverse non-public information. The Derivative Complaints seek an indeterminate amount of damages, plus interest and costs, as well as various equitable remedies. On February 1, 2017, pursuant to a stipulation among the parties, the Los Angeles Superior Court entered a stay of the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Zhou</span><span style="font-family:inherit;font-size:10pt;"> action pending conclusion of the related federal class action in the United States District Court for the Central District of California:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Ford v. Natural Health Trends Corp.</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Li v. Natural Health Trends Corp</span><span style="font-family:inherit;font-size:10pt;">. A nearly identical stipulated stay was entered in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Kleinfeldt</span><span style="font-family:inherit;font-size:10pt;"> case on February 8, 2017.  The Company believes that these claims are without merit and intends to vigorously defend against them.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>The consolidated class action, if a settlement is not finalized and approved by the Court, and the Derivative Complaints, or others filed alleging similar facts, could result in monetary or other penalties that may materially affect the Company&#8217;s operating results and financial condition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794378720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2015, the Company entered into a Royalty Agreement and License with Broady Health Sciences, L.L.C., a Texas limited liability company, (&#8220;BHS&#8221;) regarding the manufacture and sale of a product called&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Soothe</span><span style="font-family:inherit;font-size:10pt;">&#8482;.  George K. Broady, a director of the Company and beneficial owner of more than 5% of its outstanding common stock, is owner of BHS. The Company began selling this product in the fourth quarter of 2012 with the permission of BHS.  Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide.  Royalties recognized for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;"> were </span><span style="font-family:inherit;font-size:10pt;"><span>$500</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$800</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1,200</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$2,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">&#8217; notice.  Otherwise, the agreement terminates March 31, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">In February 2013, the Company entered into a Royalty Agreement and License with BHS regarding the manufacture and sale of a product called&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">ReStor&#8482;.</span><span style="font-family:inherit;font-size:10pt;">&#160; Under the agreement, the Company agreed to pay BHS a royalty of </span><span style="font-family:inherit;font-size:10pt;"><span>2.5%</span></span><span style="font-family:inherit;font-size:10pt;"> of sales revenue in return for the right to manufacture (or have manufactured), market, import, export and sell this product worldwide, with certain rights being exclusive outside the United States. On April 29, 2015, the Company and BHS amended the Royalty Agreement and License to change the royalty to a price per unit instead of 2.5% of sales revenue.  Such provision was effective retroactively to January 1, 2015.  Such royalties were </span><span style="font-family:inherit;font-size:10pt;"><span>$86,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$141,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the three months ended </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively, and </span><span style="font-family:inherit;font-size:10pt;"><span>$177,000</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$280,000</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2016</span><span style="font-family:inherit;font-size:10pt;">, respectively.  The Company is not required to purchase any product under the agreement, and the agreement may be terminated at any time on </span><span style="font-family:inherit;font-size:10pt;"><span>120 days</span></span><span style="font-family:inherit;font-size:10pt;">&#8217; notice or, under certain circumstances, with </span><span style="font-family:inherit;font-size:10pt;">no</span> notice.  Otherwise, the agreement terminates March 31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792485472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">SUBSEQUENT EVENT<div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">July&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Board of Directors declared a quarterly cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.11</span></span><span style="font-family:inherit;font-size:10pt;"> and a special cash dividend of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.25</span></span><span style="font-family:inherit;font-size:10pt;"> on each share of common stock outstanding. Such dividends are payable on </span><span style="font-family:inherit;font-size:10pt;">August&#160;31, 2017</span><span style="font-family:inherit;font-size:10pt;"> to stockholders of record on </span><span style="font-family:inherit;font-size:10pt;">August&#160;21, 2017</span>. Payment of any future dividends on shares of common stock will be at the discretion of the Company&#8217;s Board of Directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794342768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of Consolidation<div style="line-height:120%;text-align:justify;text-indent:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div>The consolidated financial statements include the accounts of the Company and all of its wholly-owned subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794359456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and Adopted Accounting Pronouncements</a></td>
<td class="text">ACCOUNTING PRONOUNCEMENTS<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-18, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows - Restricted Cash</span><span style="font-family:inherit;font-size:10pt;">, that requires amounts generally described as restricted cash or restricted cash equivalents be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The new standard will be effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years, and early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company&#8217;s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation: Improvements to Employee Share-Based Payment Accounting</span><span style="font-family:inherit;font-size:10pt;">, that simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those annual years, and early adoption was permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company&#8217;s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">, that requires organizations that lease assets, referred to as &#8220;lessees&#8221;, to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2016-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those annual years, and early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Classification of Deferred Taxes</span><span style="font-family:inherit;font-size:10pt;">. Under this guidance, entities are required to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. This guidance was effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. Entities were permitted to adopt this guidance either prospectively or retrospectively. The Company elected to early adopt this guidance prospectively as of the quarter ended December 31, 2016.  </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In July 2015, the FASB issued ASU No. 2015-11,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;Inventory: Simplifying the Measurement of Inventory.</span><span style="font-family:inherit;font-size:10pt;"> Under this guidance, inventory not measured using either the last in, first out (LIFO) or the retail inventory method are to be measured at the lower of cost and net realizable value.&#160; Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable cost of completion, disposal, and transportation.&#160; The new standard was effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, with early adoption permitted. The Company adopted this guidance as of the quarter ended March 31, 2017. The adoption of this guidance did not have a material effect on the Company&#8217;s consolidated financial statements. </span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU No.&#160;2014-09,&#160;</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</span><span style="font-family:inherit;font-size:10pt;">, that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU 2014-09 is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#160; It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract.&#160; Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard.&#160; In July 2015, the FASB approved the deferral of the effective date for annual reporting periods that begin after December 15, 2017, including interim reporting periods. Early adoption is permitted to the original effective date of December 15, 2016, including interim reporting periods. The Company is currently assessing the impact that this standard will have on its consolidated financial statements.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Other recently issued accounting pronouncements did not or are not believed by management to have a material impact on the Company&#8217;s present or future financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794276640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6743963872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text">As of <span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;">, cash and cash equivalents include the Company&#8217;s investments in debt securities, comprising municipal notes and bonds and corporate debt, money market funds and time deposits. The Company considers all highly liquid investments with original maturities of three months or less when purchased and have insignificant interest rate risk to be cash equivalents.&#160; Debt securities classified as cash equivalents are required to be accounted for in accordance with ASC 320, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Debt and Equity Securities</span><span style="font-family:inherit;font-size:10pt;">. As such, the Company determined its investments in debt securities held at </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span> should be classified as available-for-sale and are carried at fair value with unrealized gains and losses reported in accumulated other comprehensive income in stockholders&#8217; equity. The cost of debt securities is adjusted for amortization of premiums and discounts to maturity. This amortization is included in other income. Realized gains and losses, as well as interest income, are also included in other income. The fair values of securities are based on quoted market prices.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text">The carrying amounts of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts payable and accrued expenses, approximate fair value because of their short maturities. The carrying amount of the noncurrent restricted cash approximates fair value since, absent the restrictions, the underlying assets would be included in cash and cash equivalents. The Company's cash equivalents are valued based on level 1 inputs which consist of quoted prices in active markets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794272832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">NET INCOME PER COMMON SHARE<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. The dilutive effect of non-vested restricted stock is reflected by application of the treasury stock method. Under the treasury stock method, the amount of compensation cost for future service that the Company has not yet recognized and the amount of tax benefit that would be recorded in additional paid-in capital when the award becomes deductible are assumed to be used to repurchase shares.</span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables illustrate the computation of basic and diluted net income per common share for the periods indicated (in thousands, except per share data):&#160;</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,243</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.92</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,201</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,333</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.08</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,303</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,274</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,359</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.07</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended June 30,</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Numerator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Denominator)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share Amount</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,728</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,481</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,553</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-vested restricted stock</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted net income per common share:</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income available to common stockholders plus assumed conversions</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20,728</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,264</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,579</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.03</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792794880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_BalanceSheetComponentsAbstract', window );"><strong>Balance Sheet Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock', window );">Schedule of Additional Balance Sheet Components [Table Text Block]</a></td>
<td class="text">The components of certain balance sheet amounts are as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash and cash equivalents:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63,036</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash equivalents</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136,261</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125,921</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other accrued expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales returns</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,632</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Employee-related</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,087</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,541</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Warehousing, inventory-related and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,978</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,816</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,366</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14,989</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_BalanceSheetComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Components [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_BalanceSheetComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Additional Balance Sheet Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794333648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Securities [Table Text Block]</a></td>
<td class="text">Available-for-sale investments included in cash equivalents at the end of each period were as follows (in thousands):<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Gains</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Adjusted Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Gross Unrealized Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Municipal bonds and notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,895</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11,897</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43,490</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate debt securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,312</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16,303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,673</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,671</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial institution instruments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45,025</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total available-for-sale investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,232</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,225</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,470</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73,468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6957658&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792877776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text">The following table summarizes the Company&#8217;s other restricted stock activity:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22,348</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10,970</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(418</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div>The following table summarizes the Company&#8217;s restricted stock activity under the 2016 Plan:<div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:65%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Wtd. Avg. Price at Date of Issuance</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at December 31, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38,256</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56,260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Vested</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17,668</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nonvested at June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.90</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792527840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</a></td>
<td class="text">The changes in accumulated other comprehensive loss by component for the first <span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months of 2017 were as follows (in thousands):</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign Currency Translation Adjustment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unrealized Losses on Available-For-Sale Investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, December 31, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(805</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>163</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reclassified out of accumulated other comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(258</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Balance, June 30, 2017</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(907</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792794880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY Dividends (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Dividends [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Dividends Declared [Table Text Block]</a></td>
<td class="text">The following table summarizes the Company&#8217;s cash dividend activity for the <span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</span><span style="font-family:inherit;font-size:10pt;"> (in thousands, except per share data):</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:19%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Declaration Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Record Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment Date</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">April 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;9, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May&#160;19, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017 (special)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.35</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 24, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.09</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,019</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February&#160;21, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March&#160;3, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.89</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,078</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:34px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Payment of any future dividends on shares of common stock will be at the discretion of the Company&#8217;s Board of Directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803906816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET INCOME PER COMMON SHARE Net Income Per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Income (Loss) Available to Common Stockholders, Basic</a></td>
<td class="nump">$ 10,303<span></span>
</td>
<td class="nump">$ 12,201<span></span>
</td>
<td class="nump">$ 20,728<span></span>
</td>
<td class="nump">$ 23,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">11,243<span></span>
</td>
<td class="nump">11,333<span></span>
</td>
<td class="nump">11,236<span></span>
</td>
<td class="nump">11,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings Per Share, Basic</a></td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net Income (Loss) Available to Common Stockholders, Diluted</a></td>
<td class="nump">$ 10,303<span></span>
</td>
<td class="nump">$ 12,201<span></span>
</td>
<td class="nump">$ 20,728<span></span>
</td>
<td class="nump">$ 23,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">11,274<span></span>
</td>
<td class="nump">11,359<span></span>
</td>
<td class="nump">11,264<span></span>
</td>
<td class="nump">11,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings Per Share, Diluted</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 2.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796137504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEET COMPONENTS Balance Sheet Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 136,261<span></span>
</td>
<td class="nump">$ 125,921<span></span>
</td>
<td class="nump">$ 109,649<span></span>
</td>
<td class="nump">$ 104,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_AccruedSalesReturns', window );">Accrued Sales Returns</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">1,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued Employee Benefits, Current</a></td>
<td class="nump">6,087<span></span>
</td>
<td class="nump">10,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_AccruedWarehousingAndInventoryRelatedExpense', window );">Accrued Warehousing And Inventory Related Expense</a></td>
<td class="nump">1,978<span></span>
</td>
<td class="nump">2,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="nump">10,366<span></span>
</td>
<td class="nump">14,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember', window );">Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">73,225<span></span>
</td>
<td class="nump">73,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">$ 63,036<span></span>
</td>
<td class="nump">$ 52,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_AccruedSalesReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_AccruedSalesReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_AccruedWarehousingAndInventoryRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Warehousing And Inventory Related Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_AccruedWarehousingAndInventoryRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6796104160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">$ 73,232<span></span>
</td>
<td class="nump">$ 73,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">73,225<span></span>
</td>
<td class="nump">73,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nhtc_MunicipalBondsAndNotesMember', window );">Municipal Bonds and Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">11,895<span></span>
</td>
<td class="nump">43,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">11,897<span></span>
</td>
<td class="nump">43,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">16,312<span></span>
</td>
<td class="nump">1,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">16,303<span></span>
</td>
<td class="nump">1,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=nhtc_FinancialInstitutionInstrumentsMember', window );">Financial Institution Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Available-for-sale Securities, Amortized Cost Basis</a></td>
<td class="nump">45,025<span></span>
</td>
<td class="nump">28,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax', window );">Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">$ 45,025<span></span>
</td>
<td class="nump">$ 28,307<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65884222&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=73527792&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66010992&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nhtc_MunicipalBondsAndNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nhtc_MunicipalBondsAndNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=nhtc_FinancialInstitutionInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=nhtc_FinancialInstitutionInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805039360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY NARRATIVE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 24, 2017</div></th>
<th class="th"><div>Jan. 24, 2017</div></th>
<th class="th"><div>Apr. 08, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Apr. 07, 2016</div></th>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Jul. 28, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common Stock, Dividends, Per Share, Declared</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_CommonStockSpecialDividendsPerShareDeclared', window );">CommonStockSpecialDividendsPerShareDeclared</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends, Common Stock, Cash</a></td>
<td class="nump">$ 3,964,000<span></span>
</td>
<td class="nump">$ 3,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCash', window );">Dividends, Cash</a></td>
<td class="nump">$ 1,133,000<span></span>
</td>
<td class="nump">$ 1,019,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,078,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 17,300<span></span>
</td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Additional stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, amount authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Stock Repurchase Program, Remaining Authorized Repurchase Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common Stock, Dividends, Per Share, Cash Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period for compensation costs not yet recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nhtc_EquityIncentive2016PlanMember', window );">Equity Incentive Plan 2016 | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nhtc_EquityIncentive2016PlanMember', window );">Equity Incentive Plan 2016 | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_CommonStockSpecialDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Special dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_CommonStockSpecialDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nhtc_EquityIncentive2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nhtc_EquityIncentive2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804871616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2017</div></th>
<th class="th"><div>Apr. 08, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,393,873<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock Issued During Period, Value, Restricted Stock Award, Gross</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,260<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,970)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Equity Incentive Plan 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nhtc_EquityIncentive2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nhtc_EquityIncentive2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6793449776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, December 31, 2016</a></td>
<td class="num">$ (807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, March 31, 2017</a></td>
<td class="num">(907)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, December 31, 2016</a></td>
<td class="num">(805)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</a></td>
<td class="num">(258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, March 31, 2017</a></td>
<td class="num">(900)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, December 31, 2016</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, March 31, 2017</a></td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, December 31, 2016</a></td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</a></td>
<td class="num">(258)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, March 31, 2017</a></td>
<td class="num">$ (907)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=66004124&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66004921&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794300512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES NARRATIVE (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_INCOMETAXESAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</a></td>
<td class="nump">$ 19.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_INCOMETAXESAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>INCOME TAXES [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_INCOMETAXESAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6794265360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2016 </div>
<div>complaint</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=nhtc_SecuritiesClassActionMember', window );">Securities Class Action</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of complaints</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=nhtc_SecuritiesClassActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=nhtc_SecuritiesClassActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6804454992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS NARRATIVE (Detail) - Broady Health Sciences - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2015</div></th>
<th class="th"><div>Feb. 28, 2013</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nhtc_BroadyHealthSciencesMember', window );">Soothe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_RoyaltyRate', window );">Royalty rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_NumberOfDaysTerminationNotice', window );">Number of days for termination notice</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nhtc_BroadyHealthSciencesMember', window );">ReStore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_RoyaltyRate', window );">Royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
<td class="nump">$ 177,000<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_NumberOfDaysTerminationNotice', window );">Number of days for termination notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_NumberOfDaysTerminationNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of days termination notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_NumberOfDaysTerminationNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_RoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_RoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nhtc_BroadyHealthSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=nhtc_BroadyHealthSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=nhtc_SootheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=nhtc_SootheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=nhtc_ReStoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=nhtc_ReStoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6792588192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT - NARRATIVE (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Apr. 24, 2017</div></th>
<th class="th"><div>Jan. 24, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common Stock, Dividends, Per Share, Declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_CommonStockSpecialDividendsPerShareDeclared', window );">CommonStockSpecialDividendsPerShareDeclared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common Stock, Dividends, Per Share, Declared</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_nhtc_CommonStockSpecialDividendsPerShareDeclared', window );">CommonStockSpecialDividendsPerShareDeclared</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nhtc_CommonStockSpecialDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Special dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nhtc_CommonStockSpecialDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nhtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*NQZ8_?V'QM?!&4+O^Y"?@%02P,$%     @ NTD"2YE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M9<'9$'#[M7JLDP(^Q^HR*[UI[LZ<J6B%VGV440$>VLR(.%@$FB'@A #*]B2
M? ('Y-#1OP)'%Q'[!6)O!+&AQS-ZXJ<G7GIBZ,F,GBXNP$5D?H'4*Y Z],U"
MP$7D?H',*Y Y].U"P$7 R*^P\2IL7#Y<2%A(:B"==0*B*%M)E=PKD[LRBUPY
M>" KR;+U2FQ=?K*0\$!2OP2,_"45N1:R95%Y,)L5E97"A:Z%?%%9(V;^52",
M$YAO5SX_]-;P'B)7:YEC(V:NA:+5F/RE#&-'!SG/D<5D<\Q*ED%_Q4.WH-$R
MSWR89:*!V1O;$GXS[4@$%;MWIA?.=J>6MS== /R%VW[Y%?-;TXG@S*1ZZ<U[
M?&5,$N5*]*2NM%8M>EI0<I5ZNE%S;ON474C6CST83'\$RC]02P,$%     @
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M9?_5O_HJR <GH8]-4W7C[VSSTO5-/;42K-3EK\OQ<!R/YZG]MS Y *< O :
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M/)RWEYVFRT7?G*9=M/2ZE;?\#U!+ P04    " "[20)+F0W\Y$$"  "N!P
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M6:AN(ONL?T'Z@:#M\#J"\8G>_@-02P,$%     @ NTD"2XJ$(C-C!   /10
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M+XR_B".ETGNMJT8L_*.4[2P(Q/9(:R+N6$L;]<^>\9I(->2'0+2<DITAU56
MPG :U*1L_.7<S#WPY9R=9%4V](%[XE37A/\M:,4N"S_RKQ./Y>$H]42PG+?D
M0)^H_-D^<#4*ABB[LJ:-*%GC<;I?^/?1;!.%FF 0OTIZ$:-W3TMY9NQ%#[[M
M%GZH*Z(5W4H=@JC'F:YH5>E(JHX_?5!_R*F)X_=K]"]&O!+S3 1=L>IWN9/'
MA9_YWH[NR:F2C^SRE?:"$M_KU7^G9UHIN*Y$Y=BR2IA?;WL2DM5]%%5*35Z[
M9]F8YZ6/?Z6Y":@GH(&@<G]$P#T!OQ'B#PEQ3XC_-T/2$Q*0(>BT&S/71)+E
MG+.+Q[OOH27ZLXMFB5JNK9XTJV/^4WX*-7M>YO$\..LX/:3H(&@$2<-;R-J&
M1 ,B4/F'(I"KB )9='2;8&4CT@C4\&F0S8=!;LK$3J^PX>.Q5XF;'SOYL>''
M(WZ6 *\[2&H@36=DB$,,W'"@$ JA(38*A2G*@"D.%(ZS=WQ)G+H2VY>IFS]U
M\J>6+WD*?.D@R:C*#$!6-F2"$0"M;5 T!>YN'(%0^LY"ITY!J2T(V%ZD5A*P
MIU8V8A)A\$FO;1!*X I_$NA&3^;4D]EZ<J G^WR!;,@DRL$&6#M $+-Q!8JQ
M6U#N%)1;@J(0^%_DMK5 D(V8P#WH@$ U-B1U2U'WL?,$#QUB0!U%#P('2PX5
MN6"JZ8"+Y("A<&H=+2X8QC'<2L'HKJHI/YC&07A;=FJD/E9&LT-S<H_T70?F
MBVBVBASS:]W,F+OQ+7S7"?T@_% VPGMF4MVPYA[<,R:IJCZ\4TMR5,W7,*CH
M7NK75+WSK@/I!I*U?7<5#"W>\A]02P,$%     @ NTD"2[57M*LM!   DA,
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MACG)1%#I./<DDXA>$B&96 Z0B@%2EDQ6D&0F2?)H,TM)*EP#N9)]9**/C/D
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M    >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5/;CIPP#/V5*!^PF<G0BT:
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M+W-H965T,3 N>&UL;5/;;MP@$/T5Q >$7>Q<M+(M91-%K=1*JU1MGUE[?%&
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MH_,O&_M?(SKP4G97?H1:_\$60T'MPO&#/YMIS";#83__(+9\X^(G4$L#!!0
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M['^%Z,!+V5SY$6K\!YL-"94+QR_^;,8Q&PV'W?2#V/R-\[]02P,$%     @
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M\_&77$MIP%J);JR7UG;QNN!0&S?]8N=J?LOSPLAA:5.R_BN*WU!+ P04
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M^U\B.O"IK&[\"-7^@TV&A-*%XZT_FV',!L-A._X@-GWC[ -02P,$%     @
MNTD"2^W6^#"W 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M;5/;;MLP#/T501]0)4Z69(%MH.DP=, &!!W6/BLV;0O5Q97DN/O[4;+KNIU?
M))'B.3RDJ+0W]MDU )Z\*JE=1AOOVR-CKFA <7=C6M!X4QFKN$?3ULRU%G@9
M04JR9+7:,<6%IGD:?6>;IZ;S4F@X6^(ZI;C]>P)I^HRNZ9OC0=2-#PZ6IRVO
MX3?X/^W9HL4FEE(HT$X832Q4&;U='T_;$!\#'@7T;G8FH9*+,<_!^%%F=!4$
M@83"!P:.VQ7N0,I A#)>1DXZI0S ^?F-_7NL'6NY< =W1CZ)TC<9/5!20L4[
MZ1],?P]C/5\H&8O_"5>0&!Z48(["2!=74G3.&S6RH!3%7X==Z+CWP\UN/\*6
M <D(2"; (>9A0Z*H_!OW/$^MZ8D=>M_R\,3K8X*]*8(SMB+>H7B'WFN^WNU2
M=@U$8\QIB$GF,5,$0_8I1;*4XI3\!T^6X9M%A9L(WWQ0N%\FV"X2;"/!]@/!
MX5.)2S%?/R5ALYXJL'6<)D<*T^DXR3/O-+"W27R3]_!AVG]Q6POMR,5X?-G8
M_\H8#RAE=8,CU. 'FPP)E0_'/9[M,&:#X4T[_B V?>/\'U!+ P04    " "[
M20)+DC@Z@+8!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6QM
M4V%OW" ,_2N('U"27+9VIR12K].T29MTZK3N,Y<X"2K@#,BE^_<#DF99ER^
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MPMQ^",)6/55@VCA-EE0XZ#C)*^\RL/=)?)-W^#3MW[AIA;;D@LZ_;.Q_@^C
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MOW#Q*H^,*>^M*FNY\(]*-;,@D-LCJZB<\(;5^LN>BXHJO12'0#:"T9TUJLH
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MNQ6!O5$5&'$C0 1E(Q2XE< [O 1P,X$I;N) -V6941@X(P;+Z(@>W$]@BJ$
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MGLMQ%;$'H4=_/[Z<!GOZ3P]/K]^^;8EGZ^AM3&0P'V<,W6(86V(>$8:6F!W
M7!&1KO):*L%2:0KG"XH,)^ P 9\2B$6ON57CC$DF3&LP!<\SCHD$)!)NI;S
M"1*8('$K%;$U*S.&Q3>ELI7 +"ED25T6\@QH!A-D;I^"X00Y3)"#/NU5D[LS
M0ESDF*: - 5HU)KXQ\*A25)*K4'?N:@8%S+."Y);##KFMDYBA^4#BXO,1^51
M-@-4PJ9B+I5@GL%E6)>, %%B$Y%#I%M*?2UA 3-^O[ 8EB83H-C4+G8&%;?%
MTHHE'B:L889$G-E,R=T+"FN8 1$+V]0,B+$[&\)J9QF@*FRJ#%*1;TEA7V#
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M]IT.7NK32X'C* \N!JBS6;<V^,X&]1:!1N\I,$2QQB-W',]@@ B,,;( T0-
M# /,0("9!9@] "2#)%N;U-K4UN9#%J8P2PRRQ !+.F!I;>)[EKF+)0%9$H E
M@P%2$""=7LT,!,@F5#,;YYF%#I8YR#('6.8#EOF(!2413()"N/W#,4T2#OL_
M'&?C+#IRZ Q-Z([.:- >H8,(5-L*82 CAUX1K#?T'X)#L.+0%,EU1H]U==#
MDD.0YH9=@@#1N;*!-8< T8V[)!G1N+X<+$R43FF1=)R,X_Y L'P1H-_$5798
MFV@^O4$P+#P,"&_4(!@0GO-2QK#P,"2\88O@L?"02^ 8UAV&=#?LD<YHVDV"
M877B:$*;=$;IO_]H@KLIH:+B:.<CZ>WXN;;#V=UI/X.ML)TR_IJW ]PW(HYE
M+;TM5WI6L1/%@7-%=3#AD\[WI&?&?L/H09EEJM>B'9S:C>)--Q0&_61:_ %0
M2P,$%     @ NTD"2[#$,?"_ 0  UP,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL;5/;;MLP#/T501\0V;*;=H%CH.DP;, &!!W6/2LV?4%U\20Y
M[OY^NCB>U_G%(NG#PT.**B:E7TT'8-&;X-(<<6?M<"#$5!T(9G9J .G^-$H+
M9IVK6V(&#:P.28(3FB1[(E@O<5F$V%F7A1HM[R6<-3*C$$S_/@%7TQ&G^!9X
M[MO.^@ IBX&U\!WLC^&LG4<6EKH7($VO)-+0'/%C>CCE'A\ +SU,9F4CW\E%
MJ5?O?*F/./&"@$-E/0-SQQ6>@'-/Y&3\FCGQ4M(GKNT;^Z?0N^OEP@P\*?ZS
MKVUWQ \8U="PD=MG-7V&N9\[C.;FO\(5N(-[):Y&I;@)7U2-QBHQLS@I@KW%
MLY?AG&;^6]IV IT3Z)) 8R^Q4%#^D5E6%EI-2,?9#\Q?<7J@;C:5#X91A'].
MO''1:TGW64&NGFC&G"*&KC#WR0(ACGZI0;=JG.A_^72?;Q-DFR*S0)"M"-+L
M89L@WR3( T'^CX*[=UU&3)H$D(Q5/NS>ER&KP0K0;5@I@RHURK#.J^BRM8\T
M7,Q?>%SY;TRWO33HHJR[WG )C5(6G)ADY_:H<Z]L<3@TUIOWSM9QUZ)CU3 _
M([*\Y?(/4$L#!!0    ( +M) DL0:6=-Q@$  !4$   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;&U4VV[;, S]%4$?4#E*G'2!;:!I46S !@0=MCTK
M-GU!=?$D.>[^?KHXGMOYQ1*IP\-#2G0V*OUJ6@"+W@27)L>MM?V1$%.V()BY
M4SU(=U(K+9AUIFZ(Z36P*@0)3FB2[(E@G<1%%GQG761JL+R3<-;(#$(P_><$
M7(TYWN";XZ5K6NL=I,AZUL!WL#_ZLW86F5FJ3H TG9)(0YWCA\WQE'I\ /SL
M8#2+/?*57)1Z]<:7*L>)%P0<2NL9F%NN\ B<>R(GX_?$B>>4/G"YO[$_A]I=
M+1=FX%'Q7UUEVQS?8U1!S09N7]3X&:9Z4HRFXK_"%;B#>R4N1ZFX"5]4#L8J
M,;$X*8*]Q;6381WC27H+6P^@4P"= ^@VU!(3!>5/S+(BTVI$.O:^9_Z*-T?J
M>E-Z9VA%.'/BC?->"[K?9^3JB2;,*6+H.\QAQA#'/R>A:TE.=(7@?IU@NZIR
M&PAV[P@^K1/L5@EV@6"[)#@DZP3I*D'ZOX+#YD.?(B8-&!DQ'U*0Q;4(T$UX
MD :5:I!A&!;>^<T_T'"M_^!Q8+XQW732H(NR[G&$*ZR5LN"$)'=.0^MF=#8X
MU-9O#VZOXTN-AE7]-(1D_A,4?P%02P,$%     @ NTD"2P+5=4)7 @  J @
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M6TS?-2=*!9:"WD*Z6\HG=Q@0?!*JF\H^ZQ^>?B!H:]Y4,#SLQ5]02P,$%
M  @ NTD"2S"8QNP7+   G:P  !0   !X;"]S:&%R9613=')I;F=S+GAM;.U]
M:W/;1I;HY[V_HBM7LR-7@30?HD39F531%!4SD24-*3F;F[H?0*(I(@$!!@_)
MFMH??\^CN]%XD93CG;F;]8?$(M#/TZ?/^QQ\FR2IR$+_]TR.HRQ,__9-;WCV
MC?BT"<+D;]^LTW3[YO7K9+F6&S=I1UL9PIM5%&_<%'[&#Z^3;2Q=+UE+F6Z"
MU[U.Y_3UQO7#;[[[-O&_^S;][B):9AL9IF(4>F(2IG[Z+*8AC^!'H6B)9.W&
M,OGV=?K=MZ^Q#_<[%1^B,%TGT,>37OGM#UG8%OV.(WJ=[EGU9= 6O6']RSWK
M:6Q^][R5Y9?=3NOOC1UN9>Q'.(4G+MRTTE?OX'_]V[_5+5.M;"8?_"2-71CO
MVMU4!KD>W=W/1E?B_61T=?=>W,TFUQ=S,;Z9W;8;!AS#TF(W@"U[\I/X43Z7
MVXVS.,;E7_K)$MK]+-VX<0^M5K?7ZG<;IKKT QF+,?1[B.+*/*/E4L)[>.MQ
MRZ8%J_7,Y#:*4S]\$//43;,*OOQ<12$]0K39 *+-TVCYFR/FA&WB)DN3U T]
M'/#8#Q42OFH\31L<E_"P,EFYI3K^VK9_[U6@ 5T][AZX#^6W*S=(*L ?WUS/
M;ZZF%Z.[R85X-[H:78\G8OY^,KF;PZ6ZGU^(XZ-7XDC YN[649; 9JN+EDM
MPB[=E-,F3'"31*;)F\IK-UD+&%0L\0_Y>^8_N@&TKTPR#1_A<13[U1.Z2=>
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M+)0)#(CK4=N$^0,T:P.08!*IMHL4S,N6<& 9J$NQL.!R_?Y.?!]$"S?0;1=
MU[TV,# SO;(&).)I#:M[;D5/:#U)[*6O07A%N!'= %EZ_9R@_B_H[!'- 1PX
MZPH&B)X0*!LW_@TMQ_1X!)"$]K"7I[6_7",D$E!EB/KB^_O01^%U;B 8NIZ+
M_SYO8-(IL"'2&3_(3_XR8O25<?96? \W*T5A90W86S?X^PB6\F.$NM2=ZS^Y
MC/O4_*V8@\0-APJJWBCQ:[O/82<NX X<QP<W<&'3+@WPT9=IZ&[4$# !K..M
M^,$%:+ZE!I,,>4H!RL(-DDAQ-.:,LRS1 _[H_L/];8WB/\ CCK('I)% J1Y
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M(%&CJ$(B)HC<.LESE#V VDS-V=J)[BV=J%.[#\!P?ZN3\#0E(S(-*@&I1EM
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MBQ,5,PT >"@7*$0T(:;U/C_M>53!W"9NJ7E[%'!=W6-A.\]ZRR8L5TE"E%W
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M.%7=LUQ=H]5@$LGE^%H[0Q-A+5?ZV.W'+#7.W[].DO2[_P=02P,$%     @
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MN1G.44/5G9FB#<9PM#\;X<%R&+4:*&(XVE]P1AIV:0N.?PJ2'U!+ P04
M" "[20)+31R5YSL#  #5%@  #P   'AL+W=O<FMB;V]K+GAM;,6876^;,!1
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M^JS[X3O[ E!+ 0(4 Q0    ( +M) DL?(\\#P    !,"   +
M  "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +M) DMF\PM@@@   +$
M   0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ NTD"2Y'YZKCO    *P(  !$              ( !F0$  &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ NTD"2YE<G",0!@  G"<  !,
M     ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "[20)+
MJF+5PF("   4"   &               @ 'X"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ NTD"2]S[K](?!   UA,  !@
M     ( !D L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M +M) DN9#?SD00(  *X'   8              "  >4/  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " "[20)+BH0B,V,$   ]%   &
M            @ %<$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ NTD"2Q<@1'G  @  [@D  !@              ( !]18  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( +M) DNU5[2K+00  )(3
M   8              "  >L9  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " "[20)+5J^U/[ !  #2 P  &               @ %.'@
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ NTD"2_Y#B2ZV
M 0  T@,  !@              ( !-"   'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( +M) DM@0 O1M0$  -(#   8              "
M 2 B  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "[20)+
MBV0N4K8!  #2 P  &0              @ $+)   >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( +M) DMX?3(HMP$  -(#   9
M      "  ?@E  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ NTD"2VP4^#2S 0  T@,  !D              ( !YB<  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "[20)+#=)1*+0!  #2 P
M&0              @ '0*0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( +M) DM6<K]DM $  -(#   9              "  ;LK  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ NTD"2Z:;BYFT
M 0  T@,  !D              ( !IBT  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " "[20)+$\IY=[<!  #2 P  &0
M@ &1+P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +M)
M DM]ZQ5JMP$  -(#   9              "  7\Q  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ NTD"2V*0-Y#$ 0  -P0  !D
M         ( !;3,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " "[20)+$75I^[8!  #2 P  &0              @ %H-0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +M) DOMUO@PMP$  -(#
M   9              "  54W  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ NTD"2Y(X.H"V 0  T@,  !D              ( !0SD
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "[20)+G4@:
M7K8!  #2 P  &0              @ $P.P  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( +M) DOQ>0LJMP$  -(#   9
M  "  1T]  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MNTD"2RA81]ZU 0  T@,  !D              ( !"S\  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " "[20)+V1R W]4"  "<"@  &0
M            @ 'W0   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( +M) DL8OL.JC (  "<)   9              "  0-$  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ NTD"2W1[ZVVP @
M< L  !D              ( !QD8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " "[20)+LCT6"8$#  !1$   &0              @ &M
M20  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +M) DLS
M6"EY7@,   D/   9              "  65-  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ NTD"2R8HA.&G @  I0H  !D
M     ( !^E   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +M) DLPF,;L%RP  )VL   4              "
M <E<  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( +M) DL6CT+3
M30(  "$,   -              "  1*)  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ NTD"2TT<E><[ P  U18   \              ( !BHL  'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( +M) DLSW*/_@P$  &L5   :
M      "  ?*.  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( +M) DN: LD&E@$  /@5   3              "  :V0  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     K "L GPL  '22      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>55</ContextCount>
  <ElementCount>149</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>NATURE OF OPERATIONS AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare</Role>
      <ShortName>NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - INCOME TAXES INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes</Role>
      <ShortName>INCOME TAXES INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/SubsequentEvent</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation</Role>
      <ShortName>NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2207200 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements</Role>
      <ShortName>ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2208201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies</Role>
      <ShortName>NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2211201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables</Role>
      <ShortName>NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables</Role>
      <ShortName>BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - STOCKHOLDERS' EQUITY Dividends (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY Dividends (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails</Role>
      <ShortName>NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails</Role>
      <ShortName>BALANCE SHEET COMPONENTS Balance Sheet Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - INCOME TAXES NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail</Role>
      <ShortName>RELATED PARTY TRANSACTIONS NARRATIVE (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nhtc20170802_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2416401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENT - NARRATIVE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="nhtc20170802_10q.htm">nhtc20170802_10q.htm</File>
    <File>nhtc-20170630.xsd</File>
    <File>nhtc-20170630_cal.xml</File>
    <File>nhtc-20170630_def.xml</File>
    <File>nhtc-20170630_lab.xml</File>
    <File>nhtc-20170630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>51
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nhtc20170802_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 55,
   "dts": {
    "calculationLink": {
     "local": [
      "nhtc-20170630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nhtc-20170630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nhtc20170802_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nhtc-20170630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-doc-2016-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-doc-2014-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nhtc-20170630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-ref-2016-01-31.xml",
      "http://xbrl.sec.gov/dei/2014/dei-ref-2014-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nhtc-20170630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2016/elts/us-parts-codification-2016-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2016/elts/us-roles-2016-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd",
      "http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd",
      "http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd",
      "http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd",
      "http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"
     ]
    }
   },
   "elementCount": 234,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2016-01-31": 17,
    "http://xbrl.sec.gov/dei/2014-01-31": 7,
    "total": 24
   },
   "keyCustom": 7,
   "keyStandard": 142,
   "memberCustom": 7,
   "memberStandard": 9,
   "nsprefix": "nhtc",
   "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Document And Entity Information",
     "role": "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - INCOME TAXES INCOME TAXES",
     "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes",
     "shortName": "INCOME TAXES INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115100 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - SUBSEQUENT EVENT",
     "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2206201 - Disclosure - NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION",
     "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation",
     "shortName": "NATURE OF OPERATIONS, BASIS OF PRESENTATION AND CONSOLIDATION CONSOLIDATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2207200 - Disclosure - ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements",
     "shortName": "ACCOUNTING PRONOUNCEMENTS ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2208201 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)",
     "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies",
     "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerSharePolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2211201 - Disclosure - FAIR VALUE MEASUREMENTS (Policies)",
     "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies",
     "shortName": "FAIR VALUE MEASUREMENTS (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)",
     "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables",
     "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)",
     "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables",
     "shortName": "BALANCE SHEET COMPONENTS Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nhtc:ScheduleofAdditionalBalanceSheetComponentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)",
     "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables",
     "shortName": "STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables",
     "shortName": "STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - STOCKHOLDERS' EQUITY Dividends (Tables)",
     "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables",
     "shortName": "STOCKHOLDERS' EQUITY Dividends (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails",
     "shortName": "NET INCOME PER COMMON SHARE Net Income Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - BALANCE SHEET COMPONENTS Balance Sheet Components (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails",
     "shortName": "BALANCE SHEET COMPONENTS Balance Sheet Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "-3",
      "lang": null,
      "name": "nhtc:AccruedSalesReturns",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2017Q2Apr24-Apr24",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - STOCKHOLDERS' EQUITY NARRATIVE (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "STOCKHOLDERS' EQUITY NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2017Q2Apr24-Apr24",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DividendsCommonStockCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails",
     "shortName": "STOCKHOLDERS' EQUITY RESTRICTED STOCK ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FI2017Q2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2016Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
     "shortName": "STOCKHOLDERS' EQUITY ACCUMULATED OTHER COMPREHENSIVE LOSS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2016Q1QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413401 - Disclosure - INCOME TAXES NARRATIVE (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "INCOME TAXES NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "FD2016Q1QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "complaint",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414401 - Disclosure - COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2016Q1Jan01-Jan31_us-gaap_LitigationCaseAxis_nhtc_SecuritiesClassActionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "complaint",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "nhtc:RoyaltyRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415401 - Disclosure - RELATED PARTY TRANSACTIONS NARRATIVE (Detail)",
     "role": "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail",
     "shortName": "RELATED PARTY TRANSACTIONS NARRATIVE (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2015Q2Apr29_us-gaap_ProductOrServiceAxis_nhtc_SootheMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_nhtc_BroadyHealthSciencesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "nhtc:RoyaltyRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "contextRef": "D2017Q2Apr24-Apr24",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416401 - Disclosure - SUBSEQUENT EVENT - NARRATIVE (Details)",
     "role": "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails",
     "shortName": "SUBSEQUENT EVENT - NARRATIVE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "contextRef": "D2017Q3jul31-jul31_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SalesRevenueGoodsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - NATURE OF OPERATIONS AND BASIS OF PRESENTATION",
     "role": "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation",
     "shortName": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE",
     "role": "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare",
     "shortName": "NET INCOME PER COMMON SHARE NET INCOME PER COMMON SHARE",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - FAIR VALUE MEASUREMENTS (Notes)",
     "role": "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes",
     "shortName": "FAIR VALUE MEASUREMENTS (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "contextRef": "FD2017Q2YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 16,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "If the value is true, then the document is an amendment to previously-filed/accepted document.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word \"Other\".",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate \"Yes\" or \"No\" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2014-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "nhtc_AccruedSalesReturns": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Sales Returns",
        "label": "Accrued Sales Returns",
        "terseLabel": "Accrued Sales Returns"
       }
      }
     },
     "localname": "AccruedSalesReturns",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nhtc_AccruedWarehousingAndInventoryRelatedExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Warehousing And Inventory Related Expense",
        "label": "Accrued Warehousing And Inventory Related Expense",
        "terseLabel": "Accrued Warehousing And Inventory Related Expense"
       }
      }
     },
     "localname": "AccruedWarehousingAndInventoryRelatedExpense",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nhtc_AccumulatedOtherComprehensiveLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated Other Comprehensive Loss [Abstract]",
        "label": "Accumulated Other Comprehensive Loss [Abstract]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveLossAbstract",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "xbrltype": "stringItemType"
    },
    "nhtc_BalanceSheetComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Balance Sheet Components [Abstract]",
        "label": "Balance Sheet Components [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetComponentsAbstract",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "xbrltype": "stringItemType"
    },
    "nhtc_BroadyHealthSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents Broady Health Sciences.",
        "label": "Broady Health Sciences [Member]",
        "terseLabel": "Broady Health Sciences"
       }
      }
     },
     "localname": "BroadyHealthSciencesMember",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nhtc_CommonStockSpecialDividendsPerShareDeclared": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Special dividends declared during the period for each share of common stock outstanding.",
        "label": "CommonStockSpecialDividendsPerShareDeclared",
        "terseLabel": "CommonStockSpecialDividendsPerShareDeclared"
       }
      }
     },
     "localname": "CommonStockSpecialDividendsPerShareDeclared",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "nhtc_CumulativeTranslationAdjustmentRealizedInNetIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents cumulative translation adjustment realized in net income.",
        "label": "Cumulative Translation Adjustment Realized In Net Income",
        "negatedTerseLabel": "Cumulative Translation Adjustment Realized In Net Income"
       }
      }
     },
     "localname": "CumulativeTranslationAdjustmentRealizedInNetIncome",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nhtc_DocumentAndEntityInformation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Document And Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformation",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "xbrltype": "stringItemType"
    },
    "nhtc_EquityIncentive2016PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Incentive 2016 Plan",
        "label": "Equity Incentive 2016 Plan [Member]",
        "terseLabel": "Equity Incentive Plan 2016"
       }
      }
     },
     "localname": "EquityIncentive2016PlanMember",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nhtc_FinancialInstitutionInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information pertaining to financial institution instruments.",
        "label": "Financial Institution Instruments [Member]",
        "terseLabel": "Financial Institution Instruments [Member]"
       }
      }
     },
     "localname": "FinancialInstitutionInstrumentsMember",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nhtc_INCOMETAXESAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "INCOME TAXES [Abstract]",
        "label": "INCOME TAXES [Abstract]"
       }
      }
     },
     "localname": "INCOMETAXESAbstract",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "xbrltype": "stringItemType"
    },
    "nhtc_MunicipalBondsAndNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term and short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds and Notes [Member]",
        "terseLabel": "Municipal Bonds and Notes [Member]"
       }
      }
     },
     "localname": "MunicipalBondsAndNotesMember",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nhtc_NumberOfDaysTerminationNotice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents number of days termination notice.",
        "label": "Number Of Days Termination Notice",
        "terseLabel": "Number of days for termination notice"
       }
      }
     },
     "localname": "NumberOfDaysTerminationNotice",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "nhtc_ReStoreMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents a product called ReStore\u2122.",
        "label": "ReStore [Member]",
        "terseLabel": "ReStore"
       }
      }
     },
     "localname": "ReStoreMember",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "nhtc_RoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the royalty rate.",
        "label": "Royalty Rate",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRate",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "nhtc_ScheduleofAdditionalBalanceSheetComponentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Additional Balance Sheet Components [Table Text Block]",
        "label": "Schedule of Additional Balance Sheet Components [Table Text Block]",
        "terseLabel": "Schedule of Additional Balance Sheet Components [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleofAdditionalBalanceSheetComponentsTableTextBlock",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nhtc_SecuritiesClassActionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities Class Action [Member]",
        "label": "Securities Class Action [Member]",
        "terseLabel": "Securities Class Action"
       }
      }
     },
     "localname": "SecuritiesClassActionMember",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nhtc_SootheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents Soothe.",
        "label": "Soothe [Member]",
        "terseLabel": "Soothe"
       }
      }
     },
     "localname": "SootheMember",
     "nsuri": "http://www.naturalhealthtrendscorp.com/20170630",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r24",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued Employee Benefits, Current"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r29",
      "r218",
      "r230"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r54",
      "r58",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from the appreciation (depreciation) in value of securities attributable to the parent.",
        "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Balance, March 31, 2017",
        "periodStartLabel": "Balance, December 31, 2016",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r51",
      "r58",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r154",
      "r165",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r217",
      "r229"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r49"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [
      "r107",
      "r108",
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax",
        "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain (Loss), before Tax"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-sale Securities, Amortized Cost Basis",
        "terseLabel": "Available-for-sale Securities, Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r112",
      "r113",
      "r116",
      "r225",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Available-for-sale Securities [Table Text Block]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r155",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by award type pertaining to equity-based compensation.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r188",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "NATURE OF OPERATIONS AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r2",
      "r17",
      "r37",
      "r81"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS, end of period",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS, beginning of period",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails",
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets",
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r75",
      "r200"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r1",
      "r2",
      "r26",
      "r82",
      "r86",
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r2",
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r1",
      "r26"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash [Member]"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r44",
      "r125",
      "r220",
      "r234"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r44",
      "r124",
      "r129",
      "r135",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common Stock, Dividends, Per Share, Cash Paid"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common Stock, Dividends, Per Share, Declared",
        "verboseLabel": "Common (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 12,979,414 shares issued at June 30, 2017 and December 31, 2016"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r4",
      "r10",
      "r11",
      "r61"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CondensedBalanceSheetStatementTable": {
     "auth_ref": [
      "r16",
      "r91",
      "r180",
      "r224",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet Statement [Table]",
        "terseLabel": "Condensed Balance Sheet Statement [Table]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementTable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Balance Sheet Statements, Captions [Line Items]",
        "terseLabel": "Condensed Balance Sheet Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r183",
      "r186",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/NatureOfOperationsBasisOfPresentationAndConsolidationConsolidation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsSold": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs related to goods produced and sold during the reporting period.",
        "label": "Cost of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for deferred compensation arrangements payable after one year (or the normal operating cycle, if longer). Represents currently earned compensation under cash arrangements (such as a profit-sharing plan, rabbi trust, and employee contract--excluding equity-based arrangements) that is not actually paid until a later date.",
        "label": "Deferred Compensation Cash-based Arrangements, Liability, Classified, Noncurrent",
        "verboseLabel": "Long-term incentive"
       }
      }
     },
     "localname": "DeferredCompensationCashbasedArrangementsLiabilityClassifiedNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r23",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.",
        "label": "Deferred Revenue, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNoncurrent": {
     "auth_ref": [
      "r171",
      "r172",
      "r173"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.",
        "label": "Deferred Tax Liabilities, Net, Noncurrent",
        "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r79",
      "r122"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dividends [Abstract]",
        "terseLabel": "Cash dividends declared per share:"
       }
      }
     },
     "localname": "DividendsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCash": {
     "auth_ref": [
      "r142",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid cash dividends declared for classes of stock, for example, but not limited to, common and preferred.",
        "label": "Dividends, Cash",
        "terseLabel": "Dividends, Cash"
       }
      }
     },
     "localname": "DividendsCash",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Dividends, Common Stock, Cash"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Dividends Declared [Table Text Block]"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityDividendsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per common share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r95",
      "r100",
      "r102",
      "r223",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Earnings Per Share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r65",
      "r95",
      "r223",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r99",
      "r100",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonSharePolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r69",
      "r95",
      "r97",
      "r98",
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShare",
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r166"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized cost of unvested share-based compensation awards.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Share-based compensation expense not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Recognition period for compensation costs not yet recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r190",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures [Text Block]"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r86",
      "r192",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r119",
      "r120",
      "r121"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r216",
      "r221",
      "r237"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r7",
      "r90",
      "r178"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r86",
      "r169",
      "r170",
      "r176",
      "r177",
      "r179",
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInCustomerAdvancesAndDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of (a) prepayments by customers for goods or services to be provided at a later date, (b) the amount of customer money held in customer accounts, including security deposits, collateral for a current or future transactions, initial payment of the cost of acquisition or for the right to enter into a contract or agreement, or (c) a combination of (a) and (b).",
        "label": "Increase (Decrease) in Customer Advances and Deposits",
        "terseLabel": "Amounts held in eWallets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCustomerAdvancesAndDeposits",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.",
        "label": "Increase (Decrease) in Deferred Compensation",
        "terseLabel": "Long-term incentive"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r96",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r18",
      "r47",
      "r118"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r191",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r191",
      "r238",
      "r239",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r219",
      "r232"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of complaints"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/CommitmentsAndContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": {
     "auth_ref": [
      "r75",
      "r76",
      "r80"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r10",
      "r11",
      "r64",
      "r80",
      "r100",
      "r222",
      "r235"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      },
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited",
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net Income (Loss) Available to Common Stockholders, Basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net Income (Loss) Available to Common Stockholders, Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/AccountingPronouncementsAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURES OF OTHER CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r24",
      "r25",
      "r42"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails",
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r52",
      "r56",
      "r201",
      "r202",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r50",
      "r203"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": {
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r181",
      "r182",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r53",
      "r56"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax",
        "terseLabel": "Unrealized (losses) gains on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDeferredCreditsCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unearned revenue or income classified as other, expected to be taken into income within one year or the normal operating cycle, if longer.",
        "label": "Other Deferred Credits, Current",
        "verboseLabel": "Amounts held in eWallets"
       }
      }
     },
     "localname": "OtherDeferredCreditsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r42"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r6",
      "r74"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r6",
      "r74"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r8",
      "r73"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r155",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name pertaining to equity-based compensation arrangements.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the equity-based compensation arrangement plan.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductOrServiceAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by products and services or groups of similar products and services.",
        "label": "Products and Services [Axis]",
        "terseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductsAndServicesDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products and Services [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r27",
      "r28",
      "r123",
      "r233"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r58",
      "r62"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "terseLabel": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r9",
      "r13",
      "r14",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/BalanceSheetComponentsBalanceSheetComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r142",
      "r231"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesCommissionsAndFees": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primarily represents commissions incurred in the period based upon the sale by commissioned employees or third parties of the entity's goods or services, and fees for sales assistance or product enhancements performed by third parties (such as a distributor or value added reseller).",
        "label": "Sales Commissions and Fees",
        "terseLabel": "Commissions expense"
       }
      }
     },
     "localname": "SalesCommissionsAndFees",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueGoodsNet": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.",
        "label": "Sales Revenue, Goods, Net",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNet",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Available-for-sale Securities [Line Items]",
        "terseLabel": "Schedule of Available-for-sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r0",
      "r109",
      "r110",
      "r112",
      "r113",
      "r114",
      "r115",
      "r225",
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r89",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/RelatedPartyTransactionsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r155",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an equity-based arrangement under which compensation is awarded to employees, typically comprised of compensation expense; changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan; and cash flow effects resulting from the equity-based payment arrangement. Component disclosures are by type of award and plan name.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71",
      "r117"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional share-based compensation cost recognized as a result of an occurrence of an event that accelerates its recognition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost",
        "terseLabel": "Additional stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, ending balance (in shares)",
        "periodStartLabel": "Nonvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, ending balance (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r153",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity-based compensation award.",
        "label": "Equity Award [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r46",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossDetails",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityAccumulatedOtherComprehensiveLossTables",
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Issuance of treasury stock for employee awards, net"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r30",
      "r31",
      "r137",
      "r142"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Stock Issued During Period, Value, Restricted Stock Award, Gross"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, amount authorized"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r34",
      "r35",
      "r105"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r12",
      "r31",
      "r34",
      "r35",
      "r87",
      "r88",
      "r106",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEventNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r45",
      "r144"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r45",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost; 1,637,524 and 1,692,218 shares at June 30, 2017 and December 31, 2016, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r94",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r15",
      "r92",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2016-01-31",
     "presentation": [
      "http://www.naturalhealthtrendscorp.com/role/ConsolidatedStatementsOfOperationsUnaudited",
      "http://www.naturalhealthtrendscorp.com/role/NetIncomePerCommonShareNetIncomePerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Glossary": "Available-for-Sale Securities",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6505594"
  },
  "r1": {
   "Glossary": "Cash",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6506951"
  },
  "r10": {
   "Glossary": "Net Income",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=51831255"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=65016374&loc=d3e4984-109258"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "305",
   "URI": "http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=66010992&loc=d3e26610-111562"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27161-111563"
  },
  "r11": {
   "Glossary": "Other Comprehensive Income",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=51831270"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27198-111563"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27232-111563"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27290-111563"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27337-111563"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27340-111563"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=73527792&loc=d3e27357-111563"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266"
  },
  "r12": {
   "Glossary": "Preferred Stock",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6521494"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=64834752&loc=SL49117168-202975"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=35741047&loc=d3e13816-109267"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=73718637&loc=d3e25287-109308"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349"
  },
  "r13": {
   "Glossary": "Principal Owners",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6521851"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644"
  },
  "r14": {
   "Glossary": "Related Parties",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=16382449"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 13.A.4(a).Q1)",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 13.A.3(b))",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 13.A.3(b).Q1(c))",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780"
  },
  "r15": {
   "Glossary": "Weighted-Average Number of Common Shares Outstanding",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6528421"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 13.A.3(b).Q2)",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 13.A.3(c).Q3)",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 13.A.3)",
   "Topic": "605",
   "URI": "http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(c)(Schedule I))",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32247-109318"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e32280-109318"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31917-109318"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31931-109318"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=75116654&loc=d3e31958-109318"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32687-109319"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32698-109319"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32809-109319"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32840-109319"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65882285&loc=d3e32639-109319"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=d3e5283-111683"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569616-111683"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=68079674&loc=SL4569643-111683"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=d3e5614-111684"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=64809438&loc=SL4573702-111684"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5618551-113959"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=64837297&loc=SL5624163-113959"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=66048111&loc=SL6742756-110258"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13279-108611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13433-108611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13504-108611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=73719730&loc=d3e13537-108611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621"
  },
  "r2": {
   "Glossary": "Cash Equivalents",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6507016"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32022-110900"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32157-110900"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=64808268&loc=d3e32211-110900"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r207": {
   "Glossary": "Affiliate",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6504562"
  },
  "r208": {
   "Glossary": "Control",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6508935"
  },
  "r209": {
   "Glossary": "Immediate Family",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6515043"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6904-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-06)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.7-05(c)(Schedule II))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "225",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r242": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12b",
   "Subsection": "1"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Glossary": "Common Stock",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6508022"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Glossary": "Comprehensive Income",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=51831223"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Glossary": "Current Liabilities",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6509677"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e),(f),(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580"
  },
  "r6": {
   "Glossary": "Financing Activities",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6513228"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004124&loc=d3e557-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=66004921&loc=d3e1436-108581"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(a))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a))",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.21)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r7": {
   "Glossary": "Income Tax Expense (or Benefit)",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6515339"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "225",
   "URI": "http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3574-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585"
  },
  "r8": {
   "Glossary": "Investing Activities",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6516133"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=66902209&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=68058157&loc=d3e18780-107790"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Glossary": "Management",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "http://asc.fasb.org/extlink&oid=6517382"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1448-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1377-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1505-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1252-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1500-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=64863997&loc=d3e1278-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  }
 },
 "version": "2.0"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>52
<FILENAME>0000912061-17-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000912061-17-000022-xbrl.zip
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M_#.A'V70+&$;F,-^KZM9>C?M4*LU^79TZ A#]_,IX13T/#9::>9[H#N74^Y
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M !(8O&ZO*N?._UNJ6765%W79GCX4>].S$D$YKPT1RS3BSAIM"%IA"HCH?G>
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M'YEP@"643$*(I<&04,?T"F',:<PWP<<+9G0^51R&% :OYXV70>\N6[S-)Y.
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M7[ZI-HO:_6QRO9!++*WC!&N-G'>00QO/*VL/,+$2I#Y)UJ>M?$O^ 5Y<S \
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M<S>0NNM8:Z[2)2L'3=W5:0J2E*8^J?Q-3VB2+3BA*=W8Z" ?=Z\K2(0XI5P
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M5'@I%,"&<J>A%HPB=) ZR4':>R6]F\NL0PW"HMQ#3'VII#^?[91H9"K31.G
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M\=!<N@'>##C5/)6*&1W?J-2.$JL$]AYZ*@%$0!"?=(UV@#<#7KSZL[O(\F9
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M?W#?+NM'6-X&K^OU*N)4JZOX6]SM^CI?QB5G%N)PP*4!T&,!!;+<A[5F+QN
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MX7)NC^.<XV2J;L?=4]__:-Y'XIB8P/'QX<;MK]T/R<;;F0Z@#]WSY_=(;A\
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MD)Q%S=H0=T+9!N5]&BHWK$E5QG':3OU6G[:7Q^U>?"DO%_/EB>:A5\+CZ$0
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MH_N,;T8S\<,VK@/IQ79U>^-12 #"+^W#8 -2B"P_K*<V-JVVS<L1N)08&2>
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M81Z.YKWA4C#M(8.:,0<!4A8==JXP*&Q:-AH54DD!H)$6:8<IL2$4-X H"@7
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M&&8(8U;J9$]#\S3*@GG;*-]IFY;9-5J>Y_,@_",[U-]&TS4@WR?+7:3:6JG
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M<(\F5 8J&<83)PY'I:W&R79:YS\-ZYK:>/;#DH_XW7MUS+8JA06A?+""2\E
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M W=0"1F?/K4VJ-2,UUU:/]O]I*.'96NLTE)A1)06&-# "20E3!#Y.2B*#AQ
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MO[OW);T9T&\77T:SFTB*N[>>KU]@NM_!>[[+W3/059Z);*+]PH08-.>)<L4
MK23K@[*1@TL@@-M*"V$[^+G+Y616+I>A7(X7DXN;D3TCX2J&P.&-X1I)-$,K
MDDL%8%VP:$ "XQZ4(I[$$XF@[XE-\X[%,PP-]<R \A[9?;@?_.6'[MK)MDBD
MI,RI:#P%Z<&"HL%P \JD +92 J>V0EGOC>F W>D=U0H:T+$-"MUD:@"(LR*B
M22 8![2]0=2ZI'FJ^J@R0Y[$NC8FB%XTS^;9CW?KVU#YDGN^W[[EX]ZT3),O
M?_ 8%1.&2<-0)H:8Q!D#92%H+P.IM)O>S2BK*(*M=8H4C=""HQ4>/'(.G% Q
M6<#EE27A](F=0]<7]YX,\,<"._Q9??S>QO FM\YIX[32DFN* DZ!$!VCXPE-
M34UECT[*@P>6;O>G/\[OI18YGT]Q>BWW9>$_L*4BQ^";Z$V0E(-VH#GCUY@(
MPI/]HRB"RM38]3)6XW!W=5+=SQ,0RGG-DI<J*1"<:X$P;+! ^$\\R7YMZK4)
M=E?$:^CI+8U#L%R HRH1I:D0=#.V_&AUE\&S?;PE4IM*3<#:W5WR\75DPVAZ
MSTQ9VM5J,?ETN;I6OYM1E&?O1E?KS"R+Q6CVY=JMVWV@4+/Q(@F@X"S5GJ()
M"<3F2]@WJ 4KZSSI-: ,KZU1L7,)=,7;ZI;"_N?D#FZKH QB<$)$;R$Q)PDC
MZ@83&I2J$R4VH,RR S#SC@.\9T.O@Q>5$G$)4H[)6[^;H4)0;H,'(E3GO9N#
M<]B^R#6Z7<#[,OB.?SJ3*Z.LE)%(5/#2!I(8V8POVFHGCL-/>-N9R7<<K,/?
MO^K]8D63&U@L,4##&[37&BQ/-HD0$DYNSJ0EM)(2[6:4U0^K]M0LI%'(9-!1
M! /"*\.5%U9)[GA47I[8^7E]T>^9Y_7@'?Y\[SG<O='93H4E^0H;0 2:#Q^E
M5Y%'EA2SG/1X+MWL691Q0)(F4D.48!U'B@-WW@63")&NCF_RHF9X57%7/HLZ
M#-@^YO;[<IT$X-UHL;KZB"[\$H'($2Z]S=]M':HPC_=5+8B"P*/GTD6'>AQ,
MC(#B4292*Q3I,:?LMJ[?W;JH,L,/:*70%#3+SWDII2%8ZT!13@DGP7HFH-;S
MI\.;\\U18]X5Y$/2!H\"[4]2.5C%#/IL+GJ_OK\8M63:$9FXTDY!)3.WG5'?
M)>O8-@AW]>!?*B>?/J"]0CE@+"<'X#YOZUI<TN@&'^#5[A.=D,*H3)>MV<S:
M [^KO:1J(]B3IKIZ(X4PUCABO+%>1JM($L[?H&"84'4>^AP@!5MF2L6%K+88
M^B!CF'\=39Y[$WE[X<+0I%1PU! 6*>=>D\@WH]) 3BP.IPUQ[V#441@?G5S6
M+>:CLZO_NS9S/HPGY6R\+Y'U]AH%R<EQ@LOI"ZB-B3**?=WTV8<ZQ\D#Y\6A
M0INW 6A7ZN/=8GYV.5Z]77PH%]\FXWV/*SQ7O C.IN0A.F>%YF!PJLC;F:)K
MO4L^P'BJ;M>G!@#OF$KY'N--9Y=[%Z2M=0JJ.0(5?"126!\XTR%NQBB(.;%\
M$_7$_#QG:H-Z]$+T83Y?G9>[EY[[90J><^7P'*@  4!+HZ7=] O]C!.[&]2
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MB)X 4+L9%7'5GE!\0=M\W7.L98ETI>]N^WMO*'ZT/*\2LO.H2A& ZZ@=HXF
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MB262&*]D@'6,7*5 Y6Y&644E;*V#WA;Q1C'&K = C\LYH05-#(248&L]U3G
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MCKL:[GQ0_7[B7E)IX-7K;NA[5+CG.5TE&"3]]-SQFU]W]O:CG6"<I?5 QN7
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M)(0B('4$B8V8T[(<=MP(YCB[H^$M0UMF\]AJ39"Z*(#8K?[^[Z3S_ZN^Q\7
M>XK4C[2<_7J8E"/WD-%D3+\GYR=)<7W<U4AU7"8#)_@ODJRL?*NJ*.+L2^*-
M;7TY;_(IOO0_5:^K_OS=O<+-3NT]@,WUCZQ2$E A(,9<*$08%1IHA$P(+9\K
MY'<UW/GP"?_SL=;50VC[N$CB<EQ<-M:_J843%AH814ZX151BQU& ZZQ5(6)
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M':ZBABO]M@F)^U^=_3S.!AZ4>?'^3_U^DIR>OA 9Q ^9A>"L\ KHGTK-K8"
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M^;GBH>."%Q?#R=9H1UL=;34G^_!&NIKPK&F\_IS,IC+/*?<5>?6]I)UQN([
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M2#$24L#0HQ#<CH E/<#85B-XH[:>CO.1S^#5IOA]S1C$<PPJ"#GBEB(+ (U
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M&PDBH)&8442E,8)*1J7 (H+$ $N T$OT_<F*?ZH7?-4G@U /\S:U_[7U,6P
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M"PG/-L%AN4W&S49#!LV3;1*G9!HCD?8)I@FCDD= 2F M9Q&)[&,@TU:.P$V
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M(= ZPI%6+8KJEIQ18KL5\(TZ4E*7H\\7#I9TN3YNQBZGC;0"H;!$0&T%I)9
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M/-":V$2E#CC=,JN0E#&)$5$)E4B!2G[02+MCC>7<$&YCP02)M3]13)%EV&K
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M !X.M_\2'8^G\/*LFD2Z*FY]_!A&D@%S ;U^S(:@Q!=9:.#O13X!E6#6!+P
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M4*X"=1Q$(:@K:EY\'WVX\&[BF0X(].'F ;W'YUF9'YC,NW)F6:@;X/=<5*F
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M@K.G%;Q_XF.;?-G#N^N[H]6N&4BQ*R7@_CH=Y?5TD+@7=277]V39D[R?>U?
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MP._-L=:"UM4"X !B1-7Y> KC]$1VC7@6%>@.@# .*J"@L$:>A/I968:[@*M
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M P7< K4L[?"K(#M,K?S@D2,AOJ*%23X-]K:C'25=A;!'QU[:!).5ET0,& $
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M&X \_3D#OD;&(BO5'X/(&(!=X(GH0Y'6^/\#'HW6.)M!^P?IP"Y1OH8"0%2
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M,[C4<G^ P6UPL&T6E^. I\7@GD4A' 7+I1M%8$Q$Y0)6&?5!#5@'!DA;5OV
M:,!1Z8.UHOASJUN\""VI0E@[S/YN->N'N% +EV3/$;\H"UH])?3.XB]5X$&\
MV;K@*Q;>C-*(/X4%),K$3C3-@!W@L"^*C4KY#]K!TL8_DH) X S\LYL 74DS
M.UH09 * <(@*!]P QG=!)[D)[679+*)2NI"NA <OOJD9OPA?A+9' !TX2]<'
MS2RT"9Z3;ROA1Z)2*1[=4PK-&PV:=AZ:0D+ST*2L3KU3@I2L\M=#F581]5 R
M43:RESLEPGEIY6KT@BAI=@K(("CLXJUFD4F+#VL$WT7X68 7#-T#-)T#])R#
M%-+F 1I6#>7\2E BEK>N&4X24E@HU=ZEJK.AL2QMU\^\!PJ E D@EBLO6 MQ
M%@I/4Q5P'78?2-^"C>CM>:ROZ9%Z^,EQX3$[!-U#R&B9'<'R$0:FHKS/0LLN
MU/(C_%RF CI%!%F6@ F\9)2AM2HXTUB)Y"Z@# &V(5:5L3#I=165"W^&Z>S7
M]K=R*2*[]EI&U61 *(H@C.UOB*&W+B+H@76[1>@@AP6GK2+B_.BC#,4LN/$I
M*KW%E$IK/B'LT#>QR58/@VF["(UI-TR%/5L@SKVR.[W,=UDW!BBBLH2PF;U"
MU@)_B9/0YRQF-W91K*R0D%F10(@. Q1B\)6Q"Z"/@S#2<7GNAE&\6:#,T@X,
MYYF[(O$Y3^ MXOZ7UK!"VA&P!&@W*,X6=HP>$$SI8'Z"V6J)[Z#F([.508D"
M=@>RV@XQ"T0JFC[*5/\&]N((L:2T)->_%93[@]QO#MI3#.B,I\,U?3#]_ZQ?
MU2FMWW5<.W2Q$.B?F#,">P]=VO]?S7Z6U:>$+7UM-UDK'/C##@$UFV9-$A0(
MZU@K%[ C3=[3<J@)!(!'H-W!JEZ &D/=, :S61!B!0'2(>=HRZPK9+R>:T]=
MSXW7P(+%K1LD$9P/C@R*I1LM&%2/ 2]9X;'$-XR=P)OOW8PD02>9"0<V!G"Z
M ZA0&KGKLT[#9(#M6L@#PUH/[=H7PDES#]46=, 3XB0K!X!.SV0WEMXCY?7@
MFHP:L!M?S. %=KBN&]=\,R#J\"G&(EDGCUK3YJ%M0IA8H0IL?&G[\$W:MT(;
MPDW4LV<QGBYE/_K*.Z6@'=-F@)Y @I.23U"%FP2\QA/BX_A#R7Q*1U!"OMD/
M?8\2<MMPG;^]BP:]5J]K#;O#\V:KW;4FP\9Y?W ^Z7<;C:8YZ;3Q.W8.#,=8
M>UZ,1GK';Y@&G@-+?'3_G0#=QFLBVI%D[9<B L*=%:5/GW+NV" NA8Y0(TZ;
M.K[I!P%7>PL&*5JJ,0Z2.*QI0+-3@-<$N3MBV/T[5>;R83Z0OYJ-0GP\&''8
M^^MCD&E84";OV#PP6HB"JPRX1HH5)6,[H*%A[>0": [$K4?,Q,A$?,2>NB!T
M;UR4L$L;5$964$G3UU0M4&X\JBVY6PC?6 'W62 2U/#04[&%)J0*ER9]GCH#
M'4)<W6;=*L05;=_:KH=JRAGH26?HCLI=Q\P#I<N=NUAY&>T :JXET8,TZB4'
MF4? 3@KI1K80'CG)IK;_%4R169#@_K#>*Q)VI&H("MAO(0YL?;<1Z.(SLDN0
M1E1-,2K2_Y)*JM)T9PD8"?YLS66>@5>V\&4)$SK+Q!RHA@NLKX L=KI+MGU(
M+*=_4?:?*\VSO=]HU;NM@V2,66\TB.X/9FO]=@&%0&1J!^%7CNR3@@H2*/\'
MPR[-A6L*S$':2P'5/WI@ =7#NV*!5K!Z4Z-PBE;[&&Q&3T@.D4HF'1J8H*?Y
M;LH68RT9GRZC^33"*R5OB\,:OW:SA]4@6HTBTR#80_JJ:=X']<<H1<)%,2J?
M#(ENA]T/!-"A:>^Y&N_4X<H\RPONHBR/+>-QQ,SN:]>A:DCU:GMRVI+/U/5)
ML_?C(/6YJM_7:<3;$:L@<DM7 E1:3L07E4049Y"6$]ZB%EDIP)/2/;!J=BMR
M\T;Y$MFF:5%X1E6PHRB8QW<8&7#$K?""U3+-]Z!O31/7<X(DUK-'04$2WV /
M$5,7J!]?1)C0X_]P1>S;R[KQ<DC2MEHGAB1I3/'[KRR8,\?X:\OJ(%3X-W5K
MGT-[!E)@<OG%2%8WH>UPKI#P%UCC3LO(:!5.*T9VZLY$]KH5L$I8:GG*/++S
M;#QR[OHV-\'6T+]TN/=JBI/"]"CP!*,Y 27P (@((KA1T'P!6U?VFEUT[TF_
M"9((<!B$O_@V$ZL851PC6B"ZVDOR<?WXP=BOT:6,[^GHL3L\HZV7FSB"3V]^
M6W^A#[1D>[DA'10 @B6YK_I,>)[\]&_O&N_H=SC(3/V^ \37[A+0ZI.X,RZ#
MI;TUGX6+#'E[V.1"_8%'AM!?[EPG7L#3  PY<60&EV"O(O%!_;!%0N_20>+P
M"(+Z;^_,YKO_NG?..+^C:?WPLWIH\S-SOX^*7_%%7]8[^&N/#W5_XKSZ(YG[
M/A8SSV8[V!B#)K\12GXC8Y)2JFN^*_6M2Y9: #1 XS2ND,U7%_XV+GQ TOQM
MWO;;N.%+@5E_;YB+OXUK_L+Z^WWW_'0%!DS4FQ"8@H,*:A!^^,ML)L1\?BR:
MRP!L>L^P6APZ,=YC[KEK>S_N@QLO"8HR$<4^Y[L76)+"R S;(J]RCEY][-X?
M L->IRUL"&:CWMS,:CWHQ*][>?M.:*T(MPC"/3G:?'[R:];ZG<W!9 >=JB*Q
MLI'8:^E'Q6F*?]AK/GT_GUY25B!4M_\LMV_>?_U/-A:.TB9XFU9PZMJR'G%M
ME7.Z>Z-N[C/<O;3RL\*HU\8HLV8VFQ5*E0JE7E/8E$K!JNZR;'=9A+IT[+[5
MWVP_L<-UY5TM3#06"H3C<R^65I96R'E\R(G.-ZO"SB/'SO(<_%GTB7,Q#5&&
M,@@LLW+!E?K@SZ13AK.%+%I\,SZX3=VQ)$9#665O.45LH][H5RZ3"J.*],(U
MS JERH52I^&Y*4S3JFZT)#=:K-Y4*=!O[N"Y7-_FZIOA! D6A!V2[%O2U+F]
M<JL>@\]1)T;V]E$S]@=)E3E9\8:2(D?%&S9LD$:MT>U5W*'B#M7!JX.?^,')
M/OJ)&B&D?W?*T-NCR"Z>!6WILV_\EGAK-7JA6[MWE 65RV-36S7$ KY%G;<<
MU5\#GO]KHVZ:/-7"D(D3.Q^RVD;@\SP2;KF!?3N#Y3+ W0?802:)HQC6 9RJ
M&U?)+%N!IQ&L[#4UNH O#)*;)(K3$V!30UIC$7C8W N7#KE -'M8^4KJAJ&J
M"N$QVU^K"1S9VW!+N,5H:X\TT&$JU/P"QXUFH=#G<&R#L:@&.*>+D$?;_X9Z
M+QW>E,HJHI]K[:$F4 ?LK5G$O"=7T4\H5 _RJ+Y?HYV2S%Q[CMY4_Q3 6CQ7
MW H>S\*]T^34&1?]C=CMW5.S)6I&E*QP#!"W^"2>"XQHP0.&'+U'XF9WUV@1
M))Y#C,P1P-MC&DXS![W X#Y#QC2)  11I'^+9RPZ(?T9I]0PD2*_Q]'NLAEZ
MVMLS@ >%();-'/:46X$5AP).0'-W%O:M(.D4P0O=.>AR(+ 2GQBD'"."E"V'
M W#CZ[IQ,<]&_E #_:6]!F$5B^6*FI_SN,P8YP.$@BX<<2OMEZE:& /G^"IP
MB.,4F_EQ*VW@)'?I[G)XJH1B-FRH7$ M(:E_!O*AZ9,X(\:-N"_]+&&Z"D5Z
MP7HC1&R "I\N Y!\[A()'U$BO2HY-TN;(<$S'GX)A8WSQ[@1/@N)Q(^IO>G=
M N>"Y?C,DII/1X0XA(/<%=;WQ8RY ,]Y"A,WQI:J- 2/60-.OJ6U9*?5"!D4
M;,F.C"O0[1;"AHT/(M>N[QR-Q0=5I_P#!Y#2\!S:-DX:!T@A;Z$U08JL@H@'
M?:;3O'#[]/C9E!J%+VT_F8/^P&H#X';:"KZF&F#C!ZL$OCTS;&Q;R"Q/MC4,
M%2?=.!1>#H$*:0A?"'SN;(D-$K.'J!4FZ2\&B#N7],-(A+?4(S%FAEI#YNK3
M0TXZ+NM787OQ8FU\=.>",,H84:B)9GG@EFB>'_9:Q!FK9('1R ,/EX6_XVKI
MC/80QTN$(F/,MH2G0]JI&E8,7&2&HW+5/"[<"EV2[44!8T$Z*"["85X9AL+)
M_@#<F07T5FSM>8A<?T$V7ZJ979T-D];9>V97I]<;M/K#?J\S:;2MP61@=BUK
M,&YU1LWSCMEKX'>JF5W\:WYFUP@>0X\)#11,?&*&7P(@!]4'>@(,<@FL--I;
M#RY2XS!/>?H7,/GE$O/J)"O6=2 [NYZ5NAZ0H&FW>^!(GX)8SITP56]0_!/)
MKA$P7O1+4R/O\U2#O0*>+/DD+/!__M*SK,;/%_ GHU??_1BBQ!4HX![]CIL=
MV[%-WS1_5AL?^'Y"D]]07*,X/P?UVC ;9[^#]NRIWN\T,1,G.3K\ A"88J9&
M.A'J?0,AXM^ +$!%FR9=&^^O)J,?<4D>I&DVE'OCFB9;BY7J= A;R33U*'=.
MFV9G8C]?WH@.6Q":,Q=.%ZD9ZZ  PN=BQ>-"=VP:7C18PHW.;"5X4(WP@7F1
MMP6 O[2_"I373$=J\'<"RBFK%C24<CZG23T+&C/*YHWLSDH.&Q[Q@E_59[O@
M[\HCXP51HOQ+=!AM-,S6]Z0CAZ9JSI6RDV'(3LBIE^W:7XA#T!.YHVP$?>:Z
M2+_$_?75?04SJ7JH4:_XO([W&=@ VU&M86_;'%47W ^ -N(&V_(6C06H=$%(
M/ TW AH?7C1I@&I>CMSC#/<CX.#!$I:#_[(Z$NV<&AJ3TH@>.=Q.B+!Q7+@T
MG*8$6YB*^$X(QH^-JP95C";<8L-^T%ZDWTW^3B2CC:E0GC9"!^&4S*8H(]M,
M)=@N%DE7G5T'-02?TT!A4*&G 7$AT*@E#>J7*T?Z(M:&]AK^H(;4:N:_1!AZ
MR^[[9%K77R)YA,8BD'F:W9\CMG'DS"X7M,]_)<X-D5Z=X0X\+V4KTA1ETVGV
M?2#@W:BQ#F39$/6J2;8\L<W&^<F>EVU?>2EYQ 23:\IK=>ZBK8Q#XR(YW1EP
MG\TL=IP0/U>S)M2P7%%-EWB2$D>/?T"OA3O[&?M"\@5>9A<H<2:__^\^_A<Y
M/H3OT0Z%C#"@#%](=J?,/_H8[-'52K !"<8K#E2A<<]LZSIB)0@6RN"N&_DW
MH+24ICA3(YJ721@E-HM26Z&0?1,**6"1JJ0>)/UP8"]&<QX^SC1.&R$J=:.O
MA*Y!A!.N S:['2"F6Q&N%='/[!#$1LA+XVP83R#M;#XF=YH.!HQDU(2&1:MI
MW $2D-2LSNN?Z\.Z<84P8D4;)%==*4__U =6 9@%\@#9RIU<G;">&^/F'"7
M@:K3;>#L 1!T/.BE;J"O1=U:B%H4"W'IR4(5 >USBF(B0%R??!I$S4"@"<C0
M)8*95!]2E=(QUI$TLP$ZOM*2>"&I"B"QUXV!U [D2=3,<84@:C!-#J?L*)MC
M+IE2W>"HF%(V"AB94H1O'Y'I@/A"$1,Z[7),"SX,%(7/?0,YO&+YZ:TU4@-+
M(KQ!/0V@SF2I\YETIB>0!,ZX)\*I@]U!,UZB* "!KZ9K$HN3&O'&5W' "+F\
M^.N36Z5M D=BU59)6E=#=-8>Y QYJ2Z $DE?9F[&WPUFH,"633Z6T,L\\</
M\XAKKNS95]"8%-AK\K;87;@&3N@#HTY\A\(U8"F=)2MC+LA3>O\%888'<U]0
M@93YI#'9FF8Z@E'@W:JYQ( 16UM+3?@,'V=D$Z$;&V67C193A$Y2>CD[OO$
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M;W7K99\U!UAZPO0=Q [4B_#[U/<0W@/L"PP;#)1>V^X=_*S>^IL-%X#*SUK
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M..O_^M__]Z=%O/3^Z_\'4$L! A0#%     @ O$D"2YB$+ TN"@  K%X  !$
M             ( !     &YH=&,M,C Q-S V,S N>'-D4$L! A0#%     @
MO$D"2Z/'V<B]$@  EL(  !4              ( !70H  &YH=&,M,C Q-S V
M,S!?8V%L+GAM;%!+ 0(4 Q0    ( +Q) DM+6*.\UAH  .I) 0 5
M      "  4T=  !N:'1C+3(P,3<P-C,P7V1E9BYX;6Q02P$"% ,4    " "\
M20)+CECO],%I  #=Y 0 %0              @ %6.   ;FAT8RTR,#$W,#8S
M,%]L86(N>&UL4$L! A0#%     @ O$D"2VR/VT]!.0  ]\D" !4
M     ( !2J(  &YH=&,M,C Q-S V,S!?<')E+GAM;%!+ 0(4 Q0    ( +Q)
M DLRD$P)X@0! ,]##  4              "  ;[;  !N:'1C,C Q-S X,#)?
=,3!Q+FAT;5!+!08     !@ & (T!  #2X $    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
